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A B S T R A C T
Background
Despite advances in treatment, the increasing and ageing population makes heart failure an important cause of morbidity and death
worldwide. It is associated with high healthcare costs, partly driven by frequent hospital readmissions. Disease management interventions
may help to manage people with heart failure in a more proactive, preventative way than drug therapy alone. This is the second update
of a review published in 2005 and updated in 2012.
Objectives
To compare the eIects of diIerent disease management interventions for heart failure (which are not purely educational in focus), with
usual care, in terms of death, hospital readmissions, quality of life and cost-related outcomes.
Search methods
We searched CENTRAL, MEDLINE, Embase and CINAHL for this review update on 9 January 2018 and two clinical trials registries on 4 July
2018. We applied no language restrictions.
Selection criteria
We included randomised controlled trials (RCTs) with at least six months' follow-up, comparing disease management interventions to
usual care for adults who had been admitted to hospital at least once with a diagnosis of heart failure. There were three main types of
intervention: case management; clinic-based interventions; multidisciplinary interventions.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Outcomes of interest were mortality due to heart failure, mortality
due to any cause, hospital readmission for heart failure, hospital readmission for any cause, adverse eIects, quality of life, costs and cost-
eIectiveness.
Main results
We found 22 new RCTs, so now include 47 RCTs (10,869 participants). Twenty-eight were case management interventions, seven were
clinic-based models, nine were multidisciplinary interventions, and three could not be categorised as any of these. The included studies
were predominantly in an older population, with most studies reporting a mean age of between 67 and 80 years. Seven RCTs were in upper-
middle-income countries, the rest were in high-income countries.
Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Only two multidisciplinary-intervention RCTs reported mortality due to heart failure. Pooled analysis gave a risk ratio (RR) of 0.46 (95%
confidence interval (CI) 0.23 to 0.95), but the very low-quality evidence means we are uncertain of the eIect on mortality due to heart
failure. Based on this limited evidence, the number needed to treat for an additional beneficial outcome (NNTB) is 12 (95% CI 9 to 126).
Twenty-six case management RCTs reported all-cause mortality, with low-quality evidence indicating that these may reduce all-cause
mortality (RR 0.78, 95% CI 0.68 to 0.90; NNTB 25, 95% CI 17 to 54). We pooled all seven clinic-based studies, with low-quality evidence
suggesting they may make little to no diIerence to all-cause mortality. Pooled analysis of eight multidisciplinary studies gave moderate-
quality evidence that these probably reduce all-cause mortality (RR 0.67, 95% CI 0.54 to 0.83; NNTB 17, 95% CI 12 to 32).
We pooled data on heart failure readmissions from 12 case management studies. Moderate-quality evidence suggests that they probably
reduce heart failure readmissions (RR 0.64, 95% CI 0.53 to 0.78; NNTB 8, 95% CI 6 to 13). We were able to pool only two clinic-based studies,
and the moderate-quality evidence suggested that there is probably little or no diIerence in heart failure readmissions between clinic-
based interventions and usual care (RR 1.01, 95% CI 0.87 to 1.18). Pooled analysis of five multidisciplinary interventions gave low-quality
evidence that these may reduce the risk of heart failure readmissions (RR 0.68, 95% CI 0.50 to 0.92; NNTB 11, 95% CI 7 to 44).
Meta-analysis of 14 RCTs gave moderate-quality evidence that case management probably slightly reduces all-cause readmissions (RR
0.92, 95% CI 0.83 to 1.01); a decrease from 491 to 451 in 1000 people (95% CI 407 to 495). Pooling four clinic-based RCTs gave low-quality
and somewhat heterogeneous evidence that these may result in little or no diIerence in all-cause readmissions (RR 0.90, 95% CI 0.72 to
1.12). Low-quality evidence from five RCTs indicated that multidisciplinary interventions may slightly reduce all-cause readmissions (RR
0.85, 95% CI 0.71 to 1.01); a decrease from 450 to 383 in 1000 people (95% CI 320 to 455).
Neither case management nor clinic-based intervention RCTs reported adverse eIects. Two multidisciplinary interventions reported that
no adverse events occurred. GRADE assessment of moderate quality suggested that there may be little or no diIerence in adverse eIects
between multidisciplinary interventions and usual care.
Quality of life was generally poorly reported, with high attrition. Low-quality evidence means we are uncertain about the eIect of case
management and multidisciplinary interventions on quality of life. Four clinic-based studies reported quality of life but we could not pool
them due to diIerences in reporting. Low-quality evidence indicates that clinic-based interventions may result in little or no diIerence
in quality of life.
Four case management programmes had cost-eIectiveness analyses, and seven reported cost data. Low-quality evidence indicates that
these may reduce costs and may be cost-eIective. Two clinic-based studies reported cost savings. Low-quality evidence indicates that
clinic-based interventions may reduce costs slightly. Low-quality data from one multidisciplinary intervention suggested this may be cost-
eIective from a societal perspective but less so from a health-services perspective.
Authors' conclusions
We found limited evidence for the eIect of disease management programmes on mortality due to heart failure, with few studies reporting
this outcome. Case management may reduce all-cause mortality, and multidisciplinary interventions probably also reduce all-cause
mortality, but clinic-based interventions had little or no eIect on all-cause mortality. Readmissions due to heart failure or any cause were
probably reduced by case-management interventions. Clinic-based interventions probably make little or no diIerence to heart failure
readmissions and may result in little or no diIerence in readmissions for any cause. Multidisciplinary interventions may reduce the risk
of readmission for heart failure or for any cause. There was a lack of evidence for adverse eIects, and conclusions on quality of life
remain uncertain due to poor-quality data. Variations in study location and time of occurrence hamper attempts to review costs and cost-
eIectiveness.
The potential to improve quality of life is an important consideration but remains poorly reported. Improved reporting in future trials would
strengthen the evidence for this patient-relevant outcome.
P L A I N   L A N G U A G E   S U M M A R Y
Disease management programmes for heart failure
Review question
We investigated the eIects of disease management programmes on death from heart failure or from any cause, hospital readmissions for
heart failure or for any cause, adverse eIects, quality of life and cost-eIectiveness, in adults who had been admitted to hospital at least
once for heart failure.
Background
Heart failure aIects a person’s quality of life, is a frequent cause of hospital admission and has a high risk of death. Traditional drug
therapy is the main treatment, but people may benefit from additional support from disease management programmes that aim to provide
ongoing support rather than crisis management. Such programmes may be run by specialist nurses, as clinic-based interventions, or
Disease management interventions for heart failure (Review)
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by multidisciplinary teams. Community-based support of this kind could help to keep people out of hospital by improving day-to-day
symptom management and providing an ‘early warning system’ for changes requiring medical attention.
Selection criteria
We conducted a comprehensive search for all studies investigating heart failure-specific disease management interventions for adults who
had been admitted to hospital at least once for heart failure (evidence current to 9 January 2018).
Results and conclusions
We included 47 studies, with a total of 10,869 participants. Twenty-eight studies were case management interventions, seven were clinic-
based models, nine were multidisciplinary interventions and three could not be categorised as any of these. The average age of the people
in most of the studies was between 67 and 80 years old, although 10 studies had younger participants on average, and one included mostly
very elderly people. Most trials were in Europe and North America, but others took place in China, Taiwan, Iran and Japan.
We found limited evidence for an eIect on mortality due to heart failure, as few studies reported this outcome. There was some evidence
that case management may reduce all-cause mortality, and multidisciplinary interventions probably do, but clinic-based studies appeared
to have little or no eIect on this. Readmissions due to heart failure and due to any cause were probably reduced by case management
interventions. Clinic-based interventions probably make little or no diIerence to heart failure readmissions and may result in little or no
diIerence in readmissions for any cause. Multidisciplinary interventions may reduce the risk of readmission for heart failure or any cause.
Only two studies mentioned adverse events, both stating that none occurred. Many studies measured quality of life, but it is diIicult to
draw conclusions for any eIect because they tended to report this in diIerent ways and did not report it for all their participants. Data
on costs and cost-eIectiveness were limited, but indicated a slight benefit of disease management programmes, mostly due to reduced
hospital readmission costs.
Quality of the evidence
The quality of evidence was very low for mortality due to heart failure, low to moderate for all-cause mortality, low to moderate for heart
failure readmissions, and all-cause readmissions, moderate for adverse events (where available), low to very low for quality of life and low
to moderate for costs. The quality of evidence is important as it impacts on how certain we can be in the eIect of the intervention on the
outcomes we are interested in. For example, if the evidence is of very low quality, we cannot be certain of the intervention's eIect.
Disease management interventions for heart failure (Review)
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Summary of findings for the main comparison.   Case management compared to usual care for heart failure
Case management compared to usual care for heart failure
Patient or population: adults with heart failure
Setting: community
Intervention: case management
Comparison: usual care
Anticipated absolute effects* (95% CI)Outcomes
Risk with usual care Risk with case manage-
ment
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
HF mortality - - - - - Not reported
Study populationAll-cause mor-
tality
Follow-up: medi-
an 12 months
187 per 1000 146 per 1000
(127 to 168)
RR 0.78
(0.68 to 0.90)
6903
(26 RCTs)
⊕⊕⊝⊝
Low1,2
Case management may
reduce all-cause mortali-
ty.
NNTB 25 (95% CI 17 to 54)
 
Study populationHF readmissions
Follow-up: medi-
an 12 months 361 per 1000 231 per 1000
(191 to 282)
RR 0.64
(0.53 to 0.78)
2528
(12 RCTs)
⊕⊕⊕⊝
Moderate3
Case management prob-
ably reduces HF readmis-
sions: NNTB 8 (95% CI 6 to
13).
3 additional studies had
data that could not be in-
cluded in the meta-analy-
sis
 
Study populationAll-cause read-
missions
Follow-up: medi-
an 10.5 months
491 per 1000 451 per 1000
(407 to 495)
RR 0.92
(0.83 to 1.01)
4539
(14 RCTs)
⊕⊕⊕⊝
Moderate4
Case management prob-
ably reduces all-cause
readmissions slightly:
NNTB 26 (95% CI NNTH
204 to NNTB 12).
6 additional studies had
data that could not be in-
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cluded in the meta-analy-
sis
Adverse effects - - - - None of the included stud-
ies reported adverse ef-
fects
Quality of life
(MLHFQ mean
score at end of
follow-up)
Follow-up: medi-
an 6 months
Analysis 1.13 includes 8 studies, six of which show a broadly pos-
itive effect of case management interventions, however, 2 small
studies indicate that QoL may actually be lower in the case manage-
ment groups. High heterogeneity precludes pooling these studies
in a meta-analysis. 3 other studies also reported MLHFQ but for un-
clear or reduced numbers of participants. There was little evidence
for any difference between groups in studies that did not report ML-
HFQ, but only used the EQ-5D, SF-8, SF-36 or KCCQ tools.
- 1595
(8 RCTs)
⊕⊝⊝⊝
Very low5,6,7
A lower score indicates
better quality of life on the
MLHFQ.
We are uncertain about
the effect of case manage-
ment on QoL.
Costs and cost-
effectiveness
Follow-up: medi-
an 6 months
Cost-effectiveness analyses of 3 interventions generally suggest
small CE benefits over usual care, but another one reported a cost
of EUR 3746 per QALY gained with case management compared with
usual care.
7 case management studies reported the costs of their programmes,
although the wide range in dates and locations of studies compli-
cates interpretation: 2 reported higher costs for intervention groups;
4 reported lower costs (generally after taking readmission costs into
account); and 1 reported no difference in costs.
- 2369
(11 RCTs)
⊕⊕⊝⊝
Low8,9
Case management may
reduce costs and improve
cost-effectiveness slightly
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CE: cost-effectiveness; CI: confidence interval;HF: heart failure; MLHFQ: Minnesota Living with Heart Failure Questionnaire; NNTB/H: number needed to treat for an addi-
tional beneficial/harmful outcome; QALY: quality-adjusted life year; QoL: quality of life; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1We could include only 11 of the 26 studies in the sensitivity analysis, and this showed a stronger positive eIect than the main analysis. Downgraded once for risk of bias.
2Funnel plot is slightly asymmetric. Downgraded once for possible publication bias.
3Funnel plot is asymmetric and suggests publication bias - downgraded by one level.
4Confidence Interval includes the null as well as a small eIect. Downgraded once for imprecision.
5Unclear or high risk of attrition bias for majority of studies for this outcome. Study was not blind and this outcome was self-assessed. Downgraded by two levels for risk of bias.
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6High heterogeneity, and although subgroups diIer, there remains high heterogeneity in 6-month follow-up studies. Downgraded once for inconsistency.
7Downgraded once for imprecision as reported results vary widely.
8Only 4 studies had cost-eIectiveness analysis; 7 others reported costs which were hard to generalise. Downgraded once for indirectness of evidence.
9There was variation in the direction of eIect for cost studies. Downgraded once for inconsistency.
 
 
Summary of findings 2.   Clinic-based intervention compared to usual care for heart failure
Clinic-based intervention compared to usual care for heart failure
Patient or population: adults with heart failure
Setting: heart failure clinic (outpatients, community)
Intervention: heart failure clinic
Comparison: usual care
Anticipated absolute effects* (95% CI)Outcomes
Risk with usual care Risk with clinic-based inter-
vention
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
HF mortality - - - - - Not reported
Study populationAll-cause mortality
Follow-up: median 12
months 273 per 1000 238 per 1000
(186 to 300)
RR 0.87
(0.68 to 1.10)
1686
(7 RCTs)
⊕⊕⊝⊝
Low1,2
Clinic may result in little
to no difference in all-
cause mortality.
NNTB 29 (95% CI NNTH
37 to NNTB 12)
Study populationHF readmissions
Follow-up: median 18
months 345 per 1000 348 per 1000
(300 to 407)
RR 1.01
(0.87 to 1.18)
887
(2 RCTs)
⊕⊕⊕⊝
Moderate3
Clinic probably results in
little to no difference in
HF readmissions.
NNTH 290 (95% CI NNTH
17 to NNTB 23)
Study populationAll-cause readmissions
Follow-up: median 15
months 549 per 1000 494 per 1000
(395 to 615)
RR 0.90
(0.72 to 1.12)
1129
(4 RCTs)
⊕⊕⊝⊝
Low2,4
Clinic may result in little
to no difference in all-
cause readmissions.
NNTB 19 (95% CI NNTH
16 to NNTB 7)
Adverse effects - - - - Not reported
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Quality of life 
Follow-up: median 12
months
1 study reported no difference in MLHFQ between groups at 1
year, and another reported similar changes from baseline for
both intervention and control groups. 2 studies used the Not-
tingham Health Profile (NHP) rather than the MLHFQ, both re-
porting similar scores in intervention and control groups.
- 641
(4 RCTs)
⊕⊕⊝⊝
Low5
A lower score indicates
better quality of life on
both the MLHFQ and
NHP.
Clinic may result in little
to no difference in quali-
ty of life.
Costs and cost-effective-
ness
Follow-up: range 6
months to 12 months
1 study reported a cost saving of EUR 1382 per person, the
other a saving of USD 1300 per person
- 390
(2 RCTs)
⊕⊕⊝⊝
Low6,7
Clinic may reduce costs
slightly.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; HF: heart failure; MLHFQ: Minnesota Living with Heart Failure Questionnaire; NNTB/H: number needed to treat for an additional beneficial/harmful
outcome; RR: risk ratio
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1Sensitivity analysis included only 2 small studies at low risk of bias and showed more positive eIect estimate but with much wider confidence interval. Downgraded by one
level for risk of bias.
2Wide confidence interval includes null but not an important harm. Downgraded by one level for imprecision.
3Both studies were at unclear risk of bias for concealment of allocation, and one was also at unclear risk for randomisation method. Downgraded by one level for risk of bias.
4Only 1 small study was at low risk of bias for key domains. Downgraded by one level for risk of bias.
5Unblinded self-assessment of this subjective outcome. One study only collected data from fewer than half of the participants and the number of people providing data is unclear
for another study. Downgraded by two levels for risk of bias.
6Costs reported but not cost-eIectiveness. Age of one of the studies limits the generalisability of this. Downgraded by one level for indirectness of evidence.
7Small sample size. Downgraded by one level for imprecision.
 
 
Summary of findings 3.   Multidisciplinary disease management programmes compared to usual care for heart failure
Multidisciplinary disease management programmes compared to usual care for heart failure
Patient or population: adults with heart failure
Setting: community
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Intervention: multidisciplinary disease management programmes
Comparison: usual care
Anticipated absolute effects* (95% CI)Outcomes
Risk with usual care Risk with multidisciplinary
disease management pro-
grammes
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationHF mortality
Follow-up: me-
dian 12 months 159 per 1000 73 per 1000
(37 to 151)
RR 0.46
(0.23 to 0.95)
277
(2 RCTs)
⊕⊝⊝⊝
Very low1,2,3
We are uncertain about the effect of
multidisciplinary disease manage-
ment programmes on HF mortality.
NNTB 12 (95% CI 9 to 126)
Study populationAll-cause mor-
tality
follow-up: me-
dian 12 months
185 per 1000 124 per 1000
(100 to 154)
RR 0.67
(0.54 to 0.83)
1764
(8 RCTs)
⊕⊕⊕⊝
Moderate4
Multidisciplinary disease manage-
ment programmes probably reduce
all-cause mortality.
NNTB 17 (95% CI 12 to 32)
Study populationHF readmis-
sions
Follow-up: me-
dian 12 months
290 per 1000 197 per 1000
(145 to 267)
RR 0.68
(0.50 to 0.92)
1108
(5 RCTs)
⊕⊕⊝⊝
Low5,6
Multidisciplinary disease manage-
ment programmes may reduce HF
readmissions. One study reported
data that could not be included in
the meta-analysis.
NNTB 11 (95% CI 7 to 44)
Study populationAll-cause read-
missions
Follow-up: me-
dian 12 months
450 per 1000 383 per 1000
(320 to 455)
RR 0.85
(0.71 to 1.01)
1152
(5 RCTs)
⊕⊕⊝⊝
Low7,8
Multidisciplinary disease manage-
ment programmes may slightly re-
duce all-cause readmissions. 2 ad-
ditional studies reported data that
could not be included in the meta-
analysis.
NNTB 15 (95% CI NNTH 223 to NNTB
8)
Adverse ef-
fects
Follow-up:
range 6 to 12
months
2 multidisciplinary intervention trials mentioned that there
were no adverse effects, or no major side effects, in either
study arm.
- 496
(2 RCTs)
⊕⊕⊕⊝
Moderate9
Multidisciplinary disease manage-
ment programmes probably result in
little to no difference in adverse ef-
fects.
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Quality of life
(MLHFQ)
Follow-up: me-
dian 12 months
1 study reported score at
end of follow-up (34.3 in
usual-care group).
1 study reported a de-
crease from baseline of
0.5 in usual-care group
MD 12.21 lower
(16.43 lower to 7.99 lower)
1 study reported score at end of
follow-up (19.4 in intervention
group).
1 study reported a decrease
from baseline of −11 in inter-
vention group
- 140
(2 RCTs)
⊕⊝⊝⊝
Very low10,11
A lower score indicates better quality
of life on the MLHFQ.
4 other studies used the MLHFQ but
did not report data in a form that
could be included in the meta-analy-
sis. 1 study reported the KCCQ tool
but not the MLHFQ.
Overall, we are uncertain whether
multidisciplinary disease manage-
ment programmes affect quality of
life.
Costs and cost-
effectiveness
Follow-up 12
months
Only 1 multidisciplinary intervention study reported costs
or cost-effectiveness. In Gonzalez-Guerrero 2014, the cost
per additional QALY for the disease management pro-
gramme compared with usual care was EUR 38,274 from a
healthcare perspective and EUR 25,390 from a societal per-
spective.
- 117
(1 RCT)
⊕⊕⊝⊝
Low12,13
Multidisciplinary disease manage-
ment programmes may be cost-ef-
fective from a societal perspective
but less so from a healthcare per-
spective.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; HF: heart failure; KCCQ: Kansas City Cardiomyopathy Questionnaire; MLHFQ: Minnesota Living with Heart Failure Questionnaire; NNTB/H: number
needed to treat for an additional beneficial/harmful outcome; QALY: quality-adjusted life year; RR: risk ratio
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1The intervention for one of the studies (Gonzalez-Guerrero 2014), took place in a geriatric day care hospital. Whilst this was characterised as multidisciplinary due to the nature
of care, it may not be fully characteristic of the more usual multidisciplinary intervention. Downgraded by one level for indirectness.
2The largest of the two studies was at unclear risk of bias for randomisation and allocation concealment, and high risk for attrition. the other was at low risk of bias for
randomisation and allocation concealment, but unclear risk for attrition. Downgraded by one level for risk of bias.
3Small sample size and low event rate. Downgraded once for imprecision.
4Sensitivity analysis restricted to the only two studies at low risk of bias in key domains indicated a lack of evidence for an eIect, whereas the overall analysis of all eight studies
showed a positive eIect. Downgraded by one level for risk of bias.
5Only one of the five studies was at low risk of bias, so sensitivity analysis was not possible. Downgraded by one level for risk of bias.
6There was moderate heterogeneity (I2 = 48%); the second largest study showed a null result, whereas the largest and third largest showed a beneficial eIect. Subgroup analysis
by length of follow-up did not explain this. Downgraded by one level for inconsistency.
7Only one of the five studies was at low risk of bias, downgraded by one level for risk of bias.
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8Confidence interval includes a benefit but also the null. Doesn't include potential harm. Downgraded by one level.
9Only two small studies reported this outcome. Downgraded once for imprecision.
10Both studies were at low risk of bias for randomisation and allocation concealment, but quality of life was self-reported, and this was an unblinded study. Unbalanced percentage
of responders in Bernocchi 2017 (80% intervention, 63% control). Downgraded by two levels for risk of bias.
11Very small number of participants. Downgraded by one level for imprecision.
12Only reported by one small study. Downgraded by one level for imprecision.
13The only study reporting this outcome took place in a geriatric day hospital, which is not representative of the majority of multidisciplinary interventions. Downgraded once
for indirectness.
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B A C K G R O U N D
Description of the condition
Worldwide approximately 26 million adults are living with heart
failure (Bui 2011; Savarese 2017), and the condition is increasingly
common in both economically developed and economically
developing countries (Ponikowski 2014; Roger 2012). The crude
prevalence of heart failure is typically around one to two per cent in
the general population (Lloyd-Jones 2010; Ponikowski 2014). Both
the incidence and prevalence of heart failure increase with age,
with data from the USA indicating that the incidence of heart failure
approaches 21 per 1000 population for those aged 65 and over
(Benjamin 2017). The American Heart Association estimates that
the heart failure incidence rate doubles for each 10-year increase
in age from 65 to 85 years of age for men (Benjamin 2017; Karmali
2014), and triples for women between the ages of 65 to 74 and 75 to
84 (Benjamin 2017; Lackland 2012).
Most people with heart failure are elderly. In the English and Welsh
National Heart failure audit the median age of patients discharged
from hospital with a diagnosis of heart failure was 80 years - with
66% aged over 75 years and 30% aged over 85 years (NICOR 2013).
With an aging population, an increasing number of people will be
at risk of heart failure. In the UK, for example, Conrad 2018 reported
that a decline in age- and sex-standardised heart failure incidence
was seen between 2002 and 2014, but, due to the increase in size
and age of the population, the estimated number of prevalent cases
increased by 23%, from 750,127 in 2002 to 920,616 in 2014.
Despite the fact that in many countries survival has improved
in recent years, the condition carries a substantial risk of death
worldwide: 17% to 45% of people admitted to hospital die within
one year (Ponikowski 2014). In high-income countries, chronic
heart failure accounts for more than 10% of deaths (Kaur 2017). For
low- and middle-income countries, the proportion is substantially
higher, with 28% of deaths being due to chronic heart failure Kaur
2017. In addition to the risk of death, the condition has a profound
impact on patients’ quality of life (Bekelman 2007; Juenger 2002;
Stewart 1989).
A primary diagnosis of heart failure accounts for one to two per
cent of all admissions in economically developed countries and for
one to three per cent of all healthcare expenditure in Europe, North
America, and Latin America (Ponikowski 2014). The total annual
cost of heart failure to the UK National Health Service is around
GBP one billion (2% of the total NHS budget), and most of this cost
(approximately 70%), is incurred by hospital admissions (Lancet
2011; NICE 2012). The estimated cost of treating heart failure was
USD 30.7 billion in the USA in 2012, expected to rise to USD 69.7
billion by 2030 (Benjamin 2017).
Description of the intervention
Drug therapy is the mainstay of treatment for heart failure,
although invasive procedures and devices are indicated for some
patients, and patients are usually managed with a combination of
medications and lifestyle advice (NICE 2010). The management of
people with heart failure has evolved from a traditional model, with
its emphasis on crisis intervention, towards much more proactive,
preventative disease management models. These care models
oIer 'aggressive care' in hospital, home or clinic (Riegel 2001).
Riegel proposed three types of heart failure disease management
models (Riegel 2001), and we have used her typology to identify
appropriate types of intervention to include in this review.
• Case management, defined as “the active management of
high-risk people with complex needs, with case managers
(usually nurses) taking responsibility for caseloads working in an
integrated care system” (DoH 2004)• Clinical interventions such as enhanced or novel service
provision (for example the introduction of a specialist nurse led
heart failure clinic)• Multidisciplinary interventions such as disease management
interventions, defined as “a system of coordinated healthcare
interventions and communications for populations with long-
term conditions in which patient self-care is significant” (Royal
College of Physicians 2004)
In addition to diIerent settings such “clinical service interventions”
may diIer in their components, duration, intensity and the number
and type of healthcare professionals involved.
How the intervention might work
Early hospital readmission in people with heart failure is
extremely common. In the USA almost 30% of patients are re-
hospitalised within 90 days of discharge (Gheorghiade 2013). In
the EuroHeart Failure survey, which included 24 countries, 24%
of people admitted with confirmed or suspected heart failure
were readmitted to hospital within 12 weeks - heart failure was
the principal cause of readmission (20% of readmissions), and
contributed to a further 16% of readmissions (Cleland 2003).
More recently, Toback 2017 reports that 17% to 27% of people
hospitalised with heart failure will be readmitted within 30 days of
discharge (Ghosh 2016; Jencks 2009).
Disease management interventions might reduce the risk of
readmission to hospital by providing ongoing, direct support to
patients post-discharge. Facilitating earlier contact with specialists
and improving symptom monitoring could help manage patients
in their own homes and avoid the need for frequent emergency
hospital readmissions.
Why it is important to do this review
The ESC 2016 guidelines (ESC 2016), recommend multidisciplinary
care, but state that there is no evidence that non-pharmacological,
non-device or surgical interventions on their own improve
mortality, morbidity or quality of life. The current review therefore
provides a useful overview of the impact of such disease
management programmes on patients' quality of life, risk of
hospital readmission, and risk of mortality. We have also attempted
to include data on cost-eIectiveness and costs, where this
information is available for the included studies.
Since the previous update of the review, there have been a number
of new studies published in this area. There are now RCT data from
a broader range of countries and populations than were available
for the Takeda 2012 update, and inclusion of this should widen the
generalisability of findings.
O B J E C T I V E S
To compare the eIects of diIerent disease management
interventions for heart failure (which are not purely educational in
Disease management interventions for heart failure (Review)
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focus), with usual care, in terms of death, hospital readmissions,
quality of life and cost-related outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with a minimum of
six months' follow-up in the review. Both individually randomised
and cluster-randomised trials were eligible for inclusion. Cross-over
trials could be feasible in this area, so would be included if any were
identified. However, we did not identify any. Studies reported as full
text, those only published as abstracts, and unpublished data were
all eligible for inclusion.
Types of participants
This review focused on adults aged 18 years and over, who had been
admitted at least once to secondary care with a diagnosis of heart
failure. We focused on people who had been hospitalised for heart
failure, because they represented a group at high risk of frequent
readmission. We excluded studies dealing principally with people
with cardiac disorders other than heart failure, or with heart failure
arising from congenital heart disease, or valvular heart disease,
or both. Where a study in the last updated review (Takeda 2012)
included only a subgroup of relevant participants, we included
the study if the majority of participants met the inclusion criteria.
For studies identified in the most recent update, we contacted
authors to source data for the relevant subgroup. Where this was
not possible, we included the study if the majority of participants
were eligible.
Types of interventions
We included clinical service disease management interventions
(defined as inpatient, outpatient or community-based
interventions or packages of care), directed specifically at people
with heart failure. This excluded the simple prescription or
administration of a pharmaceutical agent(s) to people with heart
failure. Interventions could include or exclude patients' relatives or
carers.
We used the typology of  Riegel 2001 to classify studies for  this
review, as described in the Background section: case management,
clinic-based interventions, and multidisciplinary interventions.
We did not include the following types of interventions in this
review.
• Interventions that were purely educational in focus, without any
follow-up phone calls or interaction between the patients and
provider.• Interventions that only consisted of exercise programmes.• Interventions described as cardiac rehabilitation programmes,
unless they also had case management elements. Cardiac
rehabilitation was defined as a structured programme oIered
to individuals aNer a cardiac event to aid recovery and prevent
further cardiac illness. Cardiac rehabilitation programmes
typically achieve this through exercise, education, behaviour
change, counselling and support, and strategies that are aimed
at targeting traditional risk factors for cardiovascular disease
(Taylor 2010).
• 'Generic' interventions, not exclusively aimed at people with
heart failure, directed at reducing readmission or morbidity
in populations of older people with a variety of long-term
conditions.• Solely telemedicine interventions, where telemedicine is
defined as the “transfer of physiological data via digital
cable e.g. electrocardiograph (ECG), blood pressure (BP),
weight, pulse oximetry (SPO2), respiratory rate and medicine
administration)”, as these were the focus of another Cochrane
Review (Inglis 2015).• Interventions that only consisted of structured telephone
or videoconferencing support, including computer-assisted
education and monitoring, as these were in another systematic
review (Clark 2007).
We did not exclude interventions that included structured or
unstructured telephone or videoconferencing support alongside
other non-telemedicine components, such as attendance at a clinic
or home visiting.
The comparator of interest is 'usual care', and we acknowledge
that variation in local practice could introduce heterogeneity to
the review. We collected data on how usual care was described in
the published reports, as a source of information to explore this
possibility.
We have conducted three comparisons for this review:
• case management interventions versus usual care• clinic-based interventions versus usual care• multidisciplinary interventions versus usual care
We have provided a narrative summary to describe separately any
studies that we could not classify as one of these three types of
intervention.
Types of outcome measures
We extracted outcomes for the longest available follow-up.
Reporting of one of these outcomes was not an inclusion criterion
for the review. We included mortality due to heart failure as well
as all-cause mortality in an attempt to identify the impact of heart
failure-specific interventions, which may be masked by deaths from
other causes if the emphasis is on all-cause mortality (Sasieni 2017).
Primary outcomes• Mortality due to heart failure (where this is reported separately
from all cardiac causes)• All-cause mortality• Readmissions due to heart failure (where this is reported
separately from all cardiac related readmissions)• All-cause readmissions• Adverse eIects
Secondary outcomes• Health-related quality of life, using a validated instrument• Costs or cost-eIectiveness
Where studies reported multiple quality-of-life assessments,
we have prioritised the Minnesota Living with Heart Failure
Disease management interventions for heart failure (Review)
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Questionnaire (MLHFQ), as this was the most widely reported
instrument.
Search methods for identification of studies
Electronic searches
We searched the following databases for this update on 9 January
2018 (search strategies in Appendix 1):
• Cochrane Central Register of Controlled Trials (CENTRAL; 2018,
issue 1) in the Cochrane Register of Studies;• Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
MEDLINE Daily and MEDLINE (Ovid, 1946 to 9 January 2018);• Embase (Ovid, 1980 to 2018 Week 02);• CINAHL Plus with Full Text (EBSCO, 1937 to 9 January 2018);• DARE Issue 2 of 4, 2015 (Cochrane Library) – no longer updated.
The RCT filter for MEDLINE is the Cochrane Highly Sensitive Search
Strategy for identifying trials in MEDLINE: sensitivity-maximising
version, and for Embase, we applied terms as recommended in
the Cochrane Handbook for Systematic Reviews of Interventions
(Lefebvre 2011). We applied no language restrictions.
We also searched two clinical trials registries on 4 July 2018 (search
terms in Appendix 1):
• ClinicalTrials.gov (www.clinicaltrials.gov);• WHO International Clinical Trial Registry Platform (ICTRP,
apps.who.int/trialsearch/).
We did not search some previously searched databases for this
update, as limited resources meant we had to restrict searches to
the major databases.
Details of the searches for the previous versions of the review can
be found in the respective publications (Takeda 2012; Taylor 2005).
Searching other resources
In addition, we screened lists of included studies from relevant
systematic reviews. We contacted study authors to clarify reported
information or to obtain unpublished data.
Data collection and analysis
Selection of studies
Two review authors independently assessed the title and abstract
of each reference (AT, ST or NM for this 2018 update). Two
authors independently assessed the full texts of all potentially
eligible papers retrieved (AT, ST or NM for this 2018 update) and
coded them as 'retrieve' or 'exclude'. For non-English language
papers, which appeared to be eligible for inclusion on the basis
of the title and abstract, we sought the assistance of people
with appropriate language skills via Cochrane TaskExchange
(taskexchange.cochrane.org/). We resolved any disagreements
about eligibility by discussion between at least two authors (AT,
NM), with a third author (ST) being consulted where we could
not reach consensus. For studies with multiple publications, we
collated these so that each study rather than each report was the
unit of interest in the review. We recorded the selection process
in detail and described it in a PRISMA flow diagram (Liberati 2009;
Figure 1).
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Figure 1.   Study flow diagram for 2018 update
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Figure 1.   (Continued)
 
Data extraction and management
We developed a new data extraction form for this update, piloted
by two review authors (NM, AT). Three review authors (AT, NM,
ST), conducted the data extraction for studies published since the
2012 publication. One review author extracted study characteristics
and a second author checked them, and two review authors
independently extracted outcomes. An exception to this was
Salehitali 2009, where a volunteer (FS), with Persian language skills,
kindly carried out data extraction and assessed risk of bias. This
could only be compared against the English language abstract by a
second review author.
Disease management interventions for heart failure (Review)
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Where we were unclear about issues arising from their published
papers we attempted to contact the study authors for clarification.
We extracted the following information from included studies.
• Methods: study design, total duration of study, number of study
centres and location, study setting and date of recruitment• Participants: number randomised, number lost to follow-
up or withdrawn, number analysed, mean age, age range,
gender, severity of condition, diagnostic criteria, comorbidities,
inclusion criteria, and exclusion criteria• Interventions: intervention, comparison• Outcomes: primary and secondary outcomes specified and
collected, and time points reported• Notes: study funding, and notable conflicts of interest of study
authors
For this update, one review author (AT), transferred data into the
Review Manager 5 (RevMan 5) file (Review Manager 2014). A second
review author (NM), double-checked that data had been entered
correctly by comparing the data presented in the systematic review
with the trial reports.
Assessment of risk of bias in included studies
Two of three review authors (AT, ST, NM), assessed all new and
previously included studies by using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2017). We resolved any disagreements by discussion or by involving
a third review author. We assessed the risk of bias according to the
following domains:
• random sequence generation• allocation concealment• blinding of participants and personnel• blinding of outcome assessment (assessed separately for
objective and subjective outcomes)• incomplete outcome data• selective outcome reporting• other bias
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgment in the 'Risk of bias' table.
Categorising the interventions
We used Riegel's heart failure disease management models (Riegel
2001), to group the diIerent interventions for synthesis as follows.
Case management models
Case management models consist of intense monitoring of patients
following discharge from hospital, this is usually done by a nurse
and typically involves home visits or telephone calls, or both.
Clinic-based intervention models
Clinic-based intervention models involve outpatient clinics for
heart failure. They are usually run by cardiologists with a special
interest in heart failure or by specialist nurses using agreed
protocols to manage medication.
Multidisciplinary models
Multidisciplinary models oIer a holistic approach to the
individuals' medical, psychosocial, behavioural and financial
circumstances and typically involve several diIerent professions
working in collaboration. The gap between hospitalisation, other
healthcare delivery systems (e.g. skilled nursing facilities, hospice),
and home is bridged by a team of individuals knowledgeable about
heart failure and committed to patient care.
Measures of treatment e9ect
We analysed dichotomous data as risk ratios (RR) with 95%
confidence intervals (CI) and continuous data as mean diIerences
(MD) with 95% CIs. For quality of life, we prioritised the
widely reported Minnesota Living with Heart Failure Questionnaire
(MLHFQ). On this scale, a lower score indicates a better quality of
life. We considered a change of five points to represent a clinically
meaningful diIerence (Rector 1995). For outcomes where a pooled
RR was calculated, we calculated the number needed to treat for
an additional beneficial/harmful outcome (NNTB/NNTH), following
methods outlined in the Cochane Handbook for Systematic Reviews
of Interventions (Schünemann 2017) and using the online calculator
NNT Online. We used the assumed risk with control from the
'Summary of findings' table as the 'assumed comparator risk'.
Where the RR was greater than one, the CI for the NNTB includes a
NNTH and a NNTB, due to inclusion of the null. For example, a NNTB
of 15 could have a CI spanning from a NNTB of 8 to a NNTH of 223.
Unit of analysis issues
One study (Jaarsma 2008), had two intervention arms and a
single control arm. Since the interventions were of diIerent types
(one case management and one clinic-based intervention), we
treated these as separate comparisons, and as such, they never
appear together in the same meta-analysis. We have therefore
used the whole control arm for both comparisons. Had the two
intervention arms of this study appeared within the same meta-
analysis, we would have halved the control arm and used half
for each comparison, to avoid double counting. For trials that
reported at multiple time points, we have used the longest follow-
up. We included two cluster-RCTs (Doughty 2002; Thompson 2005).
Doughty 2002 randomised at the GP level, but then presented
results at the participant level. Whilst this would usually present a
unit of analysis problem, we accepted the study author's reasoning
that the median number of participants per GP was 1.5, so the
influence of clustering was small. We also carried out sensitivity
analysis that excluded this study. Thompson 2005 only contributed
quality-of-life data in a format that could not be pooled in the meta-
analysis, so we did not re-analyse this.
Dealing with missing data
We contacted study authors to verify key study characteristics
where these were unclear, for example, whether or not participants
had been hospitalised for heart failure. We also attempted to
obtain missing numerical outcome data from study authors where
possible (e.g. when a study was identified as abstract only). Where
this was not possible, we considered whether the missing data were
likely to introduce serious bias. If we did not consider the data to be
missing at random, we planned to explore the impact of including
such studies using sensitivity analysis for primary outcomes. Since
the only outcome with considerable attrition was quality of life (a
secondary outcome), this was not required. We used the RevMan 5
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Calculator to calculate missing standard deviations from P values
where required, and noted this in footnotes to the forest plots
(Review Manager 2014). We have not made any assumptions about
missing data, so if study authors only reported available case
data, for example for quality of life, we have used the number
of responders as the denominator, not the number of people
randomised.
Assessment of heterogeneity
We anticipated a high degree of heterogeneity due to diIerences
in interventions, usual care definitions, and participant groups.
We visually inspected forest plots to see if directions of eIect
diIered between studies, and to assess the degree of overlap
between studies. We calculated the I2 statistic (Higgins 2003) to
formally measure heterogeneity, using the following guide from
the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2017):
• 0% to 40%: might not be important;• 30% to 60%: may represent moderate heterogeneity• 50% to 90%: may represent substantial heterogeneity• 75% to 100%: considerable heterogeneity
In all cases, we considered the magnitude and direction of eIects
and the strength of evidence according to the P value from the Chi2
test when interpreting the I2 value. In particular, we considered the
substantial uncertainty associated with its value when there were
only a small number of studies in the meta-analysis (Higgins 2017).
Assessment of reporting biases
For outcomes reported by at least 10 trials, we constructed funnel
plots to assess possible publication bias (Sterne 2017).
Data synthesis
We analysed the data using Cochrane Review Manager soNware,
RevMan 5.3 (Review Manager 2014). Where possible and
appropriate, we combined the trial results statistically using meta-
analytic methods. Given the high degree of heterogeneity expected
in the studies due to diIerences in interventions, usual care
definitions, and participant groups, we applied a random-eIects
model for the meta-analyses. We used the Mantel-Haenszel method
to pool risk ratios, and the inverse variance method to combine
studies reporting health-related quality of life (to allow inclusion of
a study that only reported the mean diIerence between treatment
arms but not the group-specific data).
GRADE and 'Summary of findings' tables
We created three 'Summary of findings' tables, one for each
disease management intervention (case management, clinic-
based interventions and multidisciplinary interventions). We used
methods and recommendations described in Section 8.5 (Higgins
2017) and Chapter 12 (Schünemann 2017) of the Cochrane
Handbook for Systematic Reviews of Interventions, and used
GRADEpro GDT soNware to generate the tables (GRADEpro GDT
2015).
Each table includes all five primary outcomes and the two
secondary outcomes. Two review authors (AT, NM) used the five
GRADE considerations (study limitations, consistency of eIect,
imprecision, indirectness and publication bias) to independently
assess the quality of the body of evidence relating to the studies
that contributed data to the meta-analyses for each outcome.
Where there were studies that reported the outcomes in a way that
we could not meta-analyse, we added a narrative description to
the table. We describe justifications for downgrading decisions in
footnotes to the table and in the section Quality of the evidence .
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analysis by length of follow-up (comparing
studies with six months' or less follow-up against those with over
six months' follow-up). We also assessed the impact of delivery of
the intervention using subgroup analysis by particular professional
groups (for example pharmacists, specialist nurses).
For primary outcomes with at least 10 studies we undertook a
random-eIects meta-regression using the 'metareg' command in
Stata, weighting studies by the standard error (SE) of the log RR,
to assess whether particular intervention components were more
strongly associated with positive outcomes. We only undertook
meta-regression for case management studies, due to a lack of
suIicient trial numbers for the other categories of intervention.
Sensitivity analysis
We undertook two sensitivity analyses, for the primary outcomes
only.
• To explore the impact of the cluster-randomised control trial
(Doughty 2002), by comparing the results with and without this
study, for the only outcome that included this trial (clinic-based
intervention versus usual care, all-cause mortality).• To restrict the analyses to only those studies at low risk of bias in
the key domains of random sequence generation and allocation
concealment, and at low or unclear risk for incomplete outcome
data (attrition bias). We considered blinding separately for
objective and subjective outcomes separately, but since quality
of life was only a secondary outcome we did not undertake
sensitivity analyses for this outcome. We have therefore not
included blinding as a domain for our sensitivity analysis.
We considered a sensitivity analysis exploring the impact of missing
data. The most common area for missing data was in quality-of-life
assessments (either missing standard deviation, which had to be
imputed, or large numbers of participants missing from analyses).
As this was a secondary outcome, we did not undertake sensitivity
analysis for missing data.
R E S U L T S
Description of studies
Results of the search
Figure 1 describes the search process for this update and
the previous publication. The searches for this updated review
retrieved 7910 records from the databases and 1109 records
from the clinical trials registries. ANer deduplication 6883 records
remained for screening. We excluded 6631 records based on
title and abstract screening and assessed 252 full-text papers for
inclusion.
Based on assessment of the full texts, we excluded 160 references
reporting 124 studies. We also moved a previously excluded
abstract to a linked new full publication marked as 'awaiting
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classification', and linked a previously excluded cost-eIectiveness
analysis to one of our included studies. Adding these to the
previously excluded 93 studies (103 references) gives a total of 217
excluded studies (261 references).
We found 22 new studies for inclusion (61 references) and an
additional two references for a previously included study. In
addition to the previously included 25 studies (32 references) this
gives a total of 47 included studies (95 references), with a total of
10,869 participants.
We also identified 12 new ongoing studies (14 references) and 15
new studies that are awaiting classification (18 references). For this
update, we reassessed all studies previously listed as ongoing or
awaiting classification, moving them either to included or excluded
studies where possible.
Included studies
Control participants received 'usual' or 'routine' care in the
majority of studies. In some studies, small additional components
were mentioned. For example, both control and intervention
participants received a programme of 'optimised' medical care
aNer discharge from the index hospitalisation in Del Sindaco
2007, and guideline-standard management was described in
Lang 2018. In two studies (Leventhal 2011; Tsuchihashi-Makaya
2013), all enrolled participants received comprehensive discharge
education using an information booklet. Other studies also
mentioned information sheets or short education sessions at
discharge (Bekelman 2015; Bernocchi 2017; Gonzalez-Guerrero
2014). In others, a follow-up phone call or outpatient adjustment
to medication was standard care (Chen 2018; Ong 2016). Dunbar
2014 mentioned an "attention control" component of telephone
calls on the same schedule as the intervention participants,
with information about the trial but no heart failure-specific
information.
Just over half (25) of the studies were carried out at single centres,
and 22 were multicentre studies. Six studies took place at two
centres (Agren 2012; de Souza 2014; Kasper 2002; Kwok 2008;
Lopez 2006; Thompson 2005); 13 at three to nine centres (Atienza
2004; Bekelman 2015; Berger 2010; Bernocchi 2017; Brotons 2009;
DeBusk 2004; Dunbar 2014; Holland 2007; Kimmelstiel 2004; Naylor
2004; Ong 2016; Stromberg 2003; Tsuchihashi-Makaya 2013), and
three at 10 or more centres (Cavusoglu 2017; Jaarsma 2008; Tsuyuki
2004).
All the studies were led by professionals from secondary or tertiary
care. None of the 47 interventions were delivered in exactly the
same way by the same type of personnel, although some were
very similar and all the interventions had overlapping content (see
Table 1). The interventions varied in site, intensity and duration (see
Characteristics of included studies). Length of follow-up ranged
from six months to two years.
Inclusion and exclusion criteria
The studies diIered in their inclusion and exclusion criteria.
All of the studies identified participants during or following an
index hospital admission, or confirmed that participants had been
previously hospitalised for heart failure. Participants in Gonzalez-
Guerrero 2014 had acute heart failure according to European
Society of Cardiology (ESC) criteria. Two studies specifically
enrolled people with particular comorbid conditions; people
included in Bernocchi 2017 had to have both heart failure and
chronic obstructive pulmonary disease, and those in Dunbar 2014
had to have both heart failure and diabetes.
Two studies excluded people with diastolic heart failure or heart
failure with preserved systolic function (Blue 2001; Tsuyuki 2004).
Several of the studies mentioned excluding people with valvular
heart disease requiring surgery (DeBusk 2004; Del Sindaco 2007;
Doughty 2002; Holland 2007; Jaarsma 2000; Kasper 2002; Mejhert
2004; Stewart 1999a), or excluded people awaiting cardiac surgery
(Atienza 2004; Holland 2007; Jaarsma 2008; Thompson 2005). Agren
2012 excluded people currently undergoing cardiac surgery, and
Tsuchihashi-Makaya 2013 excluded people with end-stage heart
failure. Four studies specifically excluded heart failure associated
with acute myocardial infarction (Blue 2001; de Souza 2014;
Ducharme 2005; Kasper 2002), and one excluded heart failure
associated with cor pulmonale (Nucifora 2006). Leventhal 2011
excluded people with severe myocardial or valvular obstructive
disease. The presence of serious comorbidity or other terminal
illness was a common exclusion criterion, and most of the studies
excluded people discharged to long-term care facilities, such as
nursing homes. Clark 2015 excluded people with New York Heart
Association (NYHA) class IV heart failure.
The participants enrolled in the studies
The majority of studies (36 of 47) had between 100 and 350
participants. Ong 2016 randomised 1437 people, the COACH study,
reported by Jaarsma 2008, randomised 1049 and Bekelman 2015
randomised 392 people. Seven studies (Chen 2018; Clark 2015;
Krumholz 2002; Lang 2018; Leventhal 2011; Rainville 1999; Shively
2013) randomised fewer than 100 participants.
For the majority of the 47 included studies, the mean or median
age of participants was between approximately 67 and 80 years
old. Participants in nine studies were considerably younger on
average, with median or mean ages under 65 years (Capomolla
2002; Cavusoglu 2017; Chen 2018; Clark 2015; de Souza 2014;
Dunbar 2014; Kasper 2002; Mao 2015; Mehralian 2014). The mean
age of participants in Gonzalez-Guerrero 2014 was approximately
85 years old.
The severity of heart failure ranged across studies, with the majority
(N = 37) of the studies reporting a summary statistic for participants'
baseline NYHA class. The percentage of participants with moderate
(class III) or severe (class IV) heart failure ranged from under
one per cent in Tsuchihashi-Makaya 2013, approximately 6% in
Brotons 2009 and 16% in Lopez 2006, to 75% or more in 14 of
the studies (Berger 2010; Blue 2001; Chen 2018; Del Sindaco 2007;
Doughty 2002; Ducharme 2005; Jaarsma 2000; Mao 2015; Ong 2016;
Rainville 1999; Salehitali 2009; Stromberg 2003; Thompson 2005;
Wierzchowiecki 2006). The mean (SD) NYHA class in Gonzalez-
Guerrero 2014 was 2.5 (0.7) in the intervention arm and 2.3 (0.8) in
the control arm. Mehralian 2014 reported that the most prevalent
class was III (67.3% of the intervention group and 82% of the control
group had this level of disease).
Fewer than half of the studies were carried out in Europe (N = 23).
Others took place in the USA (N = 11), China (N = 3), Canada (N =
2), Australasia (N = 2), Iran (N = 2), and one each in Japan, Brazil,
Taiwan and Turkey. Seven of the studies therefore took place in
World Bank-defined upper middle-income countries, and the rest
in high-income countries (World Bank 2018).
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As would be expected in the generally elderly participants of these
studies, many people had comorbid conditions. For example, of the
38 studies reporting diabetes, the proportion of people with this
comorbidity ranged from 11% (Agren 2012; Leventhal 2011), to the
majority (Bekelman 2015; Mao 2015), or even 100% (Dunbar 2014),
as this was an inclusion criterion for that study.
Twenty-one studies were publicly funded, two by charities
(Jaarsma 2000; Yu 2015a), and four by a combination of public and
charity funds (Cline 1998; Leventhal 2011; Mejhert 2004; Ong 2016).
A further two studies were funded by charity and industry (Jaarsma
2008; Kimmelstiel 2004), and three more by a combination of
charity, public, and industry support (Holland 2007; Krumholz
2002; Tsuchihashi-Makaya 2013). Five studies were solely industry-
funded (Berger 2010; Doughty 2002; Ducharme 2005; Kasper 2002;
Thompson 2005), and two more were supported by both industry
and public funding (Brotons 2009; Tsuyuki 2004). The remaining
nine studies did not report their funding sources (Bohmer 2011;
Capomolla 2002; Del Sindaco 2007; Mehralian 2014; Nucifora 2006;
Rainville 1999; Shively 2013; Stewart 1999a).
Categorising the interventions
We used Riegel's classification (Riegel 2001), to group the
interventions based on the content and nature of the interventions
as they were described in the papers. In practice there appears
to be considerable overlap between these disease management
models and it was not always easy to classify them. Table 1
summarises some of the similarities and diIerences between
the interventions. One intervention involved a day hospital,
heart failure-management programme (Capomolla 2002), and
was diIicult to categorise. Two more did not fit into any
of the classifications. Agren 2012 was an educational and
psychological support intervention, and Shively 2013 was a
self-management support intervention. We considered that the
remaining interventions fell predominantly into the following
groups:
• 28 studies and the intensive intervention arm of Jaarsma 2008
were variations on the case management approach.• We classified seven studies as clinic-based intervention models
(but with aspects of case management, i.e. telephone follow-up;
Bohmer 2011); Cline 1998; Doughty 2002; Jaarsma 2008 (basic
intervention arm); Mejhert 2004; Stromberg 2003; Thompson
2005)• Nine studies had a multidisciplinary approach (Bekelman 2015;
Bernocchi 2017; Cavusoglu 2017; Chen 2018; Del Sindaco
2007; Ducharme 2005; Gonzalez-Guerrero 2014; Mao 2015;
Wierzchowiecki 2006). Of these, Gonzalez-Guerrero 2014 was
unusual in that the intervention took place in a geriatric day care
hospital, but since the intervention involved a multidisciplinary
team we included it in this group.
We also attempted to classify the studies according to the
key person delivering the intervention. A specialist nurse was
responsible for delivering the intervention in 19 of the studies
(Berger 2010; Blue 2001; Brotons 2009; Clark 2015; Cline 1998,
Dunbar 2014; Jaarsma 2000, Jaarsma 2008 (basic intervention),
Kasper 2002, Kimmelstiel 2004, Krumholz 2002 Lang 2018;
Leventhal 2011; Naylor 2004, Nucifora 2006; Stewart 1999a,
Stromberg 2003, Thompson 2005; Tsuchihashi-Makaya 2013). A
pharmacist predominantly delivered the intervention in three
studies (Holland 2007; Lopez 2006; Rainville 1999), and a nurse or
a community nurse in 11 (Agren 2012; Aldamiz-Echevarria 2007;
DeBusk 2004; de Souza 2014; Kwok 2008; Mehralian 2014; Mejhert
2004; Ong 2016; Salehitali 2009; Shively 2013; Yu 2015a). In 13 of the
studies, the intervention appeared to be delivered by two or more
professionals, although this did not necessarily mean they met
the Riegel 2001 formal classification for multidisciplinary models,
(Bekelman 2015; Bernocchi 2017; Bohmer 2011; Capomolla 2002;
Cavusoglu 2017; Chen 2018; Del Sindaco 2007; Doughty 2002;
Ducharme 2005; Gonzalez-Guerrero 2014; Jaarsma 2008 (intensive
intervention); Mao 2015; Wierzchowiecki 2006). The intervention
described by Atienza 2004 was delivered by a cardiologist,
and Tsuyuki 2004 describes the research co-ordinator as being
responsible for delivering the intervention.
Content of the interventions as described in the published
reports.
Table 1 lists the components of the interventions as described in the
published papers. Overall there appeared to be little diIerence in
reported components between the three groups of interventions.
However, it may be that the reports of the components of the
diIerent interventions were not detailed enough or systematic
enough to confidently make this comparison.
Telephone follow-up
The majority (40 out of 47) of the studies in the updated review
included telephone follow-up or help-line access for participants.
Education
Education delivered to participants, and in some cases, carers,
appears to have been a major component in 31 of the studies
included in this review. The education typically covered the
diagnosis, symptoms and treatment of heart failure, and when to
seek expert help.
Self-management
The majority (N = 33) of the interventions actively sought to
promote better patient self-management, and participants were
sometimes given heart failure diaries or notebooks to aid self-
management.
Weight monitoring
Thirty of the studies mentioned daily or regular weight monitoring,
or the importance of weight monitoring. Participants in these
studies were oNen given charts or diaries in which to log their
weight.
Sodium restriction or dietary advice, or both
Thirty-one of the studies mentioned participants receiving dietary
advice, oNen from the nurse at a home visit.
Exercise recommendation
Just under half (N = 23) of the studies mentioned advice about
exercise in stable heart failure or exercise promotion.
Medication review
Study reports mentioned that there was the opportunity to review
participants’ medications as part of the disease management
programme in 25 of the studies.
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Social support and psychological support
Only a minority (N = 10) of the studies specifically oIered social or
psychological support to participants included in the intervention.
Excluded studies
As shown in Figure 1, we excluded 217 studies in 263 references.
Of these, 75 described an intervention other than a specific heart
failure disease management programme, and 15 did not have
'usual care' as a comparator. We excluded a further 21 studies
because they had under six months' follow-up, and 46 because
they were not RCTs. heart failure hospital admission was not an
inclusion criterion for 35 of the excluded studies, and 17 had the
wrong participants. We excluded a further eight papers for other
reasons.
Risk of bias in included studies
Our risk of bias assessments are summarised in Figure 2 and Figure
3.
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Figure 2.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study
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Figure 2.   (Continued)
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Figure 2.   (Continued)
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Figure 3.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
 
Allocation
The majority of studies (N = 35) reported adequate methods
of random sequence generation, and we judged them to be at
low risk of bias for this domain. It was unclear if the remaining
12 studies had used appropriate randomisation methods or
not, as they gave insuIicient details in the publication, beyond
'randomised' (Bohmer 2011; Capomolla 2002; Cavusoglu 2017;
Clark 2015; DeBusk 2004; Del Sindaco 2007; Mehralian 2014; Mejhert
2004; Nucifora 2006; Salehitali 2009; Tsuchihashi-Makaya 2013;
Wierzchowiecki 2006). We did not judge any studies to be at high
risk of bias for random sequence generation.
We assessed only 18 studies as having a low risk of selection bias
relating to adequate allocation concealment. The majority (N =
28) did not describe this so we judged them to have an unclear
risk for this domain. We assessed one study (Del Sindaco 2007), as
having a high risk of bias, as eligible patients were randomised,
and informed consent was then given on the basis of information
relevant to the allocated study group, so selection bias is likely if
people could have withheld consent if they did not like their group
allocation.
Blinding
For completeness, we assessed 'blinding of participants and
personnel'. However, all studies were at high risk of performance
bias due to the nature of the interventions. This has an impact
on the visual impact of overall risk of bias in Figure 2 and Figure
3, which perhaps detracts from the more meaningful diIerences
between studies.
We assessed detection bias separately for objective outcomes, and
the subjective, participant-reported outcome, quality of life. For
objective outcomes, we assessed 30 of the studies as having a low
risk of detection bias. For 13 studies, it was unclear whether or not
outcome assessors were blinded to group allocation (Atienza 2004;
Bekelman 2015; Bohmer 2011; Doughty 2002; Dunbar 2014; Lopez
2006; Mejhert 2004; Nucifora 2006; Rainville 1999; Salehitali 2009;
Tsuchihashi-Makaya 2013; Tsuyuki 2004; Wierzchowiecki 2006). We
considered four studies to be at high risk of bias for this domain
(Capomolla 2002; Cavusoglu 2017; Clark 2015; Shively 2013).
We assessed the majority of studies (N = 31) as being at high risk of
detection bias for subjective outcomes, since the unblinded nature
of the trials meant that assessments of quality of life could be
influenced by knowledge of treatment allocation. The 16 studies
assessed as low risk did not report quality of life.
Incomplete outcome data
We assessed half of the studies as having a low risk of attrition bias
(N = 24). It was unclear in 18 studies whether or not attrition bias
was likely to aIect the results. We considered five of the studies to
be at high risk of attrition bias; two were particularly aIected by low
levels of completion for quality-of-life assessments (Agren 2012;
Wierzchowiecki 2006), two had a noticeably higher attrition rate in
the intervention group than in the usual-care group (Jaarsma 2000;
Yu 2015a), and Leventhal 2011 was stopped early aNer only 42 of
the required 300 participants had been recruited, so outcome data
could not be collected appropriately.
Selective reporting
It was diIicult to assess this domain for many of the older
studies, as trial registrations were not available in many cases.
We assessed the majority of studies (N = 38) as being at unclear
risk of reporting bias, as we could not identify published protocols
or trial registrations for these. We assessed six studies as being
at low risk of reporting bias (Bernocchi 2017; Dunbar 2014; Lang
2018; Nucifora 2006; Ong 2016; Thompson 2005), since publications
reported all expected outcomes. We considered de Souza 2014;
Gonzalez-Guerrero 2014; Tsuchihashi-Makaya 2013 to be at high
risk of reporting bias, as there were diIerences in outcomes listed
in protocols or trials registries and those published.
Other potential sources of bias
There were no other potential sources of bias noted for 31 of
the studies. We assessed the risk of other bias in 13 studies
as unclear (Agren 2012; Bohmer 2011; Chen 2018; Cline 1998;
Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
24
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Doughty 2002; Krumholz 2002; Mehralian 2014; Nucifora 2006;
Shively 2013; Stewart 1999a; Stromberg 2003; Tsuchihashi-Makaya
2013; Wierzchowiecki 2006).
We suspected a high risk of other bias for three studies.
The NCT record for Berger 2010 suggested that this study
had been terminated, but gave no reason for early stoppage.
Participants in the intervention arm also had more severely
reduced leN ventricular systolic function at baseline. Not all of the
intervention group in the trial by Capomolla 2002 received all the
components of the intervention. Mao 2015 gave participants in
the trial guideline-based medications in addition to the disease
management programme, and post-hoc analyses that adjusted
for this indicated that there was no evidence for the disease
management programme lowering all-cause death rates once the
eIect of the medication had been accounted for.
E9ects of interventions
See: Summary of findings for the main comparison Case
management compared to usual care for heart failure; Summary
of findings 2 Clinic-based intervention compared to usual care
for heart failure; Summary of findings 3 Multidisciplinary disease
management programmes compared to usual care for heart failure
We have presented the results of Capomolla 2002 separately
because of the unique characteristics of both the intervention
and the participants it was directed at (see Characteristics of
included studies Table). This was a day hospital programme
that oIered a number of tailored therapies and specialist
support (cardiovascular risk stratification, correction of risk factors
for haemodynamic instability; intravenous therapy; laboratory
examinations). Similarly, two other studies (Agren 2012; Shively
2013), had unusual interventions that did not fit into any of the
three categories of disease management programmes, so could not
be included in meta-analyses of the main interventions. Agren 2012
was an educational and psychological support intervention, and
Shively 2013 was a self-management support intervention. Results
of these three studies are presented under 'Other' in the section
below.
Case management versus usual care
Mortality due to heart failure
None of the case management studies reported deaths due to heart
failure.
All-cause mortality
Twenty-six studies reported all-cause mortality (RR 0.78, 95% CI
0.68 to 0.90; participants = 6903; studies = 26; I2 = 30%, low-quality
evidence; Analysis 1.1). The median follow-up was 12 months. Lang
2018 reported that there were no deaths in either arm, so we could
not add this study to the meta-analysis. Results suggest that case
management may reduce all-cause mortality. The NNTB is 25 (95%
CI NNTB 17 to NNTB 54), so you could expect one death from any
cause to be averted for every 25 people treated.
The forest plots and statistical tests did not suggest that there was
important heterogeneity. Subgroup analyses by length of follow-
up and by person delivering the intervention did not indicate any
diIerences between subgroups (P = 0.22; P = 0.93, respectively).
We undertook sensitivity analysis, which limited the meta-analysis
to only those studies at low risk of bias for randomisation and
allocation concealment, and at low or unclear risk for incomplete
outcome data (attrition bias). RR 0.67 (95% CI 0.55 to 0.82;
participants = 3514; studies = 11; I2 = 32%), indicates a stronger
eIect, with people receiving case management interventions
having on average a 33% lower risk of all-cause mortality than
people receiving usual care (Analysis 1.4).
Metaregression did not indicate that any individual intervention
components were particularly associated with the success of the
intervention (Table 2).
The funnel plot in Figure 4 was slightly asymmetrical, which may
indicate some publication bias, so resulted in downgrading of the
evidence.
 
Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
25
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 4.   Funnel plot of comparison 1. Case management vs usual care, outcome: 1.1 All-cause mortality - main
analysis
 
Readmissions to secondary care due to heart failure
Twelve case management studies reported data on heart failure
readmissions (RR 0.64, 95% CI 0.53 to 0.78; participants = 2528;
studies = 12; I2 = 51%, moderate-quality evidence; Analysis 1.5).
The median follow-up was 12 months. Case management probably
reduces heart failure readmissions, with the risk of readmission for
heart failure being approximately 36% lower in people participating
in a case management programme compared with those receiving
usual care. The NNTB is 8 (95% CI NNTB 6 to NNTB 13), so you could
expect one heart failure readmission to be averted for every eight
people treated.
Statistical tests indicated that there may be substantial
heterogeneity for this outcome. However, subgroup analysis by
length of follow-up did not indicate any diIerence between
subgroups (P = 0.33). Subgrouping by person delivering the
intervention did suggest that there was a diIerence between
groups (P = 0.002), but some subgroups contained few studies.
There was strong evidence for an eIect in the studies with
a specialist nurse (RR 0.58, 95% CI 0.47 to 0.70). The 'other'
category also showed a strong eIect, notably in Atienza 2004,
where the intervention was primarily delivered by a cardiologist.
The subgroups of studies led by non-specialist or community
nurses, or by multidisciplinary teams (within the case management
framework), did not show evidence of an impact on heart failure
readmissions, although there were only single studies in these
groups.
Restricting the analysis of heart failure readmissions to just
those studies at low risk of bias for randomisation, allocation
concealment and low or unclear risk of attrition, gave a similar
eIect to the main analysis (RR 0.62, 95% CI 0.50 to 0.77; participants
= 741; studies = 4; I2 = 0%; Analysis 1.8).
Three studies reported data in a way that meant that we
could not include them in the meta-analysis of heart failure
readmissions. Kimmelstiel 2004 reported the mean (SE) number of
hospitalisations for heart failure per patient-year to be 0.74 (0.10)
in the intervention group and 0.73 (0.10) in the control group, RR
1.02, P = 0.93. Brotons 2009 reported the mean number of heart
failure readmissions per patient to be 1.01 in the intervention arm
and 1.3 in the control group. Aldamiz-Echevarria 2007 reported the
total number of unplanned heart failure readmissions to be 55 and
57 in the intervention and control arms, respectively.
The funnel plot in Figure 5 is asymmetrical, suggesting possible
publication bias.
 
Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
26
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 5.   Funnel plot of comparison 1. Case management vs usual care, outcome: 1.5 HF readmissions - main
analysis
 
Additional Table 2 shows the results of the meta-regression. The
RR for heart failure readmission in interventions with a strong
education component was smaller than the RR for interventions
that were not largely educational (ratio of risk ratios (RRR) 0.65,
95% CI 0.46 to 0.93; P = 0.02). This would suggest that on
average, the RR for case management versus usual care in studies
with a strong educational component was only 0.65 times the
size of the RR for interventions without a strong educational
component versus usual care. Since a lower RR indicates fewer
heart failure readmissions, this would suggest that a strong
educational component is an advantage.
There was some evidence from the meta-regression that a self-
management component may have some slight association with
a lower ratio of RR (RRR 0.72, 95% CI 0.48 to 1.07; P = 0.09), but
the CI indicates that there may be no real diIerence. Conversely,
interventions with a weight management component may actually
have higher RR than those without (RRR 1.53, 95% CI 1.07, 2.18;
P = 0.03). There may be other diIerences between studies that
are not captured by the meta-regression of individual components,
however, so it is important not to over-interpret these findings.
All-cause readmissions to secondary care
Fourteen case management studies reported data on all-cause
readmissions in a format that we could include in the meta-analysis
(RR 0.92, 95% CI 0.83 to 1.01; participants = 4539; studies = 14;
I2 = 43%, moderate-quality evidence; Analysis 1.9). The median
follow-up was 10.5 months. Results suggest that case management
probably slightly reduces all-cause readmissions.  The NNTB is
26 (95% CI NNTH 204 to NNTB 12), so you could expect one
readmission for any cause to be averted for every 26 people treated
- however the CI ranges from one person potentially being harmed
(i.e. one additional readmission) for every 204 treated, to one
person avoiding readmission for every 12 people treated.
The I2 result means that moderate heterogeneity may be present.
Subgroup analysis by length of follow-up did not indicate any
diIerence between studies with six months' follow-up and those
with longer than six months follow-up (P = 0.19). There was
evidence of a diIerence between subgroups of studies depending
on who primarily delivered the intervention (P = 0.09). Notably,
the studies where a specialist nurse delivered the intervention
found that readmissions for any cause were fewer in the case
management groups (RR 0.85, 95% CI 0.73 to 0.99). There was only
one study where a pharmacist led the intervention, and Lopez 2006
reported lower readmissions in this intervention group (RR 0.68,
95% CI 0.45 to 1.03).
Sensitivity analysis restricting to studies at low risk of bias in key
domains found similar results to the main analysis (RR 0.87, 95% CI
0.74 to 1.02; participants = 2217; studies = 6; I2 = 42%; Analysis 1.12).
Six other studies reported data on all-cause readmissions, but not
in a format that could be included in the meta-analysis. Kimmelstiel
2004 reported that the mean (SE) number of hospitalisations per
patient-year was 1.48 (0.14) in the case management group and
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1.40 (0.13) in the usual-care group, RR 1.05, P = 0.70. Nucifora 2006
reported that the mean (SD) readmissions per patient were 0.8 (1.2)
for both arms. Aldamiz-Echevarria 2007 reported the total number
of unplanned readmissions (not per patient), to be 125 and 118
in the intervention and control arms, respectively. Holland 2007
reported that 72/169 intervention participants and 70/170 control
group had no emergency hospital readmissions within six months.
The mean (95% CI) number of readmissions per person in Dunbar
2014 was 0.67 (0.46 to 0.87) in the intervention group and 0.95
(0.63 to 1.33) in the control group; P = 0.21. Salehitali 2009 reported
a higher rate of readmissions for any cause in the control group
compared with the case management group (intervention 1.65 ±
1.01, control 2.74 ± 1.07; P = 0.01).
Metaregression (Table 2) indicated that the only individual
intervention component that showed any particular impact on the
RR was weight management, which appeared to result in a RR of
case management versus usual care that was approximately 33%
higher for interventions that included this component (ratio of RR
1.32 (1.09, 1.60); P = 0.008).
The forest plot in Figure 6 is broadly symmetrical so does not
suggest publication bias aIects this outcome.
 
Figure 6.   Funnel plot of comparison 1. Case management vs usual care, outcome: 1.9 All-cause readmissions - main
analysis
 
Adverse e%ects
No case management studies reported adverse eIects.
Health-related quality of life
Eight studies with a total of 1595 participants reported MLHFQ data
in a format that could be incorporated into a meta-analysis. The
median follow-up was six months. Holland 2007 only reported the
mean diIerence between groups, not the actual data, so we used
the generic inverse variance method for the meta-analysis. Where
studies additionally reported another outcome (such as EQ-5D,
SF-36), we did not included these results in this section to avoid
double counting such studies.
Analysis 1.13 shows the eight studies on a forest plot, but due to
high heterogeneity (I2 = 76%), we have not shown the pooled eIect
as it is not meaningful. Subgroup analysis indicated that there may
be a diIerence between studies reporting at six months and those
with longer follow-up (P = 0.01). However, this looks to be due to the
inclusion of two small studies that reported better improvement in
quality of life in the usual-care group than in the case management
group, both of which had the shorter period of follow-up. High
attrition for this outcome led to us downgrading the GRADE rating.
As our methods planned only to conduct sensitivity analysis for
primary outcomes, we did not explore the impact of high attrition
for this secondary outcome.
Three other studies reported using the MLHFQ tool, but did not
report results in a way that could be incorporated into the meta-
analysis. In a randomly selected subsample of 68 participants,
Stewart 1999a reported the median (interquartile range (IQR))
change in MLHFQ at six months to be −17 (−35 to −8) in the
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case management group (random sample of N = 29) and −12 (−35
to −8) in the usual-care group (random sample N = 24). Naylor
2004 reported MLHFQ scores at the end of 52 weeks, but only
with reference to quartiles, and for 75 out of 117 people in the
intervention group who completed a baseline assessment, and 74
out of 118 in the control group. At the end of follow-up, the quartile
scores were 2.8 ± 1.8 in the case management group and 2.6 ± 1.7
in the usual-care group. In this context, a score of two indicates a
first Quartile Score (435) and a score of three the second Quartile
Score (418 to 35). Although Atienza 2004 reported that 220 out of
257 participants completed the MLHFQ at one year's follow-up, it
was not clear how many participants there were in each group, so
we could not add these data to the meta-analysis. At the end of
follow-up, the mean score was 28.9 in the intervention group and
35.5 in the control group (no SD given; P = 0.01).
Four studies, which also did not report the MLHFQ, used diIerent
tools. We have not added these to the meta-analysis since the
direction of eIect is diIerent and the magnitude of scores may not
be comparable. Whilst it is possible to correct for this in the meta-
analysis, the high degree of heterogeneity already observed means
that adding further, and perhaps less compatible, studies is unlikely
to be helpful, so these are summarised below.
Lopez 2006 reported very similar EuroQol (EQ-5D) scores for
intervention and control group participants. By 12 months there
was a small diIerence between the two groups, but with high SDs
(64.0 (15.4) versus. 60.6 (17.8)).
Tsuchihashi-Makaya 2013 used the SF-8 tool to measure quality
of life. 70 of the 79 intervention group participants and 68 of the
82 control group participants completed the questionnaire at 12
months. For the physical component score, the mean (SD) score
in the intervention group was 44 (8) compared with 42 (10.5) in
the control group (P = 0.36). For the SF-8 Mental component, the
scores were 48 (8) and 46 (7.5) for intervention and control groups,
respectively (P = 0.05).
Mehralian 2014 used the Iranian version of the SF-36, and reported
that the overall score was higher in the intervention group than
in the control group (P < 0.05), but did not give the scores
themselves. For the individual components, the role-physical
domain was similar in both groups at baseline but higher in the
intervention group aNer six months (intervention: 55.74 ± 11.65
versus control: 51.32 ± 7.51; P < 0.05). The role-emotional domain
was similar at baseline and remained so at six months (58.34 ± 12.27
(intervention) versus 56.43 ± 8.67 (control); P > 0.05).
Clark 2015 used the Kansas City Cardiomyopathy Questionnaire
(KCCQ). On this scale, higher scores reflect better quality of life
and a five-point change in total score is a clinically important
diIerence. In this small study, the large SDs indicate a lack of
evidence for a diIerence between groups, either at baseline or the
end of nine months' follow-up. At baseline, the intervention group's
mean (SD) score was 55.38 (23.98), increasing to 62.21 (21.80) aNer
nine months. For the control group, the mean (SD) score was 63.08
(22.90) at baseline and 60.43 (24.12) at nine months.
Jaarsma 2000, a largely educational case management
intervention study, suIered severe attrition and we assessed it to
be of lower quality. This study assessed quality of life for three
dimensions (functional capabilities, symptoms, and psychosocial
perceptions) but did not appear to use a validated tool so we have
not included it here.
The funnel plot (Figure 7) is broadly symmetrical, so does not
suggest publication bias aIects this outcome.
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Figure 7.   Funnel plot of comparison 1. Case management vs usual care, outcome: 1.13 Quality of life (MLHFQ mean
score at end of follow-up)
 
The very low-quality evidence indicated by GRADE assessment
means that we are uncertain about the eIect of case management
on quality of life.
Cost-e%ectiveness
Four of the case management programmes were the subject of cost-
eIectiveness analyses. Ruschel (2018), reports a cost-eIectiveness
analysis of the de Souza 2014 study. The incremental cost-
eIectiveness ratio (ICER) was BRL 585 per hospital readmission
visit prevented, which was favourable from the personal health
services perspective, and dominant when analysed from the
perspective of private healthcare. Reily (2015), reports a cost-
eIectiveness analysis of the Dunbar 2014 study, finding that the
intervention lowered costs without sacrificing quality-adjusted life
years (QALYs). The eIect diIerence for change in QALY using the
change in EQ-5D from baseline to six months was 0.04 (-0.04 to
0.11).
Two economic evaluations of the COACH study (Jaarsma 2008)
were carried out. Cao (2013), stratified participants into diIerent
risk categories based on predicted 18-month mortality risk. Using
a threshold value of EUR 10,000 per life-year, they found it was
83% likely that the intensive support option would be optimal for
the low-risk participants, and 84% likely that the basic support
option would be best for the high-risk participants. Postmus (2011),
also performed an economic evaluation of the COACH study. Basic
support was more cost eIective than care as usual, and the ICER
for intensive support was EUR 8915 per QALY. For participants with
severe heart failure, cost per QALY compared with usual care was
EUR 77,335 for basic support, and EUR 59,289 for intensive support.
Moertl (2013), published a cost-utility analysis of the Berger
2010 study. The incremental cost-eIectiveness ratio for the case
management intervention compared with usual care was EUR 3746
per QALY gained.
Various case management studies reported the costs of their
programmes, although the wide range in dates of studies
and diIerent locations complicates interpretation. Lang 2018
estimated that the average cost of the REACH-HF intervention was
GBP 362.61. Lopez 2006 reported that the total cost per participant
was EUR 578 lower in the intervention group compared with
control. The intervention's mean cost (USD 11,315) was higher than
the control group's (USD 8789) in the Kasper 2002 study. Kwok
2008 reported that public healthcare and personal care costs were
similar in both groups. Naylor 2004 reported mean cost savings of
USD 4845 per participant for the case management intervention.
Tsuyuki 2004 calculated the cost of care for all-cause events, and
these were CAD 2463 lower in the patient support programme
compared with usual care. Salehitali 2009 reported lower costs
in the intervention group compared with the case management
group (intervention: IRR 2,313,000 ± 151,490; control: IRR 2,736,800
± 167,360).
The GRADE rating for this outcome was low, and results indicate
that case management interventions may reduce costs and
improve cost-eIectiveness slightly, compared with usual care.
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Clinic-based intervention versus usual care
We did not construct funnel plots to assess publication bias for any
of the outcomes, as there were too few studies.
Mortality due to heart failure
None of the seven clinic-based intervention studies reported
mortality due to heart failure as a specific outcome.
All-cause mortality
We included all seven of the clinic-based intervention studies in the
meta-analysis of the eIect of the intervention on mortality from any
cause; the median follow-up was 12 months (RR 0.87, 95% CI 0.68 to
1.10; participants = 1686; studies = 7; I2 = 37%, low-quality evidence;
Analysis 2.1). Overall, the clinic-based intervention model may
result in little to no diIerence in all-cause mortality. The NNTB is 29
(95% CI NNTH 37 to NNTB 12), so you could expect one death from
any cause to be averted for every 29 people treated, but uncertainty
associated with the wide confidence interval means you may find
one extra all-cause death for every 37 people treated, or avoid one
death for every 12 people treated.
Heterogeneity may not be important for this outcome according to
statistical tests, but the forest plot suggests some small diIerence
in eIect. However, subgrouping by length of follow-up (Analysis
2.2), or by person delivering the intervention (Analysis 2.3), did not
indicate any important diIerences between subgroups (P = 0.38
and P = 0.17, respectively).
Sensitivity analysis restricted to only those studies at low risk of
bias for randomisation and allocation concealment, and to low or
unclear risk of bias for attrition gave a diIerent result to the main
analysis (RR 0.65, 95% CI 0.23 to 1.88; participants = 296; studies
= 2; I2 = 82%; Analysis 2.4). The wide confidence intervals for this
sensitivity analysis indicate a lack of evidence for eIect, as there are
only two small studies included.
As one of the clinic-based intervention studies was a cluster-RCT
(Doughty 2002), we performed a sensitivity analysis excluding this
study (Analysis 2.5). There was no substantial diIerence between
this and the main result, although the confidence intervals and
heterogeneity both increased with removal of Doughty 2002.
Readmissions to secondary care due to heart failure
Only two clinic-based intervention studies (Jaarsma 2008; Mejhert
2004), reported heart failure readmissions in a format that could
be included in a meta-analysis, with a median follow-up of 18
months. Pooling the two studies indicated that there is probably
little or no diIerence in heart failure readmissions between clinic-
based interventions and usual care (RR 1.01, 95% CI 0.87 to 1.18;
participants = 887; studies = 2; I2 = 0%, moderate-quality evidence;
Analysis 2.6). As the RR is over 1.0, we calculated the NNTH, and
its interpretation is more complex due to the inclusion of the null.
The NNTH is 290 (95% CI NNTH 17 to NNTB 23), so you could
potentially expect one additional heart failure readmission for
every 290 people treated; but the confidence interval goes from
one person avoiding readmission for every 17 treated to one person
being readmitted for every 23 treated.
Only two studies reported data for this outcome, so we did not
carry out any subgroup analysis or sensitivity analysis. Doughty
2002 reported that there were 36 readmissions for heart failure in
the intervention arm and 65 in the control arm, but did not report
the number of participants with a readmission, so we could not pool
these data.
All-cause readmissions
We pooled four studies for this outcome (RR 0.90, 95% CI 0.72
to 1.12; participants = 1129; studies = 4; I2 = 65%, low-quality
evidence; Analysis 2.9), with a median follow-up of 15 months.
The low-quality evidence suggests that clinic-based interventions
may result in little or no diIerence in all-cause readmissions. The
NNTB is 19 (95% CI NNTH 16 to NNTB 7), so you could expect
one readmission from any cause to be averted for every 19 people
treated, but the uncertainty due to the wide confidence interval
means that there could be an additional readmission for every 16
people treated, or one admission avoided for every seven people
treated.
Heterogeneity was substantial for this outcome. Subgroup analysis
indicated that there may be a diIerence between studies with
six months' follow-up, and those with longer follow-up (P = 0.03;
Analysis 2.10). The risk of readmission following six months of
a clinic-based intervention appears to be around half that of
the usual-care arm (RR 0.51, 95% CI 0.29 to 0.91). By contrast,
there is no evidence that a clinic-based intervention reduces the
readmission rate in the longer studies. However, the test for
subgroup diIerences may well be underpowered given the paucity
of studies and the small size of the only trial with six months' follow-
up. Subgroup analysis by person delivering the intervention did
not indicate any important diIerences between groups (P = 0.27;
Analysis 2.11).
It was not possible to conduct the sensitivity analysis for this
outcome as only one study (Cline 1998), was at low risk of bias for
both randomisation method and allocation concealment.
Two other clinic-based intervention studies reported readmission
rates in a diIerent format. Doughty 2002 reported that the all-
cause readmission rate at 12 months was 1.37 readmissions
per participant per year in the intervention arm, compared with
1.84 in the usual-care group, rate diIerence = 0.47 per patient
per year (95% CI 0.16 to 0.78). Stromberg 2003 reported total
number of readmissions but not the number of participants
with readmissions. The total number of readmissions was similar
between groups (82 in the intervention arm and 92 in the control
arm, P = 0.31). However, the mortality rate was three times higher
in the control group, and once this was adjusted for in the analysis,
Stromberg 2003 reported that the intervention group tended
towards fewer readmissions.
Adverse e%ects
No clinic-based intervention model studies reported adverse
eIects.
Health-related quality of life
Four of the clinic-based intervention studies reported quality-of-
life assessments, but it was not possible to pool these due to
diIerences in tools used, and the way the data were reported.
The median follow-up was 12 months. Doughty 2002 reported that
there was no diIerence in MLHFQ total scores between intervention
and control participants at one year. Thompson 2005 reported that
the mean change in MLHFQ total score was −14.2 in the clinic-based
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intervention group and −13.7 in the usual-care group, but only
46 out of 106 trial participants completed a questionnaire. Cline
1998 and Mejhert 2004 reported the Nottingham Health Profile,
with mean (SD) scores of 25.3 (22.2) versus 23.4 (22.2) for clinic-
based intervention and usual-care groups, respectively, in the one-
year Cline 1998 study. The longer study by Mejhert 2004 reported
the total mean (SD) score at 18 months to be 134 (11*) in the
intervention group and 130 (125) in the usual-care group. The SD
denoted by * is assumed to be a typographic error, as the total
(SD) score at 12 months is 136 (107). The quality of evidence for
this outcome was low, indicating that the clinic-based interventions
may result in little or no diIerence in quality of life.
Costs
Only two clinic-based studies reported data on costs. Bohmer 2011
reported a cost saving of EUR 193.57 (EUR 1382 per person over six
months).
Cline 1998 reported that the lower readmission rate in the
intervention group in their study contributed to a mean reduction
in overall annual costs of USD 1300 per participant (P = 0.07) over 12
months. The GRADE quality assessment was low for this outcome,
indicating that clinic-based interventions may reduce costs slightly.
Multidisciplinary interventions versus usual care
We did not construct funnel plots to assess publication bias for any
of the outcomes, as there were too few studies.
Mortality due to heart failure
Only two of the nine multidisciplinary intervention trials reported
heart failure mortality in a way that could be included in the meta-
analysis (RR 0.46, 95% CI 0.23 to 0.95; participants = 277; studies = 2;
I2 = 0%, very low-quality evidence; Analysis 3.1). The median follow-
up was 12 months. The NNTB is 12 (95% CI NNTB 9 to NNTB 126),
so you could expect one death due to heart failure to be averted for
every 12 people treated.
There was no indication of heterogeneity. As there were only two
studies, we did not carry out any subgroup or sensitivity analysis for
this outcome. We are uncertain about the eIect of multidisciplinary
disease management programmes on heart failure mortality.
All-cause mortality
The pooled analysis for all-cause mortality (RR 0.67, 95% CI 0.54
to 0.83; participants = 1764; studies = 8; I2 = 0%, moderate-
quality evidence; Analysis 3.2), indicates that multidisciplinary
teams probably reduce all-cause mortality, with people receiving
this intervention having approximately 33% less risk of death from
any cause than people receiving usual care. The NNTB is 17 (95%
CI NNTB 12 to NNTB 32), so you could expect one death from any
cause to be averted for every 17 people treated. One study not in
the meta-analysis (Chen 2018), only reported composite outcomes
of death or all-cause re-hospitalisations, and death or heart failure
readmissions. We contacted the study author but were unable to
get the data for the individual outcomes.
There was no indication of heterogeneity for this outcome and
subgroup analysis by length of follow-up did not indicate any
diIerence between groups (P = 0.37; Analysis 3.3).
Senstivity analysis restricted to only those two studies at low risk
of bias for randomisation and allocation concealment, and at low
or unclear risk of bias for attrition suggested a lack of evidence for
any diIerence between multidisciplinary interventions and usual
care (RR 0.65, 95% CI 0.34 to 1.25; participants = 342; studies = 2;
I2 = 0%; Analysis 3.4). However, this analysis was dominated by the
Ducharme 2005 study, which carried 93.4% of the weight.
Readmissions to secondary care due to heart failure
Five studies of multidisciplinary interventions provided data that
could be pooled (RR 0.68, 95% CI 0.50 to 0.92; participants =
1108; studies = 5; I2 = 48%, low-quality evidence; Analysis 3.5).The
median follow-up was 12 months. Multidisciplinary interventions
may reduce the risk of readmission to hospital due to heart failure.
The NNTB is 11 (95% CI NNTB 7 to NNTB 44), so you could expect one
heart failure readmission to be averted for every 11 people treated.
Heterogeneity was moderate for this outcome, although subgroup
analysis did not suggest any diIerence between six-month studies
and those with longer follow-up (P = 0.13). We did not carry out
the subgroup analysis by person delivering the intervention for
this category, as they were all by their nature multidisciplinary.
Only one study (Ducharme 2005), was at low risk of bias for
randomisation and allocation concealment, so sensitivity analysis
could not be carried out for this outcome.
In addition to the meta-analysis, Wierzchowiecki 2006 reported that
the total number of heart failure readmissions was lower in the
multidisciplinary group than in the usual-care group (13 versus 25,
respectively).
All-cause readmissions to secondary care
Five multidisciplinary studies reported data on all-cause
readmissions that we could pool in meta-analysis (RR 0.85, 95% CI
0.71 to 1.01; participants = 1152; studies = 5; I2 = 40%, low-quality
evidence; Analysis 3.7). The median follow-up was 12 months.
Results indicate that multidisciplinary programmes may slightly
reduce all-cause readmissions. The NNTB is 15 (95% CI NNTH 223
to NNTB 8), so you could expect one readmission for any cause to
be averted for every 15 people treated. However, the uncertainty
associated with the inclusion of the null in the RR's confidence
interval means that one extra readmission for every 223 people
treated and one fewer readmission for every eight people treated
are also possible outcomes.
Statistical tests indicated that there may be some moderate
heterogeneity, but none was detected on visual inspection of the
forest plot. There was no indication that results diIered by length of
follow-up (P = 0.98). As with heart failure readmissions, we assessed
only Ducharme 2005 as being at low risk of bias, so we could not
carry out sensitivity analysis for this outcome.
Two other studies reported data in a format that could not
be pooled, presenting only the total number of readmissions
and not the number of people with at least one readmission.
Bernocchi 2017 reported that there were 21 readmissions in
the multidisciplinary group and 37 in the usual-care group.
Wierzchowiecki 2006 reported fewer all-cause readmissions in the
intervention group than in the control group (22 versus 35).
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Adverse e%ects
Two multidisciplinary intervention trials mentioned adverse
eIects. Bekelman 2015 reported that there were no adverse eIects
in either study arm during the 12-month follow-up, and Bernocchi
2017 noted that, "no major side eIects were recorded" during
the six months of the study. We assessed the evidence as being
of moderate quality using GRADE, suggesting that there may be
little or no diIerence in adverse eIects between multidisciplinary
interventions and usual care.
Health-related quality of life
Due to diIerences in reporting, only two multidisciplinary studies
could be pooled for quality of life, although four others also
reported use of the MLHFQ (MD −12.21, 95% CI −16.43 to −7.99;
participants = 140; studies = 2; I2 = 0%, very low-quality evidence;
Analysis 3.9). The median follow-up was 12 months. The very
low GRADE rating leads to the conclusion that we are uncertain
whether these interventions aIect quality of life. There was no
statistical evidence of heterogeneity and we could not carry out any
subgroup analysis as there were too few studies. We did not carry
out sensitivity analyses for this secondary outcome.
Although Wierzchowiecki 2006 also reported the MLHFQ, data
were unclear and we could not include them. Del Sindaco 2007
reported that quality of life measured by the MLHFQ total score
improved compared to baseline in the multidisciplinary group, but
did not report data for the usual-care arm. Gonzalez-Guerrero 2014
reported the MLHFQ, but only with reference to quartile scores,
where a score of two indicates a first quartile score (26 or higher),
and a score of three, a second quartile score (more than 15 to 25 or
less). At end of follow-up, the mean (SD) value for the intervention
group was 2.7 ± 1.8, compared with 2 ± 1.8 in the control group. The
median (IQR) values were 3 (1 to 4) and 2 (0 to 3), respectively (P
= 0.036). Ducharme 2005 reported a “substantial improvement” in
both emotional and physical quality-of-life scores of the MLHFQ for
multidisciplinary care compared with usual care (P < 0.001) but did
not report the actual scores.
Bekelman 2015 reported quality of life using the KCCQ. The mean
(SD) change from baseline in the intervention group was 13.5 (16.7)
compared with 13.5 (18.6) in the usual-care group.
Costs
Only one multidisciplinary intervention study reported costs
or cost-eIectiveness. In Gonzalez-Guerrero 2014, the cost per
additional QALY for the disease management programme
compared with usual care was EUR 38,274 from a healthcare
perspective and EUR 25,390 from a societal perspective. The GRADE
rating for this outcome was low, suggesting that multidisciplinary
disease management programmes may be cost-eIective from a
societal perspective, but less so from a health-services perspective.
Other types of interventions
This section reports the results of the three studies (Agren 2012;
Capomolla 2002; Shively 2013), that did not fit into one of the three
categories used in this review. The 24-month data from the study
by Agren 2012 were reported by Liljeroos 2015.
Mortality due to heart failure
None of the studies reported mortality due to heart failure.
All-cause mortality
The Agren 2012 long-term follow-up (Liljeroos 2015), reported that
all-cause mortality was lower in the intervention group (12/71,
17%) than in the usual-care group (22/84, 26%).
Readmissions due to heart failure
ANer 24 months, 31 out of 71 participants (38%) of the Agren
2012 study's intervention group were readmitted for heart failure,
compared with 33/84 (34%) in the control group; P = 0.64 (reported
by Liljeroos 2015).
All-cause readmissions
Capomolla 2002 noted a substantial reduction in hospital
readmissions in the intervention group (total number of hospital
readmissions at mean 12 (SD 3) months' follow-up: 13 versus 78,
P < 0.00001), but the generalisability and quality of this study are
very unclear. It is also unclear if these are all-cause readmissions or
readmissions for haemodynamic instability. Capomolla 2002 also
reported that eight day-hospital participants and 35 usual-care
participants had at least one rehospitalisation during follow-up (P
< 0.05).
The number of people with at least one all-cause readmission in
the long-term follow-up of the Agren 2012 study was reported by
Liljeroos 2015. In the intervention group, 51 out of 71 participants
(72%) were readmitted, compared with 58 out of 84 participants
(68%) in the control group; P = 0.72.
Shively 2013 reported data on hospital readmissions and
emergency department visits at six months' follow-up, with no
statistically significant diIerences reported between intervention
and control groups. At six months, the mean (SD) number of
hospital admissions per person was 0.21 (0.41) in the intervention
group and 0.32 (0.48) in the usual-care group.
Adverse e%ects
None of the 'other' studies reported adverse eIects.
Quality of life
Capomolla 2002 reported the time trade oI method for assessing
quality of life. In the day-hospital group this was 0.72 (SD 0.17),
meaning that participants were willing to trade 10 years of their
present health for 7.2 years of excellent health. In the usual-care
group, the mean (SD) was 0.63 (0.22), indicating that participants
were willing to trade 6.3 years of their present health.
Agren 2012 reported quality of life using the SF-36 tool. The mental
component score was very similar at end of follow-up in both
groups (intervention −4.55 (11.2); control −4.22 (11.9); P = 0.88). The
physical component score was also similar at 12 months (−1.9 (9.8)
versus −0.5 (7.9) for intervention and control, respectively; P = 0.39).
Costs
Capomolla 2002 reported a higher QALY for the day-hospital group
than the usual-care group (79.4 versus 70.5, P = 0.01). The cost/
utility ratio was better for the day-hospital model, at USD 2244
compared with USD 2409 for the usual-care group. They also
reported a cost saving of USD 1068 per QALY gained.
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D I S C U S S I O N
Summary of main results
This updated review contains 47 RCTs of disease management
interventions. Of these, 28 RCTs were of case management
interventions, seven were clinic-based interventions, and nine had
a multidisciplinary approach. One of the clinic-based studies also
had a case management arm. Three RCTs had interventions that
we could classify into one of these groups. The 47 RCTs contained
a total of 10,869 participants. We have summarised results for each
main intervention category in Summary of findings for the main
comparison; Summary of findings 2; and Summary of findings 3.
Mortality due to heart failure was poorly reported, with
many studies only reporting cardiovascular-related mortality.
There were no data for this outcome for the case
management interventions, nor for clinic-based interventions. Two
multidisciplinary interventions reported this outcome, but we
assessed the evidence to be of very low-quality, so we are uncertain
about their eIect on heart failure mortality.
Mortality from any cause was reported for all three types of
interventions. ANer taking into consideration the GRADE quality
ratings, results indicated that case management interventions
may reduce all-cause mortality, clinic-based intervention models
appear to have little to no eIect, and multidisciplinary
interventions probably reduce all-cause mortality.
Heart failure readmissions to secondary care were not always
distinguished from cardiovascular-related readmissions. Where
studies reported this outcome separately, we found that
case management interventions probably reduce heart failure
readmissions. The strongest evidence was when the intervention
was led by a specialist nurse. The clinic-based interventions
probably made little or no diIerence to the risk of readmission
for heart failure, and evidence suggested that the multidisciplinary
programmes may reduce the risk of being readmitted to hospital
for heart failure.
Case management studies probably slightly reduce readmissions to
hospital for any cause. As for heart failure readmissions, evidence
was strongest for those interventions delivered by a specialist
nurse. Clinic-based intervention models appeared to have little
to no eIect on the risk of readmission for any cause, whereas
multidisciplinary programmes may slightly reduce the risk of all-
cause readmission.
Very few studies mentioned adverse eIects. None of the
case management or clinic-based intervention models reported
this outcome, and two multidisciplinary intervention studies
mentioned that no adverse eIects were reported during the trials.
It was diIicult to assess the quality-of-life outcome due to
diIerences in reporting methods and very high attrition rates. For
case management and multidisciplinary interventions, the quality
of evidence was very low, so we are uncertain of the evidence for
these. Evidence for clinic-based intervention models suggests that
these may result in little or no diIerence in quality of life.
Low-quality evidence suggested that case management models
may reduce costs and improve cost-eIectiveness slightly,
compared with usual care. Clinic-based interventions may reduce
costs slightly, and multidisciplinary models may be slightly cost-
eIective.
Overall completeness and applicability of evidence
The review question set out to explore the evidence for disease
management interventions for heart failure. We included 47 studies
with a total of 10,869 participants. Just under half of the studies
took place in Europe and 13 were in North America; seven were
in upper-middle income countries as defined by the World Bank
2018. Mao 2015, whose study took place in Taiwan, emphasised
the importance of evaluating disease management programmes in
non-Western countries. The more extensive literature available for
this update has therefore somewhat broadened the applicability
of the evidence beyond that available at the last update (Takeda
2012).
The included studies randomised participants with a range of heart
failure severity and co-morbidities. Although participants in most
studies were aged on average between 67 and 80 years, 10 studies
had younger participants on average, and one had very elderly
participants. Some studies excluded participants with serious
co-morbidities, those awaiting surgery or those who had heart
failure associated with acute myocardial infarction. This may aIect
generalisability as people with heart failure oNen have multiple
chronic conditions. However, the diversity of the 47 studies does
appear to be broadly representative of the population of interest.
The range of interventions and countries where the studies took
place mean that the comparator 'usual care' diIered between
them. Whilst this adds heterogeneity to the analysis of outcomes, it
does to some extent reflect the 'real world' situation and widen the
applicability of findings.
Complex interventions of this kind diIer widely in terms of content,
delivery and setting. Intervention-specific factors can therefore
contribute to the success of the programme, and heterogeneity
in these can aIect the overall results described in this review.
We explored the contribution of individual components of an
intervention, but it was diIicult to clarify the exact structure of each
intervention due to limitations in reporting. The transferability of
complex interventions is also diIicult, as the interaction between
components may be equally as important as the impact of each
individual aspect. Undocumented aspects, such as the relationship
between patients and their carers, the influence of a patient's
particular domestic circumstances, and the dynamic between
members of the multidisciplinary team, may also be influential.
The outcomes for this update were more narrowly focused than
those for the previous update (Takeda 2012), aiming to provide
more succinct patient-relevant outcomes specific to the disease
and intervention in question. However, it was notable that heart
failure readmissions and mortality due to heart failure were
reported more rarely than general cardiac-related readmissions
or causes of death. This led to a less complete summary of
evidence for these outcomes. Reporting cause of death may not be
particularly reliable in this frail, elderly, multimorbid population,
and heart failure may be contributing to another cause of death.
The beneficial eIect of case management programmes in reducing
all-cause mortality is, therefore, a helpful indicator of their broader
impact.
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Quality of the evidence
Evidence from case management interventions was moderate
for heart failure readmissions, all-cause readmissions and costs.
We downgraded quality for publication bias, imprecision and
indirectness, respectively. The evidence for all-cause mortality was
low due to high risk of bias and suspected publication bias. We
assessed quality-of-life data as being very low-quality, due to risks
of attrition and detection bias, inconsistency (heterogeneity), and
imprecision.
The GRADE quality assessments for outcomes of clinic-based
interventions were low for all outcomes except heart failure
readmissions, which we assessed as having moderate-quality
evidence. Low-quality assessments for all-cause mortality and all-
cause readmissions were due to high risk of bias, imprecision
(CI including the null). The moderate rating for heart failure
readmissions was due to the only downgrade being for risk of bias.
We downgraded the quality-of-life outcome by two levels due to
risk of detection bias (unblinded outcome), and high attrition. We
downgraded the cost outcome for indirectness, due to the age
of the cost data, and for imprecision associated with the small
sample size. We assessed all-cause mortality as moderate-quality
evidence (downgraded once for risk of bias). We downgraded both
adverse events and costs once for imprecision, so we assessed
them as being of moderate quality. Our GRADE assessment for
both heart failure readmissions and all-cause readmissions was
low-quality, being downgraded once for risk of bias and once for
inconsistency due to heterogeneity (heart failure readmissions), or
for imprecision due to wide confidence intervals including the null
(all-cause readmissions). The evidence for mortality due to heart
failure was of very low quality, downgraded for indirectness, risk of
bias and imprecision due to the low event rate. Similarly, quality-
of-life evidence was very low quality, downgraded twice for risk of
bias (detection and attrition) and imprecision.
Potential biases in the review process
Although we searched key databases and trials registries, it is
possible that we did not identify some relevant publications. For
the majority of outcomes there were too few studies for a funnel
plot to be constructed, so we were not able to assess the possibility
of publication bias. There were also too few studies for robust
subgroup analyses for several of the outcomes. We had diIiculty
classifying some of the studies, so studies where the intervention
was poorly described may not have been assigned to the most
appropriate group, had the most appropriate person recorded
as delivering the intervention, or had all the components of the
intervention listed accurately. One of the key inclusion criteria for
this review was the requirement for study participants to have
been admitted to secondary care at least once for heart failure.
This was oNen unclear in the publications, and we contacted many
study authors for further information. The inclusion of such studies
may therefore be biased towards those where study authors were
responsive and able to provide the necessary information.
Agreements and disagreements with other studies or
reviews
The previous update of this review (Takeda 2012) concluded that
case management interventions led by specialist nurses reduce
heart failure readmissions, all-cause readmissions and all-cause
mortality aNer 12 months' follow-up. The authors of the previous
update found that multidisciplinary interventions may be eIective
in reducing readmissions for heart failure or any cause, but found
little evidence for eIectiveness of clinic-based interventions. In
addition to adding new studies to the review, we have used
the GRADE system to assess the quality of evidence and this
has aIected the interpretation of results. This current update
agreed with the previous review in finding that case management
interventions probably reduce all-cause mortality, readmissions for
heart failure, and probably slightly reduce readmissions for any
cause. Our subgroup analyses also indicated that interventions
led by a specialist nurse were more eIective than others in
reducing readmissions for either heart failure or any cause. As
with the previous review, we found evidence that multidisciplinary
interventions may slightly reduce the risk of readmission for
heart failure or any cause. Unlike the previous update, the larger
body of evidence reviewed now indicates that multidisciplinary
interventions probably reduce all-cause mortality. As previously,
we found little to no eIect of clinic-based interventions for heart
failure on any of the clinical outcomes in the review. Evidence
for the eIect of disease management programmes on quality
of life remains very uncertain. We reviewed costs and cost-
eIectiveness for this update but not the previous one. We found
that case management interventions probably reduce costs and
improve cost-eIectiveness slightly, that clinic-based interventions
may reduce costs slightly, and that multidisciplinary models are
probably slightly cost-eIective.
The most similar recent systematic review to our own is that
by Huntley 2016, who reviewed the impact of case management
interventions in the community for people with heart failure,
in terms of reduction in hospital admissions or readmissions.
That review included 17 RCTs and five non-RCTs, and was
not restricted to people who had been admitted to hospital
for heart failure. The authors found that hospital-initiated case
management interventions reduced readmissions, as was found
in our review. They did not find much diIerence in costs
between case management and usual care, whereas we found
that such interventions probably reduce costs and improve cost-
eIectiveness slightly.
Oyanguren 2016 conducted a meta-analysis of management
programmes for people with heart failure, which included 66 RCTs.
It is important to note that these included a broader spectrum
of management interventions than just disease management
programmes of the type described in our own review (for example
trials on use of beta-blockers), and there was also no restriction
on length of follow-up. The authors did not divide the studies into
case management, clinic-based intervention and multidisciplinary
programmes, but found overall that heart failure management
interventions reduce mortality and readmissions.
Other systematic reviews in this area include a meta-analysis and
cost-eIectiveness study of six 'care in the home' trials, broadly
comparable with case management interventions (Fergenbaum
2015). The authors reported that care in the home reduced the
number of hospitalisations (as did our review), but not all-cause
mortality (unlike our review). They also reported better quality of
life for people who had care in the home. However, the authors
also noted that the quality of evidence indicated uncertainty over
outcomes. As with our current review, they found care-in-the-home
interventions to be less costly and more cost-eIective than usual
care.
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A recent meta-analysis of 16 RCTs of multidisciplinary, heart failure
clinic-based interventions (Gandhi 2017), reported lower odds of
heart failure hospitalisation (but not all-cause hospitalisation),
and lower odds of all-cause mortality for people attending the
heart failure clinics. DiIerences between the conclusions of the
Gandhi 2017 review and our own, less optimistic, findings, are likely
due to the diIerent studies included - we excluded nine of their
studies from our own review for various reasons, including having
a follow-up of under six months, having the wrong participants or
comparator, and because hospital admission was not an inclusion
criterion.
There is some overlap in included studies between our own
review and the network meta-analysis of transitional care services
published by Van Spall 2017, although that analysis included a
wider range of interventions, and studies with shorter follow-up
than our own. Interestingly, they found that home visits by nurses
were the most eIective services in terms of decreasing all-cause
readmissions, followed by nurse case management. Both of these
would fall into the 'case management' category in our review.
It is interesting to compare our findings with the recommendations
of the 2016 ESC Guidelines (ESC 2016), which recommend the use
of multidisciplinary management programmes to reduce the risk
of heart failure-related hospitalisation and mortality. Our review
supports the likely reduction in all-cause mortality for people
treated by multidisciplinary teams, with low-quality evidence also
indicating a possible reduction in heart failure readmissions. In
addition, our review found that a case management approach,
particularly when led by specialist nurses, can also be eIective in
reducing all-cause mortality and HF readmissions.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found limited evidence for the eIect of disease management
programmes on mortality due to heart failure, with no case
management or clinic-based interventions reporting this outcome
specifically; the evidence from multidisciplinary studies was of very
low quality. However, it is diIicult to classify death due to heart
failure in this elderly, co-morbid population. The use of all-cause
mortality may therefore be a better indicator of the intervention's
impact than mortality due to heart failure.
The available evidence suggests that either case management or
multidisciplinary models are likely to deliver reductions in overall
mortality and heart failure readmissions, and may reduce all-cause
readmissions. The more limited evidence from clinic-based models
generally found little or no eIect on mortality or readmissions
for heart failure or any cause. For case management models, the
evidence suggests that a specialty trained heart failure nurse is
important, a strong education component may be beneficial, but
that weight monitoring may be of limited value.
There was a lack of evidence for adverse events, but this is not
unexpected due to the nature of the interventions. It would be
diIicult to identify and collect specific adverse eIects of disease
management interventions – for example, widening gaps in access
to services for people unable to receive home visits or answer
telephone calls.
Despite many studies reporting quality-of-life assessments, the
evidence remains of very low-quality for case management and
multidisciplinary interventions, so results are uncertain for this
outcome. The evidence for clinic-based interventions was of low
quality, and the studies appear to make little or no diIerence to
quality of life.
Variations in study location and time of occurrence hamper
attempts to review costs and cost-eIectiveness, but limited data
suggest that these models are cost-eIective.
Implications for research
Despite the inclusion of 22 new studies since the last update of this
review, there remains a gap in the evidence for quality of life, as
this outcome is poorly reported and suIers high attrition. For the
mainly elderly, heart-failure populations in the studies included in
this review, the potential to improve quality of life is an important
consideration both for patients themselves, their carers and health
professionals. Improved reporting of this outcome in future trials
would be helpful in strengthening the evidence for this patient-
relevant outcome.
The assessment of complex interventions is an active area
of research, and new methods could be useful for improving
interpretation of studies. For example, Freeman 2018 describes
methods for undertaking a component network meta-analysis to
assess the eIects of specific components of complex interventions.
Any such work would also require an improvement in the reporting
of randomised controlled trials (RCTs), as it is oNen diIicult
to identify exactly what components have been included in an
intervention and to estimate the relative time spent on each.
It is also worth considering whether a traditional meta-analysis of
RCTs is the best approach for evaluating complex interventions.
Mixed methods may be more helpful in analysing the many
interacting components of disease management programmes, and
helping to understand the various impacts on their eIectiveness.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Multicentre RCT (2 hospitals)
Recruiting: January 2005-December 2008
Follow-up: 3 and 12 months (with 24 months' long-term results in subsequent publication by Liljeroos
2015)
Intervention category: other
Person delivering the intervention: nurse
Participants Country: Sweden, setting described as hospital-based, but interventions took place in participants'
homes or the HF clinic depending on participant preference.
Participants: N = 155: 71 (46%) in intervention group, 84 (54%) in usual-care group
Mean ± SD age 69 ± 13 in intervention group, 73 ± 10 in usual-care group
Male sex: 49 (69.1%) in intervention group, 68/84 (80.9%) in control group
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, N (%)):
• intervention group, class I, N = 0; class II, N = 25 (35%); class III, N = 39 (55%); class IV N = 7(10%);• control group, class I N = 0; class II, N = 25 (30%); class III, N = 43 (51%); class IV, N = 16 (19%)
Median EF%: NR
Inclusion criteria:
• a dyad consisting of a patient diagnosed with HF based on the ESC guidelines, NYHA functional class
II-IV, with a partner living in the same household, recently discharged from hospital (i.e. 2-3 weeks)
after a HF acute exacerbation
Exclusion criteria:
• dementia or other severe psychiatric illnesses• drug abuse• difficulties in understanding or reading the Swedish language• undergoing cardiac surgery, including cardiac transplant• participating in other studies
Interventions Median duration of intervention: 12 weeks
Intervention:
• psychosocial support to maintain and strengthen physical and mental functions, knowledge, and per-
ceived control to make participants feel involved and reduce their stress and their partners’ burden.• 3 nurse-led, face-to-face counselling sessions of at least 1 h each, including education on HF with book-
lets and computer-based education using a CD-ROM program, and other written teaching materials• intervention focused on changing thoughts and behaviours and implementing strategies for self-care• dyads were also encouraged to talk about lifestyle changes, communication, and prospects and learn-
ing to live with lifelong HF
Comparator:
Agren 2012 
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• dyads in the control group received care as usual, including traditional care in hospital and outpatient
education and support. At present, this care is mainly focused on the participant’s needs. The partner
is not systematically involved in the follow-up focusing on education and psychosocial support.
Outcomes Primary outcome: unclear
Outcomes: perceived control, self-care, HRQOL, depression, caregiver burden
SF-36 for self-rated health
BDI-II
CAS: 4 items, 2 about perceived control and 2 about helplessness
EHFscBS
Caregiver Burden Scale
Notes Funding: "Funding: Grants from Linkoping University, Swedish Research Council, Swedish Institute for
Health Sciences, Heart and Lung Foundation, Heart and Lung Disease National Association, and Lions
Research Foundation".
Disclosures: none
Data source: published data only
165 dyads accepted for study participation, 10 then withdrew before baseline assessment, 155 dyads
randomised after baseline assessment, 71 (46%) randomised to experimental group and received inter-
vention, 84 (54%) randomised to control group
7 intervention participants and 9 intervention partners; 6 control participants and 9 control partners
did not complete 3 months' follow-up. At 12 months, 14 intervention participants, 13 intervention part-
ners, 21 control participants and 26 control partners did not complete follow-up.
Liljeroos 2015 reports long-term follow-up
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation code was developed using a random-number table
Allocation concealment
(selection bias)
Unclear risk No information
Blinding of participants
and personnel (perfor-
mance bias)
High risk No blinding possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "both data collectors, and researchers entering the data were blinded
to group assignment"
 
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Self-completed QoL questionnaires, no blinding of participants
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Agren 2013: 14/71 (19.7%) intervention and 21/84 (25%) control participants
did not complete - not balanced
Agren 2012  (Continued)
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Liljeroos 2015 (long-term follow-up): low for readmissions and mortality - all
randomised participants included in analysis; high for QoL data: Although
missing data in the SF-36 were imputed by the means of the subscale if only
1 item in the subscale was missing, only 62% in both intervention and control
groups completed questionnaires so 38% of dyads were not included.
Selective reporting (re-
porting bias)
Unclear risk The study was registered at ClinicalTrials.gov, identifier: NCT02398799, after
participant recruitment began.
Quote: "The reason for this is that when recruitment began, it was unusual to
register this type of intervention studies."
However, reported outcomes are in line with the study's objectives.
Other bias Unclear risk There was a higher proportion of men in the intervention group than the con-
trol group (80.9% vs 69.1%)
Agren 2012  (Continued)
 
 
Methods Single-centre RCT
Recruitment dates: February 2001- June 2002
Follow-up: 12 months
Intervention category: case management
Person delivering the intervention: nurse
Participants Country: Spain
N randomised: 279
Intervention (N = 137) vs control (N = 142)
Mean (SD) age: 75.3 (11.1) vs 76.3 (9.4)
Percentage male: 38.7 vs 40.1
Ethnicity: NR
NYHA functional class intervention/control: NR
Mean (SD) EF: 50.9 (16.6), N = 130 vs 48.3 (17.6), N = 124
Inclusion criteria:
• all participants had been hospitalised for HF• lived in area covered by the collaborating home care unit• sufficient family support
Exclusion criteria:
• severe cognitive deficits• advanced psychiatric disease• non-cardiological terminal disease• COPD
Interventions Duration of intervention: 15 days
Intervention:
Aldamiz-Echevarria 2007 
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• home visits by physicians and nurses, for clinical examination, tests/analyses as required, and adjust-
ment of medication as required (N.B. this intervention was not HF-specific, but was intended to reduce
readmissions across a range of medical and surgical conditions)• additional nursing staI home visits 2, 5 and 10 days after discharge for education for participants and
relatives about HF (basic facts and management, i.e. symptoms, life style, diet and therapy)• participants received educational manual and a phone number for queries
Compatator:
• usual care (referral to primary care physician)
Outcomes Primary: cumulative unplanned readmission or death 6 and 12 months after discharge
Secondary:
• cumulative unplanned readmissions• cumulative mortality• duration of readmission• use of emergency services during 1st 6 months after discharge
Notes Data source: published data only
Planned admissions were not considered events
Funding/CoI: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Closed envelopes prepared by the Instituto de Ciencias de la Salud. The ran-
domisation process was stratified with respect to the services involved (inter-
nal medicine, cardiology and short-stay).
Allocation concealment
(selection bias)
Low risk The sequence was concealed until interventions were assigned.
Blinding of participants
and personnel (perfor-
mance bias)
High risk Quote: “By the very nature of the intervention being tested, neither the pa-
tients taking part in this study nor the home care unit personnel were blind to
their treatment.”
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: “... staI attending them in other services were unaware of whether pa-
tients belonged to the programme or control group. Events assignment was,
therefore, blinded.”
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk QoL NR
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "There were no dropouts from the study."
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Aldamiz-Echevarria 2007  (Continued)
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Methods Multicentre RCT (3 centres)
Recruiting: January 1999- June 1999
Follow-up: median duration 509 days (IQR 365-649)
Intervention category: case management
Person delivering the intervention: cardiologist
Participants Country: Spain
Participants: 164 in intervention group, 174 in usual-care group
Median age (IQR) 69 (61-74) in intervention group, 67 (58-74) in usual-care group
Male sex (both groups) 203 (60%), (intervention group 101/164, 62%), (control group 102/174, 59%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, N):
• intervention group: class I, N = 11; class II, N = 39; class III, N = 40; class IV, N =10• control group: class I, N = 10; class II, N = 40; class III, N = 40; class IV, N = 10
Median EF% (IQR): intervention 36 (30-53); control 40 (30-55)
Inclusion criteria:
• all patients with congestive HF discharged from cardiology wards of 3 hospitals in Spain• HF diagnosis based on the presence of symptoms and signs of HF with objective evidence of major
cardiac dysfunction at rest• All patients had been hospitalised for HF 
Exclusion criteria:
• expected survival < 3 months• discharge to a nursing home or long-term care facility• living > 30 km from hospital• impossible to contact by phone• dementia or psychiatric illness• on a waiting list for invasive cardiology or heart surgery on discharge
Interventions Median duration of intervention: 509 days (IQR 365-649)
Intervention: discharge and outpatient management programme
• 1-to-1 single education session for participants and carers prior to discharge and session with primary
care physician post discharge to reinforce education• teaching brochure to reinforce education, covering: diagnosis of HF, information about the disease
(pathogenesis etc), symptoms of HF, symptoms and signs of worsening HF, what to do if condition
worsens,  lifestyle advice, medication education for carers• cardiologist outpatient clinic every 3 months, including medication review• participant given specific/tailored self-management plan• visit with primary care physician scheduled within 2 weeks of discharge• telemonitoring component; a facilitated telephone monitor (SCT) providing a 24-h mobile phone con-
tact number which participants were encouraged to contact as necessary. Participants could also tele-
phone the HF team for advice during office hours
Comparator:
Atienza 2004 
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• discharge planning according to the routine protocol of the study hospitals
Outcomes Primary outcome: event-free survival (survival without readmission to hospital) at 1 year
Secondary outcomes: total number of hospital admissions (all-cause and for HF) at 1 year
Other outcomes: readmission rate (all-cause and for HF); HRQoL (MLHFQ); costs; rate of deaths per ob-
servation year; time to readmission (all-cause + HF); time to death
Notes Data source: published data only
Funding: "Dr. Atienza was funded by the Spanish Society of Cardiology, Madrid, Spain. Prof. Mar-
tinez-Alzamora was funded by a Research Incentive Program from the Polytechnic University of Valen-
cia, Spain. Merck, Sharp & Dohme contributed financially to the edition and printing of the brochure for
HF patients used in the study"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk An independent assistant allocated participants using a computer-generated
randomisation list. Block stratified randomisation performed according to age
and sex
Allocation concealment
(selection bias)
Unclear risk No further details
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information on whether objective outcome assessment was blinded
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data analysed on ITT principles, "one patient in each arm transferred to a
nursing home during the study so their data were included in analyses but
censored at time of transfer"
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified, beyond a slight baseline imbalance: more control partic-
ipants had valvular heart disease (47/174 compared with 31/164) and fewer
were on a beta blocker 20/174 compared with 31/164)
Atienza 2004  (Continued)
 
 
Methods Multicentre RCT (4 centres)
Recruiting: May 2009-June 2011
Duration of follow-up: 12 months
Bekelman 2015 
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Intervention category: multidisciplinary
Person delivering intervention: “Each site had a collaborative care team consisting of a nurse coordina-
tor (registered nurse), a primary care physician, a cardiologist, and a psychiatrist.”
Participants Country: USA
Participants: N = 392 randomised (193 intervention, 199 usual care)
Mean ± SD age: intervention: 67.3 (9.6); usual care: 67.9 (10.6)
Male sex N (%): intervention: 178 (95.2); usual care: 193 (98.0)
Ethnicity: N (%) intervention: 149 (79.7) white; control: 165 (83.8) white
Actual severity of HF in study participants at recruitment (LVEF (%)):
• intervention: data available for N = 171: normal 78 (45.6), mildly reduced 34 (19.9), moderately reduced
46 (26.9), severely reduced 13 (7.6)• usual care: data available for N = 177: normal 84 (47.5), mildly reduced 34 (19.2), moderately reduced
32 (18.1), severely reduced 27 (15.3)
NYHA class (N (%)):
• Intervention: class I, N = 16 (8.9%); class II, N = 77 (42.8%); class III, N = 82 (45.6%); class IV, N = 5 (2.8%)• Control: class I, N = 16 (8.5%); class II, N = 85 (45.0%); class III, N = 82 (43.4%); class IV, N = 6 (3.2%)
Comorbidities
• hypertension: intervention: 158 (84.5); control:159 (80.7)• diabetes: intervention: 99 (52.9); control: 93 (47.2)
Inclusion criteria:
(1) a primary inpatient hospital discharge diagnosis of HF
(2) at least 2 secondary inpatient hospital discharge diagnoses of HF and a primary inpatient hospital
discharge diagnosis related to heart disease;
(3) at least 3 secondary inpatient hospital discharge diagnosis codes related to HF;
(4) at least 2 outpatient visit diagnoses of HF, excluding emergency department visits; and
(5) at least 2 secondary inpatient hospital discharge diagnoses of HF and at least 1 outpatient HF diag-
nosis.
Exclusion criteria:
(1) severe cognitive or psychiatric impairment;
(2) current residence in a nursing home;
(3) irreversible, noncardiac medical conditions likely to affect 6-month survival or ability to execute the
study protocol;
(4) prior heart transplantation; and
(5) alcohol abuse
Interventions Intervention: “The intervention included 3 components. These were multi-disciplinary collaborative
care HF disease management, screening for and treatment of depression, and telemonitoring with pa-
tient self-care support.” “For each intervention patient, the team reviewed the electronic health record
and baseline depression scores from the Patient Health Questionnaire 9 (PHQ-9). The team recom-
mended care changes for a given patient in accord with the American College of Cardiology and Amer-
ican Heart Association Guidelines for the Diagnosis Research Original Investigation Patient-Centered
Disease Management for Heart Failure Trial and Management of Heart Failure in Adults and the collab-
Bekelman 2015  (Continued)
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orative depression care intervention as described herein. In addition, the team met weekly to recom-
mend care changes based on review of telemonitoring data and the follow-up PHQ-9 score.” “Interven-
tion patients who screened positive for depression (PHQ-9 score, ≥10) received the depression care
component of the intervention, adapted from a successful collaborative depression care intervention.”
“Intervention patients received daily telemonitoring using home-based equipment that tracked signs
and symptoms ofHF and depression. The system collected daily measures of blood pressure, pulse,
weight, and self-reported symptoms (eg, shortness of breath and edema). Patients with depression
were asked questions about their mood and behavior. The telemonitoring system assigned a risk to
each response on the system. The nurse reviewed medium risk indicators and decided whether an ac-
tion needed to be taken (eg, for patients unable to understand a low sodium diet, the nurse provided
counseling). The nurse acted on all of the high risk indicators by contacting the patient for assessment
and then, if necessary, contacted the care team for any changes in medications or tests to be written in
the electronic medical record.”
Comparator: “Patients randomized to the usual care arm continued to receive care from their regu-
lar health care professionals and regular telehealth nurses (if enrolled in telemonitoring), with no in-
volvement of the study collaborative care team. Care was fully at the discretion of the patient’s regular
health care professionals and may or may not have included cardiology or mental health clinic care in
addition to primary care. Usual care patients were given information sheets at the enrollment visit that
described self-care for HF and were provided with a weighing scale if needed.”
Outcomes All-cause mortality
All-cause readmissions
HRQoL (KCCQ)
Cost-effectiveness planned but NR
Notes Funding/support: "The Patient-Centered Heart Failure Trial was funded by grant IIR 06-068 from the
Department of Veterans Affairs Health Services Research and Development. Dr Bekelman was support-
ed by Career Development Award 08-022 from the Department of Veterans Affairs Health Services Re-
search and Development during this study. Role of the Funder/Sponsor: The Department of Veterans
Affairs had no role in the design and conduct of the study; the collection, management, analysis, and
interpretation of the data; the preparation, review, or approval of the manuscript; and the decision to
submit the manuscript for publication.”
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “The study database was used to create the randomization sequence
using block randomization, with stratification by study site and 1:1 randomiza-
tion of patients to the intervention and to usual care”
Allocation concealment
(selection bias)
Unclear risk Quote: “The randomization sequence was concealed from the study person-
nel. Randomization occurred after baseline survey information was entered in-
to the database.“
Blinding of participants
and personnel (perfor-
mance bias)
High risk Quote: "unable to blind participants"
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk Blinding unclear for nurse co-ordinator who collected outcome data at 12
months
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk A research assistant who collected QoL data was blinded, but QoL was self-re-
ported by unblinded participants
Bekelman 2015  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 6 intervention and 2 control participants dropped out at randomisation, and
couldn't be included in results. Trial registry indicates that data were other-
wise reported for all randomised people, including those who later dropped
out/couldn't be contacted, but published paper's analysis appears to be of
165/193 intervention participants and 172/199 control participants
Selective reporting (re-
porting bias)
Unclear risk Protocol published after end of trial, but registered prospectively on clinicaltri-
als.gov. 2 secondary outcomes planned but NR
Other bias Low risk Nothing detected
Bekelman 2015  (Continued)
 
 
Methods Multicentre RCT (8 centres). 3 arms – only multidisciplinary care and usual-care groups are discussed
here, since the BM arm (N-Terminal Pro-B-Type Natriuretic Peptide-Guided, Intensive Patient Manage-
ment in Addition to Multidisciplinary Care) was not relevant to this review
Recruiting: July 2003-September 2004
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: multidisciplinary
Participants Country: Austria
Participants: N = 186: 96 in intervention group, 90 in usual-care group
Mean ± SD age: 73 ± 11 in intervention group, 71 ± 13 in usual-care group
Male sex: intervention 66/96 (68.8%); usual-care 59/90 (65.6%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment: NYHA class NR
Inclusion criteria:
• hospitalised due to HF• clinical signs and symptoms of cardiac decompensation during the present hospitalisations• NYHA functional class III or IV at admission• cardiothoracic ratio > 0.5 or LVEF < 40% as documented by echocardiography
Exclusion criteria:
• NR
Interventions Intervention:
• multidisciplinary care by a specialised HF nurse, which included 4 home visits and telephone contact,
2 pre-scheduled consultations from the HF specialist 10 days and 2 months after discharge, and con-
sultations on demand that were performed if any deterioration in the participant’s status was noted
by the HF nurse. Consultations included physical examination and laboratory testing of blood chem-
istry and blood cell count, and optimisation of medical therapy based on these.• Nurse care consisted of 4 home visits at 1, 3, 6, and 12 months after discharge by a nurse specialised in
caring for people with HF. The nurse checked and recorded weight, symptoms and signs of HF, heart
rate and blood pressure, and reviewed blood analyses on demand. In co-ordination with the HF spe-
cialist, the nurse checked for and implemented guideline-based HF medication. Nurse provided indi-
vidualised patient and caregiver education and self-management advice.
Berger 2010 
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Comparator:
• usual care. Participant's management plan sent to primary care physician, who was responsible for
patient evaluation and treatment, including assessing need for readmission. In hospitals in which the
usual patient management offered visits for selected patients at the cardiac outpatient clinic, the dis-
charging physician was allowed to arrange such visits as usual. Contact with the HF specialists of the
research team was discouraged. Neither a structured follow-up nor specialised HF nurses were avail-
able for participants in the usual-care group
Outcomes Pilot study so no primary outcome specified. End points included HF rehospitalisation, duration of time
it takes to reach the combined end point of death and HF rehospitalisation, the first HF rehospitalisa-
tion, and death
Cost utility analysis published by Moertl et al. 2013 (see Berger 2010)
Notes Funding: "This study was funded by AstraZeneca, Novartis, Roche Diagnostics, Roche Medical, Merck,
Medtronic, and Guidant, who provided the financial support for a clinical investigator, a specialised
chronic HF nurse, and data collection."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomised to groups using computer-generated permuted
block randomisation (6 participants per block)
Allocation concealment
(selection bias)
Low risk At discharge, concealed allocation was performed by sending the baseline
characteristics of each participant to an independent medical project manage-
ment institute
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: “Independent data collectors obtained information from medical re-
ports and from interviews with relatives during the follow-up at least every 3
months. During a consensus reading, 2 cardiologists, who were blinded to the
treatment groups, classified the cause of rehospitalization as being a result of
cardiac decompensation or not. If the cause of rehospitalization was classified
unclear by 1 cardiologist, the data collector provided the appropriate hospital
charts for final classification."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No loss to follow-up
Selective reporting (re-
porting bias)
Unclear risk NCT record registered after enrolment was completed, no published protocol
identified
Other bias High risk NCT record suggests trial terminated, but no reason given for early stoppage.
Generally similar at baseline, but 18/96 intervention vs 31/90 usual-care par-
ticipants had mild-moderately reduced LVSF and 73/96 intervention vs 61/90
usual-care participants had severely reduced LVSF
Berger 2010  (Continued)
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Methods Multicentre RCT (3 rehabilitation hospitals)
Recruiting: July 2013-October 2014
Duration of follow-up: 6 months
Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary (nurse and physiotherapist)
Participants Country: Italy
Participants: randomised N = 112 (N = 56 intervention, N = 56 control)
Mean ± SD age: intervention: 71 (9); control 70 (9.5)
Male sex N (%): intervention 50 (88%); control 42 (75%)
Ethnicity: NR
Participants in this trial had both HF and comorbid COPD
Actual severity of HF in study participants at recruitment (NYHA class, N (%)):
• intervention: class II, N = 25 (45%); class III, N = 22 (39%); class IV, N = 9 (16%)• control: class II, N = 29 (52%); class III, N = 19 (34%); class IV, N = 8 (14%)
Inclusion criteria:
• aged > 18 years• COPD GOLD classification, classes B, C, and D• systolic and/or diastolic HF NYHA classes II, II, and IV• ≥ 1 hospitalisation or visit due to HF or COPD exacerbation in the previous 12 months• signed informed consent
The confirmed diagnosis of HF (NYHA class II-IV) and COPD (B, C and D GOLD class) had to be docu-
mented by an echocardiogram (HF) and by a spirometry examination (COPD) performed within the pre-
vious 12 months. The majority of participants had been hospitalised for HF as the first diagnosis. Of the
112 participants enrolled, 76 of them had as first diagnosis HF
Exclusion criteria:
• physical activity limitations due to noncardiac and/or pulmonary conditions• limited life expectancy• severe cognitive impairments
Interventions Intervention:
• educational intervention from a nurse tutor and a physiotherapist tutor, who then followed partici-
pants for 4-month telerehabilitation phase• weekly structured phone call from nurse tutor to collect information about disease status and symp-
toms, offering advice regarding diet, lifestyle and medications, previously defined with the cardiolo-
gist and pulmonologist supervising the programme• participants were provided with a pulse oximeter and a portable 1-lead electrocardiograph) for re-
al-time telemonitoring of vital signs• participants could call in the case of urgent need or emergency 24 h/day 365 days/year• physiotherapist tutor designed a personalised exercise programme for each participant; who was pro-
vided with mini-ergometer, pedometer and diary.• physiotherapist tutor instructed participants and their caregivers on how to perform the exercises
correctly, focusing on the rehabilitation goals. The number/intensity of training sessions according to
participants’ progress were adjusted during 4 months or in the case of problems
Bernocchi 2017 
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• there was a ‘basic level’ and ‘high level’ programme, physiotherapist tutor assessed participant to
decide which to use• physiotherapist tutor phoned each participant weekly to verify the training level of physical activity
performed, plan the rehabilitation targets for the following week and give extra reinforcement on the
value of lifestyle changes and the importance of exercise.
Comparator:
• participants received the standard care programme (including medications and oxygen prescription,
visits from GP, and in-hospital check-ups on demand). At enrolment, participants received an edu-
cational session about healthy lifestyle and daily physical activity. Study author confirmed that this
should be considered as standard care (26.6.18)
Outcomes All-cause mortality; CV-related readmissions (but not HF readmissions); all-cause readmissions (total
not number with readmission); QoL (MLHFQ)
Notes Funding: Ministero della Salute (Italian Ministry of Health). The funding source did not influence or
comment on planned methods, protocol, data analysis or the draN report.
Study author supplied unpublished data for change from baseline to 6 months, and confirmed that the
majority of participants had been hospitalised for HF as the primary diagnosis.
Published and unpublished data. Searches identified the published protocol, study author sent the
published paper (published after search date) and also sent the unpublished data on change in quality
of life from baseline to 6 months.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer generated tables to allocate patients in fixed blocks of 4"
Allocation concealment
(selection bias)
Low risk Quote: "the allocation sequence was concealed from the investigators en-
rolling and assessing patients, in sequentially numbered, opaque, sealed en-
velopes."
Blinding of participants
and personnel (perfor-
mance bias)
High risk Quote: "Due to the nature of the trial, it was not possible to blind patients and
healthcare personnel to intervention."
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "outcome assessors and data analysts were blinded to the allocation."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported by participants who knew their allocation
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low overall (majority of participants accounted for for readmissions and mor-
tality)
High for QoL, as 80% of intervention group and 63% of control group complet-
ed this outcome - imbalance could lead to bias.
Selective reporting (re-
porting bias)
Low risk Outcomes stated in trial registry published prior to study completion, match
the outcomes of interest in the publications. Study author provided additional
data for baseline to 6 months, as this had only been published as 0-4 months
and 4-6 months.
Bernocchi 2017  (Continued)
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Other bias Low risk Quote: "We tried to standardise as much as possible the nursing and physio-
therapy approach in the three hospitals involved in the enrolment of patients,
conducting joint training of staI, organisational meetings and planning before
commencing patient enrolment."
Bernocchi 2017  (Continued)
 
 
Methods Single-centre RCT
Recruiting: March 1997-November 1998
Duration of follow-up: 12 months (mean follow-up)
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Scotland (UK)
Participants: 81 participants (41 men, 51%) in comparison group, 84 (54 men, 64%) in intervention
group
Actual age of study participants: intervention 74.4 years (SD 8.6); usual-care mean 75.6 years (SD 7.9)
Male sex: 58%
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, N (%)):
• intervention group: class II, N = 19 (23%); class III, N = 28 (34%); class IV, N = 36 (43%)• control group: class II, N = 16 (20%); class III, N = 33 (42%); class IV, N = 30 (35%)
LVEF: NR
Inclusion criteria:
• patients admitted as an emergency to the acute medical admissions unit at 1 hospital with HF due to
LV systolic dysfunction.• all patients had been hospitalised for HF
Exclusion criteria:
• unable to give informed consent or to comply with the intervention• acute MI (unless they had a previous history of HF)• co-morbidity (such as advanced malignancy) likely to lead to death or readmission in the near future• awaiting cardiac surgery• planned discharge to long-term residential care• residence outside the hospital catchment area
Interventions Duration of intervention: up to 12 months
Intervention: "Specialist nurse intervention"
During index hospitalisation:
• participants were seen by a HF nurse prior to discharge
After discharge:
• home visit by HF nurse and within 48 h of discharge• subsequent visits by HF nurse at 1, 3, and 6 weeks and at 3, 6, 9 and 12 months.• scheduled phone calls at 2 weeks and at 1, 2, 4, 5, 7, 8, 10 and 11 months after discharge.
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• participants and their families encouraged to contact nurses with problems or questions by phone
during office hours (answering machine where they could leave messages after hours)• additional unscheduled home visits and telephone contacts as required
Home visits covered:
• participant education about HF and its Rx, self-monitoring and management (especially the early de-
tection and treatment of decompensation)• participants were given a booklet about HF which included a list of their drugs, contact details for HF
nurses, blood test results and clinic appointment times• trained HF nurses used written drug protocols and aimed to optimise participant treatment (drugs,
exercise and diet)• HF nurses also provided psychological support to the participant• HF nurses liaised with the cardiology team and other healthcare and social workers as required
Comparator:
• usual care• "Patients in the usual care group were managed as usual by the admitting physician and, subsequent-
ly, general practitioner. They were not seen by the specialist nurses after discharge."
Outcomes Primary endpoints:
• unplanned readmissions within 90 days of discharge• total number of days hospitalised during follow-up (12 months)
Also looked at:
• readmission rates in the moderate-risk subgroup compared to the high-risk sub group
Notes Data source: published data only
Funding: "This study was supported by a grant from the Scottish Office, Department of Health. Compet-
ing interests: None declared."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Study nurses phoned the Robertson Centre for Biostatistics and the
patient was allocated to one or other randomisation group from a randomisa-
tion list."
Allocation concealment
(selection bias)
Unclear risk No information
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "We obtained data on admissions and deaths from the hospital records
department, the information and statistics division of the Scottish NHS (hospi-
tal admissions) and the Registrar General's Office, Scotland (deaths). All hospi-
tal admissions were adjudicated blind to treatment allocation."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes reported
Blue 2001  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 1 person withdrew
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Blue 2001  (Continued)
 
 
Methods Single-centre RCT
Recruiting: November 2006-July 2008
Duration of follow-up: 6 months
Intervention category: clinic
Person delivering the intervention: multidisciplinary
Participants Country: Austria, setting outpatient department plus phone calls to participant's home
Participants: 140 (70%) intervention group, 60 (30%) usual-care group
Mean age 68.3 years in intervention group, 73.4 in usual-care group
Male sex: intervention group 77%, usual-care group 62%
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, %):
• intervention group: class I, 21%; class II, 47%; class III, 30%; class IV, 2%• control group: class I, 23%; class II, 57%; class III, 20%, class IV, 0%
LVEF %: intervention 32%, usual care 33%
Inclusion criteria:
• patients with chronic HF (LVEF < 40%)
Exclusion criteria:
• severe non-cardiac illness with a life expectancy < 1 year;• severe disability that would make ambulatory care impossible;• planned heart surgery
Interventions The 'Kremser Model' involved education and training, testing, stepwise optimisation of drug therapy
with the aim of achieving recommended target doses, regular outpatient visits to the hospital HF clinic
(every 4 weeks) as required and regular phone calls by a trained HF nurse to check if drugs were tolerat-
ed and taken as prescribed or if other problems had arisen.
The usual-care group were discharged from hospital with usual procedures of referral to GP and inter-
nal medicine specialist, with recommendation to adjust medication according to guidelines
Outcomes No specification of primary outcome
Outcomes:
• mortality
Bohmer 2011 
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• adjustment of medication to target dose• NYHA score• well-being• LVEF• B-type natriuretic peptide
Notes Funding: NR. CoI: study authors declare no conflict of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information in paper
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information given
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes included
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 8% of the intervention group and no participants in the control group leN the
study (but intervention group was twice the size of control group). No informa-
tion on whether their data were included in the analysis
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Unclear risk There were some imbalances at baseline in this pilot study (age 68.3 (I) vs 73.4
(C); 23% female (I) vs 38% (C)
Bohmer 2011  (Continued)
 
 
Methods Multicentre RCT (4 hospitals)
Recruiting: January 2004-September 2005
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Spain, participants recruited from 2 university hospitals and 2 community hospitals for a
home-based intervention
Participants: N = 283 randomised, 144 to intervention, 139 to control
Mean (SD) age: intervention: 76.6 (7.5) control: 76 (8.9)
Brotons 2009 
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Male sex: intervention: 66 (45.8%), control: 61 (43.9%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA at hospital discharge (class, N, %)):
• intervention: class I, N = 61 (42.2%); class II, N = 75 (52.1%); class III, N = 7 (4.9%); class IV, N = 1 (0.7%)• control: class I, N = 77 (55.4%); class II, N = 52 (37.4%); class III, N = 8 (5.8%); class IV, N = 2 (1.4%)
Inclusion criteria:
• no age limits• either sex• hospitalised for suspected HF based on dyspnoea with signs of pulmonary or systemic hypertension,
consistent with the Framingham criteria (2 major criteria, or 1 major and 1 minor criterion were re-
quired)• diagnosis at hospital discharge had to show HF in the first or second position
Exclusion criteria:
• concomitant diseases and an expected survival of < 1 year• cognitive deficit• possibility of being outside the geographic area during the following year• participation in a clinical trial within the previous 3 months
Interventions Intervention:
• pre-discharge information about disease and treatments, with a participant booklet on HF• monthly home visits for 1 year (including education and recognition of warning symptoms, assess-
ment of adherence to prescribed medication and lifestyle habits, plus checking of functional status
and vital signs)• telephone calls from nurse every 15 days to evaluate clinical status• nurses contacted the participant’s family physician or cardiologist when they deemed it was neces-
sary to start a new treatment or modify the existing one
Control:
• participants randomised to the usual care were referred to their family physician and/or referral car-
diologist
Outcomes Primary: combination of all-cause death and hospital readmissions due to worsening of HF.
Secondary:
• CV death• hospital readmissions due to CV disease (hospital emergencies not considered)• QoL (MLHFQ, adapted for use in Spain)• adherence to therapy• satisfaction
Notes Funding: "This study was funded by a subsidy from the Agència d’Avaluació de Tecnologia i Recer-
ca Mèdiques (084/03/02), a research grant from the Acadèmia de Ciències Mèdiques i de la Salut de
Catalunya i Balears (2005), and unrestricted funds from Novartis, Pfizer, Almirall-Prodesfarma, As-
traZeneca, and Sanofi-Synthelabo. "
Risk of bias
Bias Authors' judgement Support for judgement
Brotons 2009  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Randomisation was performed by computer, stratified for each hospital
Allocation concealment
(selection bias)
Low risk At the end of each interview, the nurse telephoned a central data management
site to request random assignment of participants
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "The endpoints were assessed by a committee of clinical events, blind-
ed to the patient’s treatment group."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Potentially high risk for QoL as participant-reported outcome
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low for events: only 1 participant lost to follow-up;
high for QoL (101/133 in intervention group responded at 1 year, 97/129 in con-
trol group)
Selective reporting (re-
porting bias)
Unclear risk Trial registration (ISRCTN35096435) was after enrolment started
Other bias Low risk Nothing identified
Brotons 2009  (Continued)
 
 
Methods Single-centre RCT
Recruitment: January 1999-January 2000
Duration of follow-up: mean follow-up of 12 months
Intervention category: other (day hospital)
Person delivering the intervention: multidisciplinary
Participants Country: Italy
Participants: N randomised = 234:122 participants (102 men, 84%) in comparison group, 112 (94 men,
84%) in intervention group
Actual age of study participants: mean age 56 years (SD 10)
Male sex: 84%
Ethnicity: NR
Actual severity of HF in study participants at baseline:
• NYHA class I-II/III-IV: 158/81 (68% I-II)• LVEF: 29% (SD 7)
Inclusion criteria:
• patients with HF referred for admission to the HF Unit at 1 centre or the Heart Transplantation Pro-
gramme (unclear if at the same centre)• a diagnosis of HF supported by clinical history, physical signs and symptoms, and by LVEF < 40%
Capomolla 2002 
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• all participants had been hospitalised for HF
Exclusion criteria:
• None given
Interventions Duration of intervention: not clear
Intervention:
• comprehensive HF outpatient management programme delivered by the day hospital
During index hospitalisation:
• cardiac prognostic stratification and prescription of individual tailored therapy following guidelines
and evidence
After discharge:
• attendance at day hospital staIed by a multidisciplinary team (cardiologist, nurse, physiotherapist,
dietician, psychologist and social assistant). Participant access to the day hospital, "modulated ac-
cording to demands of care process"• care plan developed for each participant• tailored interventions covering: cardiovascular risk stratification; tailored therapy; tailored physical
training; counselling; checking clinical stability; correction of risk factors for haemodynamic instabil-
ity; and healthcare education• participants who deteriorated re-entered the day hospital through an open-access programme• day hospital also offered intravenous therapy, laboratory examinations and therapeutic changes as
required• education given covered: knowledge about HF and drug treatments; and self-management, including
daily weights, fluid restriction and nutrition
Comparison Group:
• usual care
During admission:
• cardiac prognostic stratification and prescription of individual tailored therapy following guidelines
and evidence
After discharge:
• "The patient returned to the community and was followed up by a primary care physician with the
support of a cardiologist"
Outcomes Primary outcomes (evaluated at a mean of 12 months):
• readmissions because of haemodynamic instability• deaths from cardiac causes• cardiac mortality and urgent heart transplant
Secondary outcomes (evaluated at a mean of 12 months):
• "Tailored therapy management"• QOL• NYHA functional class
Also looked at:
• cost utility of the 2 strategies
Capomolla 2002  (Continued)
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Not clear if analysis done on ITT basis
Notes Data source: published data only
Funding/CoI: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “Patients referred to our HFU had a prognostic evaluation, their thera-
py was optimised, and they were then randomised to one of two management
strategies.”
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
High risk After 12 months all participants were re-evaluated in the HF Unit and the day
hospital is part of this unit
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No information
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias High risk Not all the 112 participants in the intervention received all the components of
the intervention: 76% received education and physical training; 47% received
cardiovascular risk stratification; 45% received tailored therapy; 19% received
multidisciplinary intervention.
There were 49 "open access interventions" in the intervention group, which in-
cluded interventions that would have required admission in the control group.
Capomolla 2002  (Continued)
 
 
Methods Multicentre RCT (10 centres)
Recruiting: March 2010-April 2013
Duration of follow-up: 6 months
Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary
Participants Country: Turkey
Participants: randomised N = 248 (125 intervention; 123 control)
Cavusoglu 2017 
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Mean ± SD age intervention: 60.6 ± 14.3; control: 61.1 ± 13.2
Male sex (%): intervention 76%; control 70%
Ethnicity: NR
Actual severity of HF in study participants at recruitment
LVEF (%) mean (SD): intervention 27.4 ± 7.1; control: 26.2 ± 7.1
NYHA class III-IV (%): intervention 60%; control 61%
Diabetes: intervention35%; control 37%
Inclusion criteria:
• > 18 years• discharged from hospital with a diagnosis of HF within 6 months of randomisation• current symptoms of HF despite optimal medical therapy consistent with recent guidelines (ACEI or
angiotensin receptor blocker, beta blocker, mineralocorticoid receptor antagonist, and diuretics)• NYHA functional class II–IV• LVEF < 40% as measured by transthoracic echocardiography
Exclusion criteria:
• severe renal failure requiring dialysis• serum creatinine > 2.5 mg/dL• severe COPD• chronic or intermittent inotropic support• acute coronary syndromes defined by progressive angina or chest pain at rest or new ECG changes
and/or serial increase in cardiac troponin levels• recent percutaneous coronary interventions (PCI), cardiogenic shock, hypertrophic cardiomyopathy,
acute myocarditis, severe primary valvular heart disease, dysfunction of a prosthetic heart valve, peri-
cardial disease• pregnancy• uncontrolled thyroid disease• currently enrolled in another HF study• life expectancy < 6 months
Interventions Intervention:
• a cardiologist and nurse provided education on HF management during discharge and gave partici-
pants an education booklet and digital home scales• a printed HF education booklet was prepared in to unify the education content between centres• 1 session of HF education was implemented by a cardiologist together with a nurse at randomisation,
in which the primary educator was the cardiologist• participant education took almost 1 h (30 min by the cardiologist and 30 min by the nurse), or more
if needed• phone calls from cardiologist or nurse at months 1, 3• phone call or hospital visit at 6 months to collect clinical data and go over HF education material• also assessed adoption of life style changes and adherence to medications, and reminded participants
about salt and fluid intake, weight monitoring, daily routine activities, and exercise training• correction of doses or regimen of medication were made by a cardiologist or a nurse under the super-
vision of a cardiologist.• participants were invited to come to the hospital if needed
Baseline education included:
• description, causes, symptoms, prognosis and treatment of HF• lifestyle changes: salt intake, fluid and alcohol intake, the importance of weight monitoring, managing
weight gain, daily measurement of blood pressure, adherence to medications, participation in daily
Cavusoglu 2017  (Continued)
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routine activities, exercise training, recognition of worsening HF symptoms, and when to contact the
cardiologist.
Comparator: usual care
• participants were discharged from hospital without receiving any education or follow-up instructions• prescriptions were given along with the suggestion of a follow-up office visit
Outcomes • CV mortality (not specifically HF mortality)• all-cause mortality• all-cause readmissions• HF readmissions
Notes Funding: "This study had been designed, supported and conducted by the Working Group on Heart
Failure of the Turkish Society of Cardiology."
Published data only. Study author (Cavusoglu) confirmed by email 27 June 2018 that data for HF-mor-
tality are not available, only data for CV-mortality.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)
Unclear risk No information
Blinding of participants
and personnel (perfor-
mance bias)
High risk Quote: "because of the design of this study, both patients and investigators
could not be blinded to treatment groups"
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
High risk Study nurses collected data at phone follow-up
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Not applicable - QoL NR
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No information on losses to follow-up, ITT analysis conducted
Selective reporting (re-
porting bias)
Unclear risk No protocol or clinical trials registry entry found
Other bias Low risk Nothing identified
Cavusoglu 2017  (Continued)
 
 
Methods Single-centre RCT
Recruiting: December 2013-June 2015
Duration of follow-up: 6 months
Chen 2018 
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Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary
Participants Country: China
Participants: N = 62 randomised, intervention N = 31; control N = 31
Mean ± SD age: intervention 61.1 (14.2); control 62.4 (14.9)
Male sex N (%): intervention 22 (71.0); control 15 (48.4)
Ethnicity: NR
Actual severity of HF in study participants at recruitment:
LVEF (mean (SD)%): intervention 39.9 (13.4); control 47.1 (13.4)
NYHA class N (%):
• intervention: class II, N = 1 (3.2%); class III, N = 15 (48.4%); class IV, N = 15 (48.4%)• control: class II, N = 1 (3.2%); class III, N = 16 (51.6%); class IV, N = 14 (45.2)
Diabetes: intervention 6 (19.4) ; control 8 (25.8)
Inclusion criteria:
• HF diagnosis with NYHA class II to IV• > 18 years old
Exclusion criteria:
• cognitive impairment (people with scores < 24 on the MMSE questionnaire• inconvenience of home visit• inaccessible by telephone• concurrent inclusion in another study• diagnosis of COPD• diagnosis of other diseases whose life expectancy is < 1 year• diagnosis of other conditions that would restrict participant’s activity
Interventions Intervention: follow-up by HF team (3 cardiologists, 1 coach nurse, 10 nurses, 1 dietician, 1 psychiatrist)
• individualised discharge education with cardiologist (HF info, weight monitoring, when to contact for
help, self-care, medication adherence, dietary advice• psychiatrist and dietician involved where necessary• physical exercise training, individually tailored• home visit by coach nurse 2 weeks after discharge to check changes in signs and symptoms• phone contact every 2 weeks by cardiologist to monitor physical exercise, check medication adher-
ence, reinforce education• intensified education by coach nurse at 90 and 180 days, tailored to participant's understanding of
HF and self-care• during outpatient clinic visits, the coach nurse delivered specialised education and physical exercise
training based on the participant’s QoL, physical performance, and self-care behaviours
Comparator: usual care
• a telephone call within 2 weeks after discharge by a nurse• 2 follow-up visits for adjustment of medications by a cardiologist at outpatient clinic at 90 days and
180 days after discharge.• contacts with the cardiologists and nurses on HF team were discouraged
Outcomes • HF readmission
Chen 2018  (Continued)
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• all-cause readmissions• HRQoL (MLHFQ - Chinese version)
Outcomes only reported for combined endpoint (death or hospitalisation)
AT emailed study author 11 July 2018 for individual outcomes, no response
Notes Funding: Chia Family Health Fellowship granted by the Yale-China Association; Fundamental Research
Funds for the Central Universities of Central South University granted by the Central South University.
No CoI
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A computer-generated randomisation list was created by a statistician for pa-
tient randomisation
Allocation concealment
(selection bias)
Low risk Randomisation list was generated by the statistician not the study team
Blinding of participants
and personnel (perfor-
mance bias)
High risk Blinding not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "Nurses who recruited patients, collected patients’ data, and adminis-
tered questionnaires were blind to the patient randomization."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Participants themselves were aware of allocation, so self-reported MLHFQ not
blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Data appear to be reported for all participants, but mortality and readmissions
only reported as composite outcome
Selective reporting (re-
porting bias)
Unclear risk No protocol or trial registration found
Other bias Unclear risk The proportion of eligible patients was low (of 264 people diagnosed with HF,
202 were excluded before randomisation (90 declined to participate, 56 did
not meet inclusion criteria, 51 lived too far away, 5 died). May limit generalis-
ability
Chen 2018  (Continued)
 
 
Methods Single-centre RCT
Recruiting: NR
Duration of follow-up: 9 months
Intervention category: case management
Person delivering intervention: specialist nurse
Participants Country: USA
Clark 2015 
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Participants: randomised N = 50; intervention N = 25; control N = 25
Mean ± SD age: intervention 61.7 (10.3); control 63.0 (11.7)
Male sex N (%): intervention 9/25 (36%); control 15/25 (60%)
Ethnicity: intervention 20/25 (80%) white; control 20/25 (80%) white
Actual severity of HF in study participants at recruitment:
NYHA class N (%):
• intervention: class I, N = 3 (12%); class II N = 10 (40%); class III, N = 12 (48%)• control: class I, N = 4 (16%); class II, N = 11 (44%); class III, N = 10 (40%)
Diabetes: 48% of all participants
Inclusion criteria:
• diagnosed with NYHA class I-III 28 systolic or diastolic HF• aged ≥ 45 years• willing to participate in a randomised 9-month study• living at home independently• able to speak, read, and write in English• a score of at least 23 on the MMSE
Exclusion criteria:
• major CVD (e.g. stroke• NYHA class IV HF
Interventions Intervention: "this study was underpinned by the health promotion model and self-efficacy theory, and
the APRN’s support in building participants’ self-efficacy was a key part of the intervention."
• 100-page booklet containing 8 modules formed the main educational material: HF information, signs
and symptoms, diet, lifestyle, medications; when to seek help; memory enhancement techniques;
diet; exercise; stress; depression; self-management; goal setting.• participants also received a book on improving memory
First 3 months:
• education-support intervention delivered by APRNs with expertise in HF• meeting every 10–14 days for 1–1.5 h to present the educational content
Next 3 months:
• phone and/or email support by APRN but no visits (average contact was 5-15 min every 3-4 weeks• Final 3 months without contact with the research team• All participants received a USD 25 cash appreciation giN
Comparator:
"The control group received a loose-leaf notebook of selected pages containing information on health
promotion for adults/older adults information obtained from the National Institute of Aging website;
Centers for Disease Control and Prevention, American Cancer Society, and the American Geriatric So-
ciety. Sample topics were: fall prevention; crime and older adults; arthritis; and bladder control. No
content about HF was included. Meetings were scheduled during the first 3 months depending on the
needs and interest of the participant. No phone or email teaching was done. Instruments were com-
pleted at the same 4 time periods (baseline, 3 months, 6 months, and 9 months) and retention giNs
were provided ($25 each testing period). Usual medical care was received. All participants were offered
the chance to receive the intervention at the end of the study; the majority received it."
Clark 2015  (Continued)
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Outcomes • KCCQ; total score data extract higher scores reflect better QoL. A 5-point change in total score is a
clinically important difference.
Notes Funding: NIH/NINR
Study author checked all participants' data and confirmed that the majority had been admitted to hos-
pital for HF at least once.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk States 'randomized' with no further details. 2 participants who dropped out
were replaced, NR whether allocation of these was randomised or not.
Allocation concealment
(selection bias)
Unclear risk No details given
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
High risk Nurse delivered intervention and collected outcomes
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL was self-reported by participants who knew group allocation
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "Two participants lost to follow-up were replaced (one moved out of
state; the other moved and could not be located) and their data were eliminat-
ed from the analysis" - not clear which group they were from, or whether the
replacement participants' data were included in the analysis.
Selective reporting (re-
porting bias)
Unclear risk No protocol or trial registration identified
Other bias Low risk Nothing noted
Clark 2015  (Continued)
 
 
Methods Single-centre RCT
Recruitment: December 1991-October 1993
Duration of follow-up: 12 months
Intervention category: clinic
Person delivering the intervention: specialist nurse
Participants Country: Sweden
Participants: 190 participants; intervention: 80 (44 men, 55%); control 110 (57 men, 52%)
Actual age of study participants: mean 75.6 years (SD 5.3)
Male sex: 53%
Ethnicity: NR
Actual severity of HF in study participants at baseline:
Cline 1998 
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NYHA class, mean:
• intervention 2.6 (SD 0.7)• control 2.6 (SD 0.7)
LVEF: 75% LVEF < 40%
• intervention mean 31.6% (SD 8.4)• control mean 35.7% (SD 12.3)
Inclusion criteria:
• patients hospitalised primarily because of HF• HF diagnosed on symptoms and signs with "at least one objective sign present on admission such as
pulmonary rales, peripheral oedema, congestion on chest radiograph, or a third heart sound"• aged 65-84 years
Exclusion criteria:
• the presence of other serious disease that either prevented participation or was expected to signifi-
cantly influence QoL, morbidity or mortality in the following year• foreseeable follow-up problems, including residence outside the hospital catchment area• serious alcohol or drug abuse• psychiatric disease• inability to understand or answer study questionnaire• participation in another clinical trial• discretion of treating physician
Interventions Duration of intervention: 12 months
Intervention: "Management programme for heart failure"
During index hospitalisation:
• Patients received an education programme from HF nurse consisting of two 30 minute visits.
After discharge:
• 2 weeks after discharge participants and their families were invited to a 1-h group education session
led by the HF nurse. which included an oral presentation by the nurse, and educational video and a
question and answer session• participants were also offered a 7-day medication dispenser if deemed appropriate• participants were followed up at a nurse directed outpatient clinic and there was a single presched-
uled visit by the nurse at 8 months after discharge• HF nurse was available for phone contact during office hours• participants encouraged to contact the study nurse at their discretion, if unsure, if diuretic adjust-
ments did not ameliorate symptoms in 2-3 days, or if there were "profound changes in self manage-
ment variables"• participants were offered cardiology outpatient visits 1 and 4 months after discharge
The inpatient and outpatient education programme covered:
• HF pathophysiology, pharmacological and non-pharmacological treatment• participants were also given guidelines for self-management of diuretics in the event of fluid overload
or fluid depletion• participants were given a "heart failure diary" containing information on HF, list of HF medications,
names and contact phone numbers for the HF clinic and in which to regularly record bodyweight,
ankle circumference and HF symptoms
Comparator: usual care
Cline 1998  (Continued)
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• participants "followed up at the outpatient clinic in the department of cardiology by either cardiolo-
gists in private practice or by primary care physicians as considered appropriate by the discharging
consultant."
Outcomes Primary endpoint: unclear, abstract states that main outcome measures were:
• time to readmission• days in hospital• healthcare costs during 1 year
Other endpoints:
• QoL (at 1 year) using The Quality of Life in Heart Failure Questionnaire, Nottingham Health Profile and
patients' global self assessment (all self-administered)
Also looked at:
• Deaths at 90 days - not included in this review as < 6 months• Event-free (i.e. death or readmission) survival at 90 days - not included in this review as < 6 months
Notes Data source: published data only
Funding: "The study was supported by grants from the Swedish Heart and Lung Foundation, the re-
search foundation administered by Malmö University Hospital, and the Council for Health Care Re-
search, Lund University."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer generated random allocation"
Allocation concealment
(selection bias)
Low risk Quote: "Patients were invited to participate and informed consent was given
on the basis of information relevant to the allocated study group. This proce-
dure avoided bias arising from control patients being informed of the interven-
tion strategy."
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk No objective outcomes at 6 months
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-assessed
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All participants were accounted for and deaths were verified by hospital
records or death certificates, but QoL is the only included outcome here, and it
is not clear how many people completed this at follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol identified
Other bias Unclear risk Slightly lower LVEF in intervention group at baseline: mean (SD) LVEF (%) inter-
vention: 31.6 (8.4) < 0.05; control: 35.7 (12.3)
Cline 1998  (Continued)
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Methods Multicentre RCT (2 centres)
Recruiting: August 2009-April 2012
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: nurse
Participants Country: Brazil
Participants: randomised N = 252; intervention N = 123; control N = 129
Mean ± SD age: intervention 62 ± 14; control: 63 ± 12
Male sex N (%): intervention 75 (61.0%); control 83 (64.3%)
Ethnicity: intervention 83 (67.5% white); control 81 (62.8% white)
Actual severity of HF in study participants at recruitment:
EF mean SD %: intervention 29.2 ± 8.2; control 30.1 ± 9.5
NYHA class N (%)
• intervention: class I, N = 6 (4.8%); class II, N = 48 (39.0%); class III, N = 52 (42.2%); class IV, N = 14 (11.3%)• control: class I, N = 10 (7.7%); class II, N = 47 (36.4%); class III, N = 64 (49.6%); class IV, N = 11 (8.5%)
Inclusion criteria:
• Adult patients (≥ 18 years old)• LV systolic dysfunction (LVEF ≤ 45%)• admitted because of acute decompensated HF• diagnosis of acute HF was confirmed by the attending physician, and all enrolled participants had to
be on i/v diuretic therapy and to present the expected HF signs and symptoms.
Exclusion criteria:
• an acute HF episode secondary to sepsis, myocarditis or MI• major communication barriers• residence > 20 km from the hospital• lack of the possibility of telephone contact
Interventions Intervention:
• 4 home visits, about 1 h each, 1st within 10 days of discharge, approx. days 30, 60 and 120 days after
discharge• included physical examination, knowledge/self-care assessment and adherence to recommenda-
tions, medications, weight control, hydro-saline restriction, physical activity, vaccination, weight
monitoring, signs and symptoms to watch for and therapeutic strategies.• consultant would adjust drugs where necessary• 4 reinforcement phone calls, about 10 min each both led by trained nurses, to reinforce the info given
at the home visit, check use of medications, and clarify any issues• Outpatient clinic visit at 180 days follow-up to finalise assessment
Comparator: usual care
• medical outpatient visits in which they received instructions regarding pharmacological and non-
pharmacological therapeutic strategies.
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• no specific management plan was applied and each hospital decided the approach for each partici-
pant.• Typically, participants were followed-up by a GP after hospital discharge.• No home visits or telephone contact
Outcomes • All-cause mortality• HF readmissions• All-cause readmissions• Cost-effectiveness
Notes Funding: Fundo de Incentivo à Pesquisa e Eventos do Hospital de Clínicas de PortoAlegre (FIPE); Fun-
dação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS); Conselho Nacional de Desen-
volvimento Científico e Tecnológico (CNPq). No CoI
Study author confirmed that this study (HELEN II) has the outcomes from the previously identified on-
going HELEN I study (a related paper by Mussi 2013 was previously excluded as no relevant outcomes
reported)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Simple sequence randomisation was used, generated electronically on the
website www.randomization.com
Allocation concealment
(selection bias)
Low risk Quote: "A healthcare professional who was not a member of the research
group was responsible for the patient allocation list. The intervention nurses
were blinded to the patients’ allocation group until all instruments had been
completed
in the baseline period."
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible to blind
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk A nurse who was blinded to group allocation was responsible for the final eval-
uations and for assessment of clinical outcomes.
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Not applicable: QoL NR
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Study flow chart indicates all randomised participants included in follow-up
(perhaps just for Kaplan Meir survival analysis?) Outcome table indicates
117/123 intervention participants and 126/129 control participants included in
clinical outcomes at 6 months
Selective reporting (re-
porting bias)
High risk Trial registered after it had started. NCT trial register states original primary
outcome (2010) was to be absolute number readmissions and visits to ED for
decompensation of HF. Changed in 2014 to a composite endpoint of a first visit
to ED, or a first hospital readmission, or all-cause death
Other bias Low risk Nothing identified
de Souza 2014  (Continued)
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Methods Multicentre RCT (5 centres)
Recruitment: May 1998-October 2000
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: nurse
Participants Country: USA
Number randomised: 462 (intervention N = 228, control N = 234)
NYHA class, N (%)
• intervention group: class I-II, N = 103 (50%); class III-IV, N = 103 (50%)• control group: class I-II, N = 112 (50%); class III-IV, N = 113 (50%)
Median EF%: NR
Mean age: all: 72 years (SD 11);
• intervention: < 60 years: 35 (15%); 60-70 years: 52 (22%); 70-80 years: 92 (40%); > 80 years: 49 (21%)• control: < 60 years: 32 (14%); 60-70 years: 55 (24%); 70-80 years: 86 (37%); > 80 years: 49 61 (26%)
Ethnicity, N (%):
• intervention: white 195 (86); black 13 (5); American Indian 9 (4); Hispanic 7 (3); Asian 4 (2)• control: white 191 (82); black 14 (6); American Indian 18 (8); Hispanic 7 (3); Asian 4 (2)
Inclusion criteria:
• hospitalised with a provisional diagnosis of HF in study hospitals as indicated by new onset or wors-
ening HF on the basis of shortness of breath (dyspnoea at rest, orthopnoea or paroxysmal nocturnal
dyspnoea)
 
Exclusion criteria:
• scheduled for coronary artery bypass surgery or valvular surgery• undergone cardiac surgery in preceding 8 weeks• serum creatinine value ≥ 5 mg/dL• receiving dialysis• awaiting renal Tx• history severe pulmonary disease on home O2• ≥ 1 additional diagnoses expected to result in death within the year• cognitive mental deficits• substance abuse• severe psychiatric disorders• expected to move from area within 1 year
Interventions Duration of intervention: 12 months
Intervention: "specialist nurse intervention"
• I-h educational session with a nurse in the participant’s medical centre• participant received printed educational materials including methods for self-monitoring symptoms,
body weight and medications; a dietary management workbook; food frequency questionnaires• participants viewed a video portraying the treatment process
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• participants received instructions on how to access emergency care in case symptoms abruptly wors-
ened• 45-min baseline telephone counselling session within 1 week of randomisation by experienced nurse
care manager• subsequent nurse contacts tailored to meet needs of the participant• nurse initiated follow-up phone calls to participant weekly for 6 weeks, biweekly for 8 weeks, monthly
for 3 months, bimonthly for 6 months• nurse care managers obtained permission from physicians to initiate and regulate pharmacologic
therapy for HF according to study protocol• nurses communicated with physicians about participant's medical status• nurses co-ordinated treatment plan with participants and physicians
 Comparator: usual care (no details given)
Outcomes Outcomes (1 year)
Primary outcome:
• time to first hospitalisation HF and all-cause
Secondary outcomes:
• time to composite outcome of death,• readmission or ED visit for cardiac cause or for any cause• rate of outpatient and ED visits
Notes Data source: published data only
Funding: "The National Heart, Lung and Blood Insitute reviewed and financially supported the project
but did not participate in the design, conduct, or reporting of the study or in the decision to submit the
manuscript for publication."
"Potential financial conflict of interest: none disclosed."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Research staI who were not associated with delivering the intervention ran-
domly assigned participants to treatment conditions by using sealed assign-
ments. Equal numbers of participants were allocated to the 2 groups in each
medical centre using the Efron procedure.
Allocation concealment
(selection bias)
Low risk Research staI who were not associated with delivering the intervention ran-
domly assigned participants to treatment conditions by using sealed assign-
ments.
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "Research staI who were not associated with, and were blinded to, the
intervention conditions measured health outcomes at 12 months. Two cardiol-
ogists who were not associated with implementing the intervention reviewed
medical records on deaths, rehospitalizations, and emergency department
visits to determine whether these events were primarily due to heart failure
or due to other causes. They did not use discharge diagnoses recorded in the
medical record to make these judgments."
DeBusk 2004  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Slightly unbalanced drop out rate (15/234 6% in usual care, 8/228 3.5% in in-
tervention group) but ITT analysis used
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing noted
DeBusk 2004  (Continued)
 
 
Methods Open RCT
Recruitment: January 2001-December 2002
Duration of follow-up: 24 months
Intervention category: multidisciplinary
Person delivering the intervention: multidisciplinary
Participants Country: Italy
Number randomised: 184 (control N = 87, intervention N = 86)
NYHA:
• intervention: class I, N = 0 (0%); class II, N = 32 (37.2%); class III, N = 44 (51.2%); class IV, N = 10 (11.6%)• control: class I, N = 0 (0%); class II, N = 34 (39.1%); class III, N = 49 (56.3%); class IV, N = 4 (4.6%)
LVEF: intervention: 33.5 (SD 11); control: 32.5 (SD 10)
Age: intervention: 77.4 (SD 5.9); control: 77.5 (SD 5.7)
Percentage male: intervention: 51.2; control: 52.8
Ethnicity: NR
Inclusion criteria:
• ≥ 70 years• discharged home after hospitalisation due to HF• NYHA III-IV for ≥ 24 h requiring i/v therapy on admission• diagnosis determined according to ECS guidelines
Exclusion criteria:
• valvular heart disease requiring planned surgical correction• active substance abuse• severe gait impairment• confined to bed• severe dementia• psychiatric disease likely to limit compliance• co-existent non-cardiac disease likely to reduce life expectancy• need for long-term i/v inotropic therapy
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• unwillingness to provide informed consent• living in a nursing home• Living outside the area served by the clinical sites
Interventions Duration of intervention: 24 months
Intervention: DMP combining hospital clinic-based and home-based care
• teams included a cardiologist experienced in geriatrics, 2-4 specialised nurses and the participant’s
primary care physician• components of the programme were; discharge planning, continuing education, therapy optimisa-
tion, improved communication with healthcare providers, early attention to signs and symptoms and
flexible diuretic regimes• participants given a written list of recommendations, a weight chart, a contact number available 6 h/
day, and an education booklet• follow-up via hospital clinic visits, periodical nurse’s phone calls• participants attended HF clinics within 7-14 days of discharge and at 1, 3 and 6 months thereafter for
optimisation of treatment and education• primary care physicians assessed adherence to treatment, evaluated adverse effects and co-morbidi-
ties, and monitored diet
Control: usual care
• optimised treatment and standard education• all treatments and services ordered by primary care physician and/or cardiologist• baseline clinical evaluation and therapeutic plan documented
Outcomes Primary:
• composite of all-cause death and hospital admissions from HF at 24 months
Secondary (24 months):
• all-cause and HF hospitalisations• cumulative number of hospitalisations• all cause and HF related mortality• QoL• perceived health status• functional status and indexes of quality of care (such as % of participants taking beta-blockers) - not
recorded here
Notes Data source: published data only
Funding/CoI: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given, just states "randomised"
Allocation concealment
(selection bias)
High risk Eligible patients were randomised and informed consent was given on the ba-
sis of information relevant to the allocated study group
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Del Sindaco 2007  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "Outcomes were evaluated in a blinded manner by a central endpoint
committee composed of three cardiologists, who had no knowledge of the
treatment assignment."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants included in table of outcomes at 2 years.
Quote: "A relatively high rate of patients abandoned the hospital component
of the programme and continued care with their primary care physicians and/
or personal cardiologists. The participation of these patients until the end
of the follow-up would have further improved the effects of intervention be-
cause, on intention-to-treat analysis, this high drop-out rate was not associat-
ed with a significant decline in the efficacy of the model."
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Del Sindaco 2007  (Continued)
 
 
Methods Single-centre, cluster-RCT, GP as the unit of randomisation (but see note)
Recruitment: during 1997 and 1998
Duration of follow-up: 12 months
Intervention category: clinic
Person delivering the intervention: multidisciplinary
Participants Country: New Zealand
Participants: 97 participants; intervention 100 (64 men, 64%); control (54 men, 56%)
Actual age of study participants: mean 73 years (SD 10.8, range 34-92 years)
Male sex: 60%
Ethnicity: 'NZ European' 79%
Severity of HF in study participants at index admission: NYHA class, N (%)
• intervention: class II, N = 24 (24%), class III, N = 76 (76%)• control: class II, N = 24 (25%), class III, N = 73 (75%)
Severity of HF in study participants at baseline: LVEF
• intervention group 30.6% (SD 12.7)• control group mean 33.8% (SD 12.7)
Inclusion criteria:
• Patients admitted to general medical wards with a primary diagnosis of HF
Exclusion criteria:
• surgically remediable cause for HF• consideration for heart transplantation• terminal cancer• participation in another trial
Doughty 2002 
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• inability to provide informed consent
Interventions Duration of intervention: 12 months
Intervention: integrated heart failure management programme
After discharge:
• outpatient review at HF clinic within 2/52 of discharge from hospital: clinical status reviewed, phar-
macological treatment based on evidence based guidelines, 1-to-1 education with study nurse, edu-
cation booklet provided• participant diary for daily weights, Rx record and clinical notes provided• detailed letter faxed to GP and follow-up phone call to GP• GPs encouraged to discuss management with clinic team• Follow-up plan aiming at 6 weekly visits alternating between GP and HF clinic• Group education sessions for participants run by cardiologist and study nurse: 2 sessions offered with-
in 6 weeks of discharge and 1 at 6 months post-discharge• telephone access to study team for GPs or participants during office hours
Group education sessions covered:
• education about disease• monitoring daily body weight and action plans for weight changes• medication• exercise• diet
Comparison: usual care
Outcomes Primary endpoints (12 months):
• time to first event i.e. death or hospital readmission• HRQL measured using MLHFQ at baseline and 12 months
Other endpoints (12 months):
• all-cause hospital readmissions• HF hospital readmissions• all-cause hospital bed-days
Also looked at:
• medications at 12 months
Notes Data source: published data only
Funding: "The study was funded by a project grant from the National Heart of New Zealand and an
unrestricted educational grant from Merck Sharp Dohme (NZ) Ltd. RND was the recipient of the New
Zealand Heart Foundation BNZ Senior Fellowship. "
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "General practitioners were randomly allocated using computer gener-
ated random numbers…after consent was obtained the patient was informed
of their group allocation based on the randomisation of their current general
practitioner."
Doughty 2002  (Continued)
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Allocation concealment
(selection bias)
Unclear risk NR. GPs were randomised before participant recruitment - possibility that
team were aware of assignment of GP before recruitment of patient into study
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only one participant lost to follow-up
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Unclear risk This was a cluster-RCT, but outcomes were reported for individual partici-
pants. Paper states that,
Quote: "Data were analysed using two approaches. Firstly the unit of random-
ization was assumed to be the individual, as if simple randomization had been
performed. ... In other analyses the unit of randomization was the GP, con-
sistent with the actual method of cluster randomization. ...Since the median
number of participants per general practitioner was small (1·5 in each arm) the
influence of clustering was small and only results from the first approach are
presented. In no case did statistical significance differ depending upon the ap-
proach adopted."
Doughty 2002  (Continued)
 
 
Methods Single-centre RCT
Recruitment: January 1998- January 2000
Duration of follow-up: 6 months
Intervention category: multidisciplinary
Person delivering the intervention: multidisciplinary
Participants Country: Canada
Participants: intervention N = 115/control N = 115
Mean (SD) age: 68 (10)/10 (10)
% male: 83 (73)/82 (71)
Ethnicity: NR
EF% (SD): 34 (14)/35 (15)
NYHA class, N (%)
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intervention: class II, N = 8 (7%); class III, N = 68 (59%); class IV, N = 39 (34%)
control: class II, N = 14 (12%); class III, N = 63 (55%); class IV, N = 38 (33%)
Inclusion criteria
• seen at the ED of or admitted to the Montreal Heart Institute with a primary diagnosis of congestive HF• radiologic confirmation of congestive HF or known impaired LVEF (< 45%)
Exclusion criteria:
• a primary diagnosis of acute MI• discharge to a chronic care facility, scheduled cardiac surgery• unwillingness to sign informed consent or to attend the outpatient clinic• participation in another research trial• residence in an outlying area
Interventions Duration of intervention: 6 months
Intervention: multi-disciplinary HF clinic with phone follow-up from nurses
• evaluation at clinic within 2 weeks of hospital discharge• HF clinic provided rapid access to cardiologists, clinician nurses, dieticians and pharmacists, with ac-
cess to social workers and other medical specialists as required• clinic allowed observation for up to 5 h and i/v diuretics if required• follow-up phone call from nurse within 72 h of hospital discharge and then monthly, unless a problem
necessitated more frequent contact• After baseline evaluation, clinic cardiologists individualised treatment plan (including pharmacologic
treatment) for participants• 1-on-1 education of the participant and family with the study nurse initiated at 1st clinic visit. Individ-
ualised advice on the disease process, symptoms and signs of HF (changes in symptoms indicative
of worsening HF), fluid and sodium intake restrictions, the importance of daily monitoring of body
weight and action plans to remedy changes in weight, effects of medications and the importance of
compliance, and recommendations regarding exercise and diet• participant diary for daily weight measurement,medication record, clinical notes and appointments,
physical activity recommendations, an education booklet and a telephone number for clinic during
business hours• individualised dietary assessments by registered dietician at baseline, instructions reinforced by
nurse at subsequent visits• pharmacist evaluated medications for each participant and assessed participant's knowledge• individualised follow-up plan included monthly visits with both a cardiologist and nurse at the clinic• study team available for ad hoc consultation during normal working hours. Participants advised to
call clinic nurse if symptoms worsened. During calls nurse evaluated signs of clinical deterioration and
adverse effects and participants were referred to clinic cardiologist as required
Comparator: usual care
Outcomes Primary endpoints:
• all-cause hospital readmissions• total number of associated hospital days at 6 months
Secondary outcomes (at 6 months):
• number of ED visits• QoL• mortality
Notes Data source: published data only
Ducharme 2005  (Continued)
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Funding: "competing interests: none declared" but "James Brophy and Michel White receive support
from les Fonds de la recherche en santé du Québec". "unrestricted educational grants from Merck
Frosst and GlaxoSmithKline"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Eligible patients who agreed to participate were randomly assigned to
the control group or intervention group using consecutively numbered opaque
envelopes that contained a random number generating group assignment."
Allocation concealment
(selection bias)
Low risk Consecutively numbered opaque envelopes used
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "It is also possible that incomplete blinding of the data extractors may
have introduced another bias. To minimize the potential impact of such a bias,
we selected outcomes (repeat hospital admission and duration of hospital
stay) that are not typically affected by subjective interpretations. The unblind-
ing of the study physicians is also unlikely to have influenced hospital admis-
sion patterns since the physicians represent fewer than 10% of the cardiolo-
gists with admission privileges at the institution."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported by participants who knew allocation (although question-
naire administered by blinded personnel)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Analyses were ITT
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Ducharme 2005  (Continued)
 
 
Methods Multicentre RCT (4 centres)
Recruiting: 2010-2013
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: research nurse
Participants Country: USA
Participants: N = 134 randomised (intervention N = 70; control N = 64)
Age mean ± SD, range: intervention 57.7 (10.5), 31-81; control 57.0 (10.8), 29-76
Dunbar 2014 
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Male sex N (%): intervention 47 (67.1%); control 41 (64.1%)
Ethnicity N (%): intervention African American, 52 (74.3%); control African American, 41 64.1%)
Actual severity of HF in study participants at recruitment:
• LVEF (mean (SD) %): intervention 32.3 (16.6); control 35.7 (18.6)
NYHA class:
• intervention: class I, N = 1 (1.4%); class II, N = 28 (40.0%); class III, N = 36 (51.4%); class IV, N = 5 (7.1%)• control: class I, N = 0 (0.0%); class II, N = 28 (43.8%); class III, N = 31 (48.4%); class IV, N = 5 (7.8%)
Diabetes: all participants had both diabetes and HF, as this was a specific inclusion criterion
Inclusion criteria:
• current or recent hospitalisation for HF within the past 3 months• age 21-80 years• NYHA functional class II-IV symptoms• type II DM• planned discharge to home and not to an assisted living or skilled nursing facility• English language fluency• baseline guideline-derived medical therapy unless there was documented contraindication, ambula-
tory and eligible for a walking physical activity programme,• eligible for a low-sodium and low-carbohydrate diet
Exclusion criteria:
• newly diagnosed or 1st HF admission• positive screenings for depressive symptoms and cognitive difficulty, which would interfere with abil-
ity to participate in the intervention or perform adequate self-care• uncorrected hearing or vision problem• undergoing cardiac transplantation or mechanical circulatory assist device implantation or evalua-
tion at the time of enrolment• renal failure requiring renal replacement treatment• lack of telephone access• severe COPD and earlier stroke if they impeded ability to ambulate
Interventions Intervention:
• individualised educational and counselling session by trained research nurse including: overview of
HF and DM, self-care diet, medications, symptom monitoring; weight monitoring; physical activity• HF-DM tool kit provided for home use• home visit by research nurse 48-72 h later to review self-monitoring, reinforce information and assess
diet and medication congruent with discharge instructions• scripted phone call at 7-10 days to review self-monitoring and check diet and medication, physical
activity mentioned• 2 weeks – clinic visit that incorporated physical activity counselling• scripted phone calls at 1, 2 and 4 months to review and promote self-monitoring, diet, physical activity
and medication-taking
Comparator: usual car
• after randomisation given publicly available informational brochures. Standard hospital discharge
teaching from staI in the enrolling institutions and follow-up clinic appointments• control group participants received ‘‘attention control’’ telephone calls on the same schedule as the
intervention participants with information about the trial, number of participants enrolled to date,
and a reminder of their next set of study activities.
Dunbar 2014  (Continued)
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Outcomes • All-cause mortality• All-cause readmissions• HRQoL (MLHFQ)• Cost-effectiveness
Notes Funding: NIH, NINR; National Center for Advancing Translational Sciences of the National Institutes of
Health; Atlanta Veterans Administration Medical Center. No CoI
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A table of random numbers was used to create group assignments
that were placed in sealed envelopes until baseline data were collected."
Allocation concealment
(selection bias)
Unclear risk Sealed envelopes used, but doesn't specify that these are opaque and sequen-
tially numbered.
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-assessed
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear: imbalance in loss to follow-up, bias could affect completion of QoL
assessments. Paper indicates that mutlilevel mixed models were run to adjust
for attrition over time.
Selective reporting (re-
porting bias)
Low risk Outcomes listed on trial registration site (after study initiation but before
study completion) include MLHFQ
Other bias Low risk Nothing identified
Dunbar 2014  (Continued)
 
 
Methods Single-centre RCT
Recruiting: March 2007-November 2009
Duration of follow-up: 12 months
Intervention category: multidisciplinary team in geriatric day care hospital (categorised as multidisci-
plinary for this review)
Person delivering intervention: multidisciplinary
Participants Country: Spain
Participants: randomised N = 120 (intervention N = 60; control N = 60; 1 intervention and 2 control dis-
continued post-randomisation but before intervention so have no baseline assessment)
Gonzalez-Guerrero 2014 
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Mean ± SD age: intervention 85 (6.4); control 85 (6.3)
Male sex N (%): intervention 17/59 (28.8%); control 15/58 (25.8%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment: previous NYHA class, mean (SD):
• intervention 2.5 (0.7)• control 2.3 (0.8)
Diabetes N (%): intervention 26 (44.1); control 19 (32.8)
Inclusion criteria:
• Consecutive patients diagnosed with acute HF and discharged from the Geriatric Service of the
Cáceres Hospital Complex (Spain)• diagnosis according to ESC criteria• hospital stay of > 1 days
Additional information from trial registry:
• participants aged > 65;• discharged home or to a nursing home without medical staI• hospitalisation due to HF of ≥ 48 h (determined according to the ESC guidelines)
Exclusion criteria:
• terminal disease (expected survival < 6 months)• bedridden• severe dementia or other serious psychiatric disease• impossible to follow-up• in retirement homes with own medical service
Interventions Intervention:
• DMP multidisciplinary team (geriatrician (case manager), nurse, social worker) evaluated participants
and their caregivers prior to the hospital discharge.• participants were given an information manual about the disease, diet, weight control, exercise,
lifestyle, and medication, as well as how to recognize cardiac decompensation symptoms.• phone call from nurse 48 h after hospital discharge, to record any problems• After 10 days, the team examined the participants in the geriatric day-care hospital, using educational
reinforcements and evaluating for possible cardiac decompensation• Follow-up at the geriatric day-care hospital 1 and 6 months after discharge. Team assessed treat-
ment compliance, reinforced health education, and assessed participants’ ability to fulfil recommen-
dations; prescriptions and doses were adjusted according to clinical guidelines. Re-evaluation of glob-
al therapeutic regime and comorbidities considering possible changes in functional, cognitive, affec-
tive, and social capacities.• phone call from geriatrician during month 3. Geriatrician was also available by phone during
09:00-14:00, and all participants could receive attention in the hospital or via phone for unscheduled
evaluation of clinical decline due to a medical problem• all follow-up involved health-educational reinforcement and evaluation of possible cardiac decom-
pensation
Comparator:
• before the hospital discharge, each participant and the caregiver received an information manual ex-
plaining the HF education.• following hospital discharge, treatment and follow-up were provided by the primary care physician• visits were scheduled, and treatment was prescribed depending on the case
Gonzalez-Guerrero 2014  (Continued)
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• outpatient appointments at the Geriatric Service or other medical facilities were provided by non-
members of the research study
Outcomes • HF-mortality• All-cause mortality• HF readmissions• All-cause readmissions• HRQoL (MLHFQ)• Cost-effectiveness
Notes Funding: Research Group Grant, co-financed by Regional Government of Extremadura (Spain) and Eu-
ropean Union (FEDER). "The funder did not influence the design, methods, subject recruitment, data
collections, analysis, or preparation of paper."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The patients were separated randomly using a computer-generated
list."
Allocation concealment
(selection bias)
Unclear risk Quote: "Upon hospital discharge, the patients and the researchers ignored the
group assigned to each patient."
Blinding of participants
and personnel (perfor-
mance bias)
High risk Blinding not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "The results were obtained from the patients and their relatives, the
hospital records, and the National Death Index.The result variables were adju-
dicated by a researcher of the Department of Patient Management, who was
unaware of the group to which the patients belonged."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL participant-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Analyses includes all randomised participants who received the intervention
(excluding 1 intervention and 2 control participants who moved out of the area
before receiving intervention).
For MLHFQ, the missing values from censored cases were included. 3 partic-
ipants were censored during the follow-up as they were hospitalised and re-
ferred to other medical services (2 from the intervention group and one from
the control group)
Selective reporting (re-
porting bias)
High risk Study registered retrospectively (ISRCTN10823032) with a different title, em-
phasising cost-effectiveness analysis as a co-primary outcome with event-free
survival. No cost-effectiveness results published on trials registry or in litera-
ture to date.
Other bias Low risk Nothing identified
Gonzalez-Guerrero 2014  (Continued)
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Recruitment: December 2003-March 2005
Duration of follow-up: 6 months
Intervention category: case management
Person delivering the intervention: community pharmacist
Participants Country: UK
Number randomised: 339
169 allocated to intervention, 170 to control
20 intervention and 26 control participants excluded post-randomisation. Study involved 149 interven-
tion participants and 144 control group participants
NYHA: 
• intervention: class I, N = 6 (4.0%); class II, N = 43 (28.9%); class III, N = 52 (34.9%); class IV, N = 48 (32.2%)• control: class I, N = 11 (7.6%); Class II, N = 37 (25.7%); class III, N = 47 (32.6%); class IV, N = 49 (34.0%)
LVEF: NR
Age: intervention: 76.4 (9.5); control: 77.6 (9.0)
Percentage male: intervention: 63.2; control: 63.8
Ethnicity: NR
Inclusion criteria:
• adults (aged ≥ 18 years), admitted as an emergency in which HF was an important ongoing clinical
condition, i.e. all participants had been hospitalised for HF• prescribed ≥ 2 drugs (from any drug class) on discharge
Exclusion criteria:
• living in a residential or nursing home• awaiting surgery for ischaemic or valvular heart disease• awaiting heart transplantation• terminal malignancy
Interventions Duration of intervention: 6-8 weeks
Intervention: community pharmacist home visits within 2 weeks of discharge, where
• pharmacist provided education to participant and carer on HF, drugs, exercise, diet and smoking ces-
sation, in line with British Heart Foundation's 'Living with Heart Failure' booklet *which was leN with
participants• participants encouraged to complete simple sign and symptom monitoring diary card (including
weight)• pharmacist fed back recommendations to GP and any need for drug adherence aid to local pharmacist• An additional follow-up visit was made 6-8 weeks after discharge to review progress and reinforce
original advice
Control group: usual care
Outcomes  Primary:
• total emergency admissions to hospital in 6 months
Secondary:
Holland 2007  (Continued)
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• deaths at 6 months• QoL (EQ-5D) and MLWHF at 6 months
Notes Data source: published data only
Funding: "Research costs were funded by a project grant from the British Heart Foundation. Excess
treatment costs were funded by Great Yarmouth and Southern Norfolk Primary Care Trusts. This trial re-
ceived support for the educational training events from Pfizer UK."
CoI: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “We used third party telephone randomisation based on a computer
generated random allocation sequence.”
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "Emergency admission data came from Hospital Episode Statistics. The
Office for National Statistics provided mortality data".
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "We analysed patient data according to randomisation group, irrespec-
tive of whether or not they received the intervention as planned (the intention
to treat principle)." but flow chart indicates only 148/169 (87.6%) intervention
group and 143/170 (84%) control group analysed
Selective reporting (re-
porting bias)
Unclear risk Trial retrospectively registered: ISRCTN59427925
Other bias Low risk Nothing identified
Holland 2007  (Continued)
 
 
Methods RCT
Recruitment: May 1994-March 1997
Duration of follow-up: 9 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: the Netherlands
Participants (patients enrolled and surviving to discharge): 84 participants in intervention group* 95
participants in comparison group
Jaarsma 2000 
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Actual age of study participants: NR for original group, those who remained at 9 months were mean age
72 years (SD 9) at baseline
Male sex: of those who remained at 9 months, 60%
Ethnicity: NR
Actual severity of HF in study participants at recruitment: NR
Inclusion criteria:
• participants admitted to the cardiology unit of 1 hospital with HF symptoms and diagnosis verified
with Boston score• NYHA III or IV• HF diagnosis for > 3 months• Aged ≥ 50 years• Dutch literate
Study exclusion criteria:
• coexisting, severe, chronic debilitating disease• discharge to a nursing home• psychiatric diagnosis• CABG, angioplasty or valve replacement in past 6 months or expected to have such treatment in next
3 months
Interventions Duration of intervention: up to 10 days after discharge from index admission, on average one week*
Intervention: "Supportive educational intervention"
During index admission:
• intensive education by study nurse using standard nursing care plan
After discharge:
• study nurse phoned participant within 1 week of discharge to assess potential problems and made
appointment for home visit• Home visit on average 1 week after discharge*. At home visit education continued.• If required, study nurse wrote to participant's home care nurse about participant's specific needs• Between discharge and home visit participant could contact study nurse if they encountered prob-
lems• After home visit participant encouraged to contact their cardiologist, GP or emergency heart centre
with any problems
Educational component covered:
• symptoms of worsening failure• sodium restriction• fluid balance• compliance and individuals' problems,• included education and support to participant's family
Comparison: usual care
• "A nurse or physician, depending on his or her individual insight into the patients' questions, provided
these patients with education about medication and lifestyle"• Usual care participants did not receive structured education
Outcomes Primary endpoints: NR
Jaarsma 2000  (Continued)
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Measures of QOL:
• Heart Failure Functional Status Inventory (to assess functional capabilities at baseline, 3 and 9
months)• symptom occurrence (at baseline, 1, 3 and 9 months), severity and distress questionnaire, designed
for this study (at 3 and 9 months)• Psychosocial Adjustment to Illness Scale (at baseline, 3 and 9 months)• Cantril's Ladder of Life (to measure overall well-being at baseline, 1, 3 and 9 months)
Measures of self-agency and self-care behaviour:
• participants' ability to care for themselves using the Appraisal of Self-care Agency Scale (ASE) (at base-
line, 3 and 9 months)• participants' self-care behaviour using a Heart Failure Self-care Behaviour Scale, designed for this
study (at baseline, 1, 3 and 9 months)
Healthcare resource use:
• participants' report of number and reason for contact with GP, cardiologist, medical specialists, phys-
ical therapists, social care providers and alternative health specialists• hospital readmissions and outpatient visits from hospital database• reasons for readmission form patient charts
Also reported:
• deaths at 9 months
Notes Data source: published data and author contacted for clarification (indicated by *)
Funding: "Supported by the Netherlands Heart Foundation, grant 43.033,and Zilveren Kruis, part of
Achmea"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "By drawing from an envelope patients were randomly assigned to re-
ceive either care-as-usual or the supportive-education intervention".
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "The 2 study nurses were involved in data collection as researcher and
research assistant. However, the person who collected the data was never the
same nurse who visited the patient for the intervention. Health care personnel
(cardiologists or staI) involved in the care for the patients did not know if the
patient was in the intervention or control group."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Participants themselves knew their assignment, which could have affected
self-reported QoL outcome. The 2 study nurses who delivered the intervention
were also involved in the study as data collectors and were aware of the allo-
cation status of the participants
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 186 participants enrolled in to the study and 132 (71%) remained at 9 months.
58/84 (69%) remained in the intervention group whilst 74/95 (78%) remained
in the control group. Analyses on self-care abilities and behaviour were adjust-
Jaarsma 2000  (Continued)
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ed in an attempt to compensate for the influence of attrition - this adjustment
assumed that those who dropped out did not improve their self-care and self-
agency from baseline this assumption may not have adequately adjusted for
attrition.
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Jaarsma 2000  (Continued)
 
 
Methods RCT (17 centres)
Recruitment: October 2002-February 2005
Duration of follow-up: 18 months
Basic intervention
Intervention category: clinic
Person delivering the intervention: specialist nurse
Intensive intervention
Intervention category: case management
Person delivering the intervention: multidisciplinary
Participants Country: Netherlands
Total number randomised = 1049 (basic intervention N = 348, intensive intervention N = 353, control N =
348) 26 died before discharge, leaving 1023 in the total group
Actual severity of HF in study participants at recruitment: NYHA class, N (%):
• basic intervention: class I, N = 0 (0%); class II, N = 171 (51%); class III, N = 159 (47%); class IV, N = 8 (3%)• intensive intervention: class I, N = 0 (0%); class II, N = 165 (48%); class III, N = 163 (48%); class IV, N =
13 (4%);• control: class I, N = 0 (0%); class II, N = 177 (54%); class III, N = 139 (42%); class IV, N = 13 (4%)
LVEF:  basic: 34 (SD 14); intensive: 33 (SD 15); control: 34 (SD 14)
Age: basic: 71 (SD 11); intensive: 70 (SD 12); control: 72 (SD 11)
Percentage male: basic: 66; intensive: 61; control: 60
Ethnicity: NR
Inclusion criteria:
• admitted to hospital with HF NYHA functional class II-IV• aged ≥ 18 years• evidence of structural underlying heart disease as shown at CV imaging• systolic and diastolic dysfunction (preserved LVEF)• stable on standard HF medication before discharge
Exclusion criteria:
• concurrent inclusion in another study or HF clinic
Jaarsma 2008 
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• inability to complete the questionnaires• invasive procedure or cardiac surgery intervention performed within the last 6 months• such procedure or intervention planned to be performed within the next 3 months• ongoing evaluation for heart transplantation• inability or unwillingness to give informed consent
Interventions Duration of intervention: 18 months
Intervention: NR
Basic intervention:
• during index hospital stay: participant (and family) education by HF nurse according to protocol and
guidelines, behavioural strategies used to improve adherence      • within 2/52 of discharge telephone call to participant from HF nurse• during regular visits to cardiologist at the outpatient clinic (at 2, 6, 12 and 18 months after discharge)
additional visits to HF nurse• additional visits just to the HF nurse at the outpatient clinic at one, 3, 9, and 15 months after discharge• telephone access to HF nurse Monday-Friday, office hours, participants (and families) encouraged  to
contact their nurse if any change in their condition or any questions
Intensive intervention:
• as for the basic intervention plus:• home visit by HF nurse within 10 days of discharge to assess coping, HF health status general health,
and medical, health care and social support.  Second home visit 11 months after discharge• weekly telephone calls by the HF nurse in the 1st month after discharge then monthly calls• Out-of-hours back-up to provide 24-h telephone coverage• HF nurse to consult multidisciplinary team at least once during both index admission and once during
follow-up to optimise her advice for each participant
Control: standard management by cardiologist and, subsequently, GP
Outcomes Primary (18 months):
• time to death (all-cause) or hospitalisation because of HF (composite outcome)• number of days lost to death or hospitalisation• number of readmissions per participant
Secondary (18 months):
• death from any cause• hospitalisation because of HF• QoL• costs (cost-effectiveness results published by Cao (2013) and Postums (2011))
Notes Data source: published data only
"Financial Disclosure: None reported. Funding/support: This study was supported by grant 2000Z003
from the Netherlands Heart Foundation and by additional unrestricted grants from Biosite France
SAS, Jouy-en-Josas, France (brain natriuretic peptide), Roche Diagnostics Nederland BV, Venlo, the
Netherlands (N-terminal prohormone brain natriuretic peptide), and Novartis Pharma BV, Arnhem, the
Netherlands."
Some differences in number of contacts with the cardiologist in all groups:
• 40% more cardiologist visits and phone calls in basic group• 10% more cardiologist visits and phone calls in intensive group• 33% more cardiologist visits in control group
Jaarsma 2008  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “The computer-generated randomisation scheme used random per-
muted blocks of 6 patients stratified per centre to ensure balanced assignment
of patients to each of the 3 groups in each of the 17 participating centres.”
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "blinded endpoint evaluation"
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Zero loss to follow-up after intervention started (8 basic group, 9 intensive
group, and 9 control participants died before hospital discharge and didn't re-
ceive intervention)
Selective reporting (re-
porting bias)
Unclear risk Trial retrospectively registered (NCT 98675639) after enrolment complete
but before follow-up completed. Costs and QoL mentioned as secondary out-
comes, but NR in Jaarsma 2008. Cost evaluation in Cao 2013 and Postums
2011.
Other bias Low risk Nothing identified
Jaarsma 2008  (Continued)
 
 
Methods RCT (2 centres)
Recruitment: December 1996-December 1998
Duration of follow-up: 6 months from recruitment (plus additional 3 months)
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Participants: 102 participants (66 men, 65%) in intervention group, 98 (55 men, 56%) in comparison
group
Actual age of study participants at recruitment: median 63.5 years (range 25-88 years)
Male sex: 61%
Ethnicity: "white" 64%
Actual severity of HF in study participants at baseline NYHA class, N (%):
• intervention group: class II, N = 38 (37%); class III, N = 57 (56%)• control: class II, N = 33 (34%); class III, N = 60 (61%)
LVEF:
Kasper 2002 
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• intervention group 27.1% (SD 13.8, range 10-70)• control group mean 27.5% (SD 13.9, range 5-60)
Inclusion criteria:
• admitted to 1 of 2 hospitals with a primary diagnosis of NYHA class III/IV HF• English speaking.• Permission from participant's "primary physician"• judged to be at high risk of HF readmission, i.e. ≥ 1 of the following criteria:* aged > 70 years* LVEF < 35%* ≥ 1 other hospital admission for HF in previous year* ischaemic cardiomyopathy* peripheral oedema at hospital discharge* < 3 kg weight loss while in the hospital* PVD• or any 1 of the following during the index admission:* pulmonary capillary wedge pressure > 25 mmHg* cardiac index < 2.0 L/min/m2* SBP > 180 mmHg* DBP > 100 mmHg
Exclusion criteria:
• valvular heart disease requiring surgery• active substance abuse• cardiomyopathy (peripartum, hypertrophic with LV outflow tract obstruction or restrictive). Constric-
tive pericarditis• psychiatric disease• dementia likely to limit compliance• non-cardiac illness likely to cause repeat hospital admission• heart Tx likely to occur within 6 months• uncorrected thyroid disease• serum creatinine ≥ 3.0 mg/dL• long-term home i/v inotropic therapy• cardiac surgery or MI during the index admission• active participation in another research trial• residence in a nursing home, rehabilitation facility or outside the area served by the 2 hospitals
Interventions Duration of intervention: 6 months
Intervention: "multidisciplinary program"
During index hospitalisation:
• HF cardiologist designed an individualised treatment plan for each participant before randomisation,
which included medication, diet and exercise management
After discharge:
• "Telephone nurse co-coordinator" phoned participants within 72 h of discharge and then weekly for
1st month, bi-weekly in 2nd month and then monthly. (Content of phone calls: set script with prob-
lems pursued as clinically indicated . No medication adjustments over phone.)• Monthly follow-up with HF nurses (usually in HF clinic)• "Primary care physicians" (66% internal medicine physicians, 29% cardiologists) received regular up-
dates from HF nurses and were notified of abnormal lab results.
Kasper 2002  (Continued)
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• All intervention participants received: pill sorter, list correct medications, list of dietary and exercise
recommendations, 24-h telephone contact number and participant educational material• If required and financial resources limited, participants also received: 3 g sodium 'Meals on Wheels'
diet, weigh scale, medications, transport to the clinic and a phone• HF cardiologist saw participants at 6 months
Content of HF nurse follow-up:
• aimed to implement the treatment plan designed by HF cardiologist by using a pre-specified 55-page
algorithm (also designed by the HF cardiologists), which included initiation and titration of drugs, a
low sodium diet and exercise recommendations
Comparison group: usual care
• this was care by the participants' primary physicians (73% internal medicine physicians, 26% cardiol-
ogists).• HF cardiologist designed treatment plan for each participant "documented in patient's chart without
further intervention"
Outcomes Primary endpoint (6 months):
• total number of HF hospital admissions• all-cause deaths (i.e. composite endpoint)
Secondary outcomes (6 months):
• death• HF hospital admissions• all-cause hospital admissions• change in HRQOL (MLHFQ)• change in activity status (Duke Activity Status Index)• process indicators including: proportion of participants with systolic dysfunction receiving ACEI ac-
cording to published guidelines or appropriate alternative treatment if intolerant of ACEI; percentage
participants euvolaemic according to defined goal weight; compliance with dietary guidelines using
locally developed sodium score and cost data
Notes Data source: published data and information supplied by study author for 'Rsk of bias' assessments (in-
dicated by*)
Funding: "Partial funding was provided by CardioContinuum, Inc., Rockville, Maryland. Under a licens-
ing agreement between The Johns Hopkins University and CardioContinuum, the University and, in
particular, its Division of Cardiology, are entitled to royalty on the use of the HF management program
described in this study. The University also owns CardioContinuum stock, which is subject to certain
restrictions under University policy. The University, in accordance with its conflict of interest policies,
is managing the terms of this arrangement. None of the investigators, with the exception of Ms. Van
Anden (once an employee of CardioContinuum), have personal stock, royalty interests or consulting
arrangements with CardioContinuum."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The coordinating centre made treatment assignments by using an au-
tomated telephone response system".
Allocation concealment
(selection bias)
Low risk Quote: "Random number schedules were prepared before initiation of patient
recruitment and were unknown to the clinical investigators".
Kasper 2002  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "An independent central telephone data collector, who had no knowl-
edge of the patients’ treatment assignment, collected data monthly from
all patients during the nine months after enrollment. Medical document co-
ordinators blinded to treatment assignment searched the on-line medical
records.... The coordinating center deleted from all documents and records in-
formation that revealed personal identity or treatment assignment.... A com-
mittee composed of three cardiologists, who had no knowledge of the treat-
ment assignment, categorized each hospital admission and death using docu-
ments prepared by the coordinating center."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT principle for main outcomes. QoL data available for 94/102 (92%) interven-
tion and 85/98 (87%) control group at 6 months
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Kasper 2002  (Continued)
 
 
Methods Multicentre RCT (6 centres)
Recruitment period: 22 months, dates NR
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Number randomised: 200 (control N = 97, intervention N = 103)
Actual severity of HF in study participants at baseline NYHA class, %:
• intervention: class I, 0%; class II 50.5%; class III 49.5%; class IV 0%• control: class I 1.9%; class II 58.3%; class III 35.9%; class IV 3.9%
LVEF: intervention: 30 (SD 14); control: 31 (SD 12)
Age: intervention 70.3 (SD 12.2); control: 73.9 (SD 10.7)
Percentage male: intervention: 57.7; control: 58.3
Ethnicity: NR
Inclusion criteria:
• participants were enrolled during an index HF hospitalisation or within 2 weeks of discharge
Kimmelstiel 2004 
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• participants with HF resulting from ischaemic heart disease, dilated cardiomyopathy, valvular heart
disease (either surgically treated or deemed inoperable), or hypertensive heart disease
Exclusion criteria:
• noncardiac debilitating illness such as active malignancy• severe liver disease• severe renal insufficiency (creatinine 3.0 mg/dL)• dementia• obstructive lung disease requiring hospitalisation• angina at rest or as the principal cause of activity limitation• MI or revascularisation procedure during the index hospitalisation or within the preceding 30 days• planned revascularisation or valvular surgery• restrictive myopathy• pericardial constriction• hypertrophic cardiomyopathy
Interventions Duration of intervention: 90 days, followed by passive surveillance (nurse-manager available for incom-
ing calls but didn't make scheduled calls) for clinically stable participants or continuation for partici-
pants with overt clinical instability (class A)
Intervention: Specialized Primary and Networked Care in HF (SPAN-CHF)
• home visit from nurse-manager within 3 days of discharge, focusing on dietary and medical compli-
ance, daily weights, self-monitoring,and early reporting of changes in weight or clinical status• teaching tool 'Patient and Family Handbook' given to participants during home visit, including sec-
tions on HF (definition), medications, low-salt diet, importance of daily weight, and clinical signs and
symptoms that should prompt a call to the SPAN-CHF nurse or primary care physician (plus contact
phone numbers)• during home visit, nurse performed cardiovascular examination and symptom assessment• Weekly or biweekly phone calls from nurse-manager to participants focused on identifying changes
in clinical condition and education reinforcement• participants had 24-h/7-day telephone access to nurse managers, and were instructed to report
changes in clinical status and relevant weight change• Frequent communication between nurse-managers, primary care physicians and HF specialist
Comparator: usual care
Outcomes Primary:
•  hospitalisations for HF during the first 90 days after enrolment
Secondary (90 days):
• cardiac hospitalisations and all-cause hospitalisations• number of days hospitalised per patient-year of follow-up for HF, cardiac and all-cause hospitalisa-
tions at 1 year• costs presented by Gregory 2006, but only for 90-day data not full length of follow-up
Notes Data source: published data only
Funding: "This study was funded in part by grants from the Fannie E. Rippel Foundation and the
Hewlett-Packard Corporation."
Risk of bias
Bias Authors' judgement Support for judgement
Kimmelstiel 2004  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomization lists were generated independently for each hospital
(in blocks of 4 patients), stratifying patients first by level of care needed.”
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: “Non-nurse study coordinators, blinded to treatment assignment, per-
formed telephone follow-up in all patients at 3 and 12 months after enrolment
to ascertain clinical events. Events were adjudicated by an investigator blind-
ed to treatment group.”
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Subjective outcomes NR
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Numbers included in analysis NR
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Kimmelstiel 2004  (Continued)
 
 
Methods Single-centre RCT
Recruitment period: October 1997-September 1998
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Participants: 44 participants (21 men, 48%) in intervention group; 44 participants (29 men, 66%) in
comparison group
Actual age of study participants: median age 74 years, intervention 75.9 (SD 8.7); control mean age 71.6
(SD 10.3)
Male: 57%
Ethnicity: "74% Caucasians"
Actual severity of HF in study participants at recruitment:
Mean EF: intervention group 38% (SD 17); control group 37% (SD 16)
NYHA: NR
Inclusion criteria:
• aged ≥ 50 years• needed to have either admission diagnosis of HF or radiological signs of HF on admission chest X-ray.
All participants had been hospitalised for HF• reviewed within 3 days to verify additional set of criteria derived from NHANES-1
Study exclusion criteria:
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• participants transferred from other hospitals or nursing homes• participants with HF secondary to high output states or non-cardiac disease• participants with another terminal illness (e.g. expected survival < 6/12)
Interventions Duration of intervention: 1 year
Intervention: "Education and Support"
After discharge:
• initial hour-long face-to-face consultation with experienced cardiac nurse within 2 weeks of discharge
using a teaching booklet (45% of these consultations took place in participant's home, remainder in
hospital clinic)• following this weekly telephone contact for 4 weeks, bi-weekly for 8 weeks then monthly until 1 year• initial consultation covered 5 sequential care domains for chronic illness including: patient knowledge
of illness; the relation between medication and illness; the relation between health behaviours and
illness; knowledge of early signs and symptoms of decompensation, and where and when to obtain
assistance. Follow-up phone calls reinforced the 5 care domains but did not modify current regimens
or provide recommendations about treatment. However the nurse could recommend that the partic-
ipant consulted his/her physician when their condition deteriorated sharply or when they had prob-
lems, in order to help participants to understand when and how to seek and access care
Comparison: usual care
• All usual care treatments and services ordered by their physicians
Outcomes Primary endpoint:
• readmission or death at 12 months' follow-up
Secondary endpoints (12 months' follow-up):
• all-cause admissions• HF or other CVD-related readmissions• cumulative number of days in hospital• cost of readmission
Notes Data source: published data and information from author*
Funding: "This study was funded in part by grants from the Fannie E. Rippel Foundation and the
Hewlett-Packard Corporation."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Computer generated"*
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk "One-year outcomes included deaths, ascertained through next-of-kin, hos-
pital records, active monitoring of obituaries and information about readmis-
sions obtained from patients, their families, discharge summaries and hospital
Krumholz 2002  (Continued)
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records to confirm the event and classify the cause, based on the assessment
of a clinician blinded to the patients’ intervention allocation."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk QoL NR
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk States ITT analysis used, but numbers included in analysis NR
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Unclear risk Intervention group significantly older with lower incidence of prior CABG and
fewer prescribed calcium channel blockers
Krumholz 2002  (Continued)
 
 
Methods RCT (2 centres)
Recruitment: September 1999-February 2001
Duration of follow-up: 6 months
Intervention category: case management
Person delivering the intervention: community nurse
Participants Country: China (Hong Kong)
Number randomised: 105 (intervention N = 49, control N = 56)
NYHA: NR
LVEF < 40% : 15 (30%) 9 (18%) (intervention, N = 43); (control, N = 50)
Age (years): intervention: 79.5 (SD 6.6); control: 76.8 (SD 7.0)
Percentage male: intervention: 45; control: 45
Ethnicity: NR
Inclusion criteria:
• hospitalised with a principal diagnosis of HF• age > 60 years• residing within the region and had ≥ 1 hospital admission for HF in the 12 months prior to the index
admission.
Exclusion criteria:
• communication problems but without caregivers• residing in a nursing home• terminal disease with a life expectancy of < six months
Interventions Duration of intervention: 6 months
Intervention: community nurse-supported hospital discharge programme
Kwok 2008 
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• community nurse (CN) visited participants prior to discharge, to provide health counselling, informa-
tion on drug compliance, dietary advice• home visit by CN within 7 days of discharge, then weekly for 4 weeks, then monthly, to check vital signs
and signs of poorly controlled HF (ankle swelling, dyspnoea and basal crepitation on auscultation).
Medications checked and dietary/exercise advice given• home care and day care services arranged if social support insufficient• participants encouraged to contact CN via a telephone hotline during office hours when they devel-
oped symptoms• following liaison with geriatrician or cardiologist, CN able to alter medication, arrange appointments
and clinical admission as appropriate• CN monitored participants refusing further home visits by telephone
Control: usual medical and social care, but with follow-up in the hospital outpatient clinics by the same
group of designated geriatricians or cardiologists
Outcomes Primary:
• percentage of participants who ever had unplanned hospital readmissions within 6 calendar months
of discharge
Secondary (6 months):
• number of unplanned hospital readmissions• changes in 6-minute walking test• London Handicap Scale (LHS) domain scores
Notes Data source: published data only
Funding: "The research was funded by the Health Services Research Committee/Health Care & Promo-
tion Fund (HSRC/HCPF) of Hong Kong"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “The ward nurses then phoned a second research assistant who as-
signed trial grouping according to a random number table.”
Allocation concealment
(selection bias)
Low risk See above
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: “The research nurse was not aware of the randomisation grouping of
the subjects.”
Quote: "All hospital admissions, including attendance to the A&E, throughout
Hong Kong were traced by an electronic database maintained by the Hospital
Authority"
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk QoL NR
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 1 intervention and 2 control group participants dropped out. Cost analy-
sis based on ITT
Kwok 2008  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Kwok 2008  (Continued)
 
 
Methods Single-centre pilot RCT
Recruiting: April 2015-June 2016
Duration of follow-up: 6 months
Intervention category: case management
person delivering intervention: specialist nurse
Participants Country: Scotland, UK
Participants: randomised N = 50 (intervention N = 25; control N = 25)
Mean ± SD age: intervention 71.8 (9.9); control 76.0 (6.6)
Male sex N (%): intervention 9 (36%); control 14 (56%)
Ethnicity: intervention and control both 100% white
Actual severity of HF in study participants at recruitment NYHA class:
intervention: class I, N = 1 (4%); class II, N = 15 (60%); class III, N = 9 (36%); class IV, N = 0 (0%)
Control: class I, N = 1 (4%); class II, N = 16 (64%); class III, N = 8 (32%); class IV, N = 0 (0%)
Inclusion criteria: 
• aged ≥ 18 years• a confirmed diagnosis of HF by EF on echocardiography, radionuclide ventriculography or angiogra-
phy (i.e., LVEF ≥ 45% within the last 6 months prior to randomisation)
Exclusion criteria: 
• cardiac rehab undertaken within 6 months prior to enrolment• any contraindication to exercise testing or exercise training (with consideration of adapted ESC guide-
lines for HF)
Interventions Intervention: 
Participants were provided with:
• REACH-HF manual, relaxation CD, chair-based exercise DVD, a ‘Progress Tracker’ tool for patients and
a ‘Family and Friends Resource’ for caregivers• participants and caregivers worked through the REACH-HF manual over 12-weeks, facilitated by 2
trained cardiac nurses (at least 1 face-to-face and 2 phone contacts)• REACH-HF manual includes:* progressive exercise training programme, tailored to participant’s ability and choice of a walking
programme or a chair-based exercise DVD, or a combination* managing stress/breathlessness/anxiety.* HF symptom monitoring* taking medication* understanding HF (and why self-management helps).
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The core priorities for caregiver elements of the intervention were:
• to facilitate improvement in patient HRQoL by helping them to achieve the core priorities for change• to improve HRQoL for caregivers by acting to maintain their own health and well-being
Comparator:  usual medical management for HF according to current guidelines
Outcomes • All-cause mortality• HF readmissions• All-cause readmissions• Serious adverse events• HRQoL (MLHFQ) (EQ-5D and others also reported but not data-extracted as MLHFQ)
Notes Funding: "National Institute for Health Research (NIHR) under its Programme Grants for Applied Re-
search Programme (Grant Reference Number RP-PG-1210-12004). NB, CA, CJG and RST are also sup-
ported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied
Health Research and Care (CLAHRC) South West Peninsula at the Royal Devon and Exeter NHS Founda-
tion Trust; KJ by CLAHRC West Midlands and SS by CLAHRC East-Midlands"
Study author confirmed majority of participants hospitalised for HF
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from protocol: "Randomisation numbers will be computer generated
and assigned in strict sequence. At the point of randomisation, participants
will be assigned the next randomisation number in the sequence. To maintain
concealment and minimise selection bias, randomisation will be performed af-
ter the baseline visit by a member of Peninsula Clinical Trials Unit (CTU), inde-
pendent from investigator teams, using a secure, web-based randomisation
system."
Allocation concealment
(selection bias)
Low risk Quote from protocol: "To maintain concealment and minimise selection bias,
randomisation will be performed after the baseline visit by a member of Penin-
sula Clinical Trials Unit (CTU), independent from investigator teams, using a
secure, web-based randomisation system."
Blinding of participants
and personnel (perfor-
mance bias)
High risk Quote: "Given the nature of the REACH-HF intervention, it was not possible to
blind participants or those involved in the provision of care."
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "The statistician undertaking the data analysis was blinded to treat-
ment allocation and we also blinded researchers undertaking collection of
outcome data to minimise potential bias. We assessed the fidelity of blinding
by asking outcome assessors at each follow-up visit to guess patient group al-
location. Unblinding of groups did not take place until after data analysis and
the blinded results had been presented to the Trial Management Group and in-
terpretation of results was agreed. "  
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL outcomes self-reported by participants not blind to treatment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Losses to follow-up were small and similar between arms (3/25 (12%) in inter-
vention group, 2/25 (8%) in control group, no reasons given)
Lang 2018  (Continued)
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Selective reporting (re-
porting bias)
Low risk Reported outcomes reflect published protocol, although this was  published
after enrolment began
Other bias Low risk Nothing noted
Lang 2018  (Continued)
 
 
Methods Single-centre RCT
Recruitment: July 2003-February 2005
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Switzerland
N randomised = 42, 20 to intervention, 22 to control
Age, mean (SD): intervention: 76.7 (7.1); control: 77.6 (6.0)
Percentage male: intervention: 59.1 (13%); control: 65.0 (13%)
Ethnicity: NR
NYHA at discharge: NR
Inclusion criteria:
• adult patients hospitalised with decompensated HF (NYHA II-IV), irrespective of LVEF• brain natriuretic peptide (BNP) ≥ 100 pg/mL• history of dyspnoea• increased fatigue or weakness• ability to speak German and to comprehend a telephone conversation• discharge to a home setting
Exclusion criteria:
• acute MI within 8 weeks prior to inclusion• severe myocardial or valvular obstructive disease• uncontrolled angina pectoris• co-morbid conditions compromising prognosis (life expectancy of < 12 months)• planned (except heart Tx) or previous cardiac surgery within 3 months• on dialysis• unstable psychiatric disorders or substance abuse• cognitive impairment (MMSE score < 24)• enrolled in another study• refused to sign an informed consent
Interventions Intervention:
• participant education (HF-educational booklet and kit (Swiss Heart Foundation))• support with self-care including recognition of warning signs of deterioration• advice on diet, fluids and sodium management• importance of daily weighing
Leventhal 2011 
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• identifying actions to take in case of increasing symptoms, individualised care plans, communication
with primary care physician• Intensity and complexity: intervention duration 12 months, beginning with home visit from specialist
HF nurse, followed by 17 structured telephone calls (weekly x 4, bi-monthly x 4, monthly x 6) plus
additional calls when needed; 1 call with primary care physician following home visit, additional calls
when needed;• nurse consultation with study internist, study cardiologist or dietician when needed.• home visit consisted of a physical, psychosocial and environmental assessment, the provision of ed-
ucational, behavioural, and supportive care to build self-care abilities, and individualised participant
goal-setting to increase self-efficacy.• follow-up telephone calls included discussions of questions or problems the participants had due to
their HF identification of signs and symptoms signifying possible decompensation of HF, review of
current medications, reinforcement of self-care activities and setting new goals
Comparator:
• all participants received similar care during hospitalisation. This consisted of the normal medical and
nursing care provided by hospital staI• all study participants were examined by the study HF-cardiologist who recommended lifestyle mod-
ifications and made suggestions for optimal medical management to the participant’s primary care
physician• all participants were given a HF education booklet published by the Swiss Heart Foundation• these efforts were made to standardise usual care, to remove unnecessary variability in care provided
to the control participants• following hospitalisation, medical care was provided by the primary care physician (usual-care group
protocol)
Outcomes Primary:
• mortality (all causes)• readmission (HF related and all causes)
Secondary:
• QoL (EuroQol- 5D (EQ-5D) and MLHFQ)• length of stay
Notes Funding: "Funding for this study was provided by the Swiss National Foundation # 3200-068000
(www.snf.ch) and the Swiss Heart Foundation. There are no potential competing interests."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Following discharge, the participant was randomised by an independent cen-
tre, according to a computer-generated list (blocked, variable block size)
Allocation concealment
(selection bias)
Low risk The study nurse called the randomisation centre, stated the chronological
study recruitment number and was given the group assignment. Participants
were notified of their group assignment by telephone
Blinding of participants
and personnel (perfor-
mance bias)
High risk Quote: "Patients, care-givers, primary care physicians and the intervention
nurses were not blinded to group assignment."
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "Mortality data were obtained from the Department of Birth and Death
Records and re-admission data were obtained from hospital records, exam-
Leventhal 2011  (Continued)
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ined and adjudicated by a senior researcher blinded to group assignment, and
entered into the database by the study coordinator."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Quote: "Patients were sent the follow-up study questionnaires with a pre-ad-
dressed, stamped reply envelope and an appointment for a follow-up tele-
phone interview with a special data collector blinded to group assignments.
Questionnaires were entered into the database by research assistants, blinded
to group assignment, and checked by random sample by the data analyst."
However, participants themselves knew their group assignment, so QoL as-
sessment open to detection bias
Incomplete outcome data
(attrition bias) 
All outcomes
High risk The trial planned to recruit 300 participants, but the trial was stopped early
due to recruitment problems, and only 42 participants were recruited. Kaplan
Meier survival analysis was planned to compare time to mortality and time to
re-admission. However, since fewer participants were included than was ini-
tially planned, preventing calculation of reliable estimates, only a graphical
representation of the survival curves were given, without formal testing.
Selective reporting (re-
porting bias)
Unclear risk QoL data only reported as a random intercept regression analysis.
No protocol found
Other bias Low risk Nothing identified
Leventhal 2011  (Continued)
 
 
Methods RCT (2 centres)
Recruitment: September 2000-August 2002
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: pharmacist
Participants Country: Spain
Number randomised: 134 (intervention N = 70; control N = 64)
Age: intervention: 75.3 (SD 8.4); control: 76.1 (SD 9.4)
Percentage male: intervention: 41.4; control: 46.9
Ethnicity: NR
Actual severity of HF in study participants at recruitment
NYHA class, N (%):
• intervention: class I-II, N = 58 (84.1%); class III-IV, N = 11 (15.9%)• control: class I-II, N = 54 (87.1%); class III-IV, N = 8 (12.9%)
LVEF: intervention: 54.5 (SD 14.4); control: 47.4 (SD 17.3)
Inclusion criteria:
• patients admitted to the General Hospital of Vic and the Municipal Hospital of Badalona for HF who
met 2 major or 1 major and 2 minor Framingham criteria
Exclusion criteria:
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• regularly living out of the area of influence of the hospital• regularly living in an old people's home• moved to a social-health centre or to other centres for acute patients• suffering any type of dementia or disabling psychiatric disease• refusing to participate in the study
Interventions Duration of intervention: 12 months
Intervention: Active Information Program, carried out by a pharmacist with 2 key components:
• information -personal interview on day of discharge, covering information about the disease, diet ed-
ucation, information on drug therapy and the need for compliance• telephone support - participants given pharmacist's name and phone number, and encouraged to
contact about any doubts arising during treatment, or questions about the disease. Monthly during
the 1st 6 months and every 2 months thereafter, participants received home phone calls (not clear
from whom) to reinforce the intervention and solve any problems or questions arising
Comparison: no details given
• Follow-up visits at 2, 6 and 12 months to check compliance, QoL and participant satisfaction
Outcomes Primary (2, 6 and 12 months):
• time to the first readmission for HF or for another cause• percentage of participants with readmission• total number of readmissions• total of hospital stay days during the study period
Secondary (2, 6 and 12 months):
• treatment compliance (NR here)• QoL (EuroQol)• participant satisfaction with the care received and death during the follow-up (NR here)
Notes Data source: published data only
Funding: "This study (PI00/0665) was co-financed with a grant from the Health Research Fund (Fondo
de Investigación Sanitaria, FIS) and the European Regional Development Fund (ERDF)." CoI of study au-
thors not provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “The patients were randomised to one of the two groups through a ran-
domisation software. Lists were generated in blocks of 4 to assure a consistent
patient distribution in both groups.”
Allocation concealment
(selection bias)
Low risk Quote: “Neither the physician nor the nurse responsible for the patient knew
the allocation until the educational intervention, the day of discharge”.
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information
Lopez 2006  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Self-reported QoL outcome
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not clear if readmissions reported on an ITT basis. Cost analysis stated to be
ITT, but 3 participants were excluded due to missing data on outpatient ap-
pointments
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified, although intervention group had slightly higher baseline EF
than controls
Lopez 2006  (Continued)
 
 
Methods Single-centre RCT
Recruiting: June 2010-May 2012
Duration of follow-up: 24 months
Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary
Participants Country: Taiwan
Participants: randomised N = 349 (intervention N = 174; control N = 175)
Mean ± SD age: intervention 59.2 (13.6); control 61.5 (12.6)
Male sex, N (%): intervention 127 (73.0); control 117 (66.9)
Ethnicity: NR
Diabetes, N (%): intervention 66 (37.9); control 82 (46.9)
Actual severity of HF in study participants at recruitment:
LVEF, mean (SD) %: intervention 36.9 (15.8); control 35.1 (14.3)
NYHA class N (%):
• intervention: class II, N = 34 (19.5); class III, N = 134 (77.0); class IV, N = 6 (3.4)• control: class II, N = 34 (19.4); class III, N = 130 (74.3); class IV, N = 11 (6.3)
Inclusion criteria:
• typical signs and symptoms of HF and NYHA functional classification II-IV• hospitalised because of acute cardiogenic pulmonary congestion based on chest X-rays after noncar-
diogenic causes were excluded• structural abnormalities documented by echocardiograms• aged 20-85 years• both patients with impaired LVEF and those with preserved LVEF were enrolled
Exclusion criteria:
• having a disorder other than HF that might compromise survival within the next 6 months• bedridden for > 3 months• serum creatinine of ≥ 3 mg/dL
Mao 2015 
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• dialysis within previous 2 weeks• severe coronary artery disease without complete revascularisation therapy• being pregnant
Interventions Intervention:
• participants were cared for by a HF team consisting of 2 cardiologists specialising in HF care, one psy-
chologist, one dietary assistant, one pharmacist, and 2 case managers (nursing practitioners). Team
provided individualised HF education and information on self-monitoring, optimised guideline-based
HF medication and complete cardiac and laboratory assessments• 1:1 education sessions with the case manager in hospital; participant diary for daily weight, medica-
tion and intake/output; educational booklet (symptoms; importance of monitoring body weight, in-
take/output; action plans; drug effects and the importance of compliance; diet and exercise• during follow-up: prescheduled outpatient visits to the combined clinic of a cardiologist and case
manager 7 days after discharge, then at least monthly or on demand for 6 months (included adjust-
ment of diuretic dose, nutritional consultation, education, drug titration, weighing)• After 6 months, if stabilised, participants visited clinic every 2–3 months, or on demand, with phone
contact every month; and 24/7 phone access to case manager
Comparator: 
• primary care cardiologist was responsible for participant evaluation, treatment, and clinic visits (usual
care for Taiwan).• neither scheduled follow-up nor specialised HF nurses were provided.• contact with the HF specialists of the research team was discouraged.• participants were advised to contact their primary care cardiologist if they had questions about HF
management
Outcomes • All-cause mortality• HF readmissions
Notes Funding:  National Science Council of Taiwan and Chang Gung Memorial Hospital ClinicalTrials.gov
Identifier: NCT01416285. No CoI
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer-generated permuted block randomization"
Allocation concealment
(selection bias)
Unclear risk Paper doesn't specify whether block size is concealed or random, so possible
to guess assignment of last participant in block
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "A committee of three cardiologists adjudicated all hospitalisations
without knowledge of the patients' clinical data to determine whether events
were related to worsening heart failure."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Not applicable - QoL NR
Incomplete outcome data
(attrition bias) 
Low risk 5% of intervention group and 0% of control group lost to follow-up
Mao 2015  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Unclear risk Trials registry states mortality (cardiac and non-cardiac) as an outcome,
whereas only all-cause mortality is presented here
Other bias High risk Intervention included using guideline-based medications. Post-hoc analysis
found that, after adjusting for this, the HR moved closer to the null and there
was no evidence for the disease management intervention lowering all-cause
death rates
Mao 2015  (Continued)
 
 
Methods Single-centre, single-blind RCT
Recruiting: September 2011-June 2012
Duration of follow-up: 6 months
Intervention category: case management
person delivering intervention: nurse
Participants Country: Iran
Participants: randomised N = 110 (intervention N = 55; control N = 55)
Mean ± SD age: intervention 61.28 ± 13; control 62.7 ± 10
Male sex: intervention 54%; control 62.2%
Ethnicity: NR
Actual severity of HF in study participants at recruitment, NYHA class:
• intervention - class III most prevalent (67.3%)• control: class III most prevalent (82%)
Inclusion criteria:  
• having HF diagnosed by cardiologist• aged > 18 years• NYHA class II–IV• EF < 45%• ability to read and write
Exclusion criteria:
• history of other diseases requiring surgery during study period• psychological disorder
Interventions Intervention: HF education
• nurses visited participants in their homes, using a checklist:* information about their disease* usual signs and symptoms and potential complications of their illness* prescribed medications* potential change in their lifestyle* special signs and symptoms which they have to know in order to go to the hospital on time* any other information about the illness which participants may request to be answered.
Mehralian 2014 
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• participants also received a simplified booklet about HF• Home-visits were scheduled twice a month in 1, 3 and 6 months after participants' discharge from
hospital• participants and their families were encouraged to make contact in the event of problems
Comparator: usual education
• provided by nurses 1 h before hospital discharge• nurses visited participants in their room and answered any questions
Outcomes • All-cause mortality• HRQoL (SF-36 - Iranian version)
Notes Funding: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned" with no further information
Allocation concealment
(selection bias)
Unclear risk No details given
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Study described as "single blind" but not clear who this applies to - partici-
pants were aware of their group assignment due to the nature of the interven-
tion.
 
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported by participants
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants accounted for 
Selective reporting (re-
porting bias)
Unclear risk No protocol available
 
Other bias Unclear risk More people in the control arm had NYHA class III disease (82% vs 67.3% in in-
tervention group). Not clear whether there were more or fewer people with
class IV disease, so possible that disease severity was worse in the control
arm. 
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Methods Single-centre RCT
Recruitment: January 1996-December 1999
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Mean (SD) follow-up: 1122 (405) days
Intervention category: clinic
Person delivering the intervention: nurse
Participants Country: Sweden
Number randomised: 208 (control N = 105, intervention N = 103)
NYHA:
• intervention: class II, N = 60 (58%); class III, N = 43 (42%); class IV, N = 0 (0%)• control: class II, N = 69 (66%); class III, N = 34 (32%); class IV, N = 2 (2%)
LVEF (%): intervention: 34 (SD 12); control: 35 (SD 11),
Age: intervention: 75.9 (SD 7.7); control: 75.7 (SD 6.6)
Percentage male: intervention: 56; control: 59
Ethnicity: NR
Inclusion criteria:
• All participants ≥ 60 years of age• hospitalised with HF according to NYHA class II-IV and LV systolic dysfunction by echocardiography
Exclusion criteria:
• acute MI or unstable angina pectoris within the previous 3 months• valvar stenosis• dementia• severe concomitant disease• refusal to participate
Interventions Duration of intervention: ≥ 18 months, mean follow-up was 1122 (405 ) days
Intervention: "nurse based outpatient management programme"
• regular visits to the outpatient clinic and participant encouraged to keep contact with nurse (not clear
how regular)• nurse checking symptoms and signs of HF, blood pressure, heart rate, and weight at each visit• nurses can institute and change medication doses according to standard protocol• participant instructed to check weight regularly and monitor early signs of deterioration• participants with good compliance instructed to change dosing of diuretics on their own• dietary advice recommends restricted sodium, fluid, and alcohol intake• information repeated in booklets and computerised educational programmes
Comparator:
• treated by GPs according to local health care plan for HF.• all participants had clinical examinations and detailed control of medication at 6, 12, and 18 months
at the Cardiovascular Research Laboratory
Outcomes Primary:
• QoL (6, 12 and 18 months)
Secondary:
• cardiac function (NR?)• medication (6, 12 and 18 months)
Mejhert 2004  (Continued)
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• hospitalisation (18 months)• mortality (18 months)
Notes Data source: published data only
Funding: "This study was supported by the Vårdal Foundation, the Swedish Heart and Lung Founda-
tion, the Swedish Society of Medicine, and Karolinska Institutet. " CoI for study authors not provided.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "patients were enrolled and underwent random assignment" but gives
no further details on method
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported by participants
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Appears to report for all participants
Selective reporting (re-
porting bias)
Unclear risk Cardiac function stated as a secondary outcome, but doesn't appear to be re-
ported.
No protocol found
Other bias Low risk No other apparent sources of bias
Mejhert 2004  (Continued)
 
 
Methods Multicentre RCT (6 centres)
Recruitment: February 1997-January 2001
Follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Participants: number randomised = 239 (control N = 121, intervention N = 118)
NYHA:
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• NR
Documented EF, N (%) intervention 88 (72)/control 98 (80)
< 20% 12 (14) / 17 (17) P = 0.755
20 to < 25% 10 (11) / 9 (9) P = 0.760
25 to < 35% 28 (32) / 30 (30) P = 0.914
35 to < 45% 26 (30) / 28 (28) P = 0.942
45% or more: 12 (14) / 14 (14) P = 1.00
Age: intervention: 76.4 (SD 6.9); control: 75.6 (SD 6.5)
Percentage male: intervention: 40; control: 44
Ethnicity: intervention: 66% white; control: 62% white; remainder of participants, African American
Inclusion criteria:
• all patients aged ≥ 65 admitted to study hospitals from their homes February 1997-January 2001 with
a diagnosis of HF (diagnosis-related group 127 validated at discharge) were screened for participation• speak English• be alert and oriented• be reachable by telephone after discharge• reside within a 60-mile radius service area of the admitting hospital
Exclusion criteria:
• end-stage renal disease
Interventions Duration of intervention: 3 months
Intervention: transitional care delivered by 3 APNs, who received standardised training before the
study commenced.
• Quality-Cost Model of APN Transitional Care management strategies, including:* identification of participants’ and caregivers’ goals* individualised plans of care developed and implemented by APNs in collaboration with partici-
pants’ physicians* educational and behavioral strategies to address participants’ and caregivers learning needs* continuity of care and care co-ordination across settings• evidence-based protocol, guided by national HF guidelines, included:* APN discharge planning* initial APN visit within 24 h of index hospital admission, and at least daily during the index hospi-
talisation for comprehensive assessment of participants and carers* ≥ 8 APN home visits (1 within 24 h of discharge), weekly during the first month then bimonthly
during 2nd and 3rd months to check clinical status* additional APN visits based on participants’ needs* APN telephone availability 7 days/week (8 am-8 pm, weekdays; 8 am-noon, weekends)* if readmission to hospital required during 1st 3 months, APN resumed home visits* APNs had email/phone access to multidisciplinary team for consultation of cases as required* APNs collaborated with each participants physician regarding adjustments in medications and
other therapies or worked under specific guidance from physician* self-management of symptoms was promoted by APNs teaching participants and caregivers about
early symptom recognition and effective treatment, such as the use of as-needed diuretics* taped teaching material was leN with participants
Comparators:
• routine care (including site-specific discharge planning and clinical paths)• standard home agency care if referred, consisting of comprehensive skilled home health services 7
days/week.
Naylor 2004  (Continued)
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• On-call registered nurse available 24 h/day.• 58% of control participants received skilled nursing or physical therapy after index discharge
Outcomes Primary:
• time to first readmission or death during 52 weeks
Secondary (52 weeks' follow-up):
• time to first readmission• total rehospitalisations• QoL• functional status• participant satisfaction• medical costs• cumulative days of rehospitalisation• mean readmission length of stay• number of unscheduled acute care visits after discharge• other treatments and healthcare utilisation• cost of post-index hospitalisation readmission
Notes Data source: published data only
Funding: "The National Institute for Nursing Research, National Institutes of Health funded this study"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “research assistants (RAs) blinded to study aims and groups obtained
baseline sociodemographic and health status data and notified the project
manager, who assigned patients to study groups using a computer-generated,
institution-specific block 1:1 randomisation algorithm.”
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "RAs blinded to study aims and groups conducted standardized pa-
tient telephone interviews at 2, 6, 12, 26, and 52 weeks after index hospital
discharge to obtain information about rehospitalizations and unscheduled
acute care visits to physicians, clinics, and emergency departments; quality
of life ...Two cardiologists specializing in the treatment of HF blinded to study
group validated reasons for rehospitalizations and categorized them as index
related, comorbid (diagnoses abstracted from medical record during index
hospitalization), or new health problem."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported by participants
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT principle used, missing QoL data accounted for in analysis (statistical
methods described in paper)
Naylor 2004  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Naylor 2004  (Continued)
 
 
Methods Single-centre RCT
Recruitment: March 1999-January 2001
Duration of follow-up: 6 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Coutry: Italy
Number randomised: 200 (control N = 101, intervention N = 99)
NYHA:
• intervention: class I, N = 0 (0%); class II, N = 33 (33%); class III, N = 63 (64%); class IV, N = 3 (3%)• control: class I, N = 2 (2%); class II, N = 37 (37%); class III, N = 61 (61%); class IV, N = 1 (1%)
LVEF: intervention: 43 (SD 16); control: 43 (SD 19)
Age: intervention: 73 (SD 9); control: 73 (SD 8)
Percentage male: intervention: 62; control: 62
Ethnicity: NR
Inclusion criteria:
• Aged ≤ 85 years• admitted to internal medicine department with a diagnosis of HF during recruitment period• HF diagnosed by 2 major or 1 major and 2 minor Framingham criteria
Exclusion criteria:
• chronic cor pulmonale• terminal illness in addition to HF• severe dementia or other psychiatric illness• indication for surgical therapy in the next 6 months• refusal to participate
Interventions Duration of intervention: 6 months
intervention: "HF management programme"
• pre-discharge intensive education by an experienced CV research nurse using a teaching booklet, cov-
ering causes of HF, recognition of symptoms of worsening HF, the role of sodium restriction and phar-
macological therapy, the importance of fluid and weight control, physical activity and complete ab-
stinence from alcohol and smoking• phone call from nurse 3-5 days post discharge to assess any problems, promote self-management and
check compliance, weight and lifestyle issues• participants had telephone access from 8.00 am to 9.00 am, Monday to Friday, and out of hours an-
swering machine
Nucifora 2006 
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• outpatient visits to doctor at 15 days, 1 and 6 months after discharge, to evaluate test results, physical
condition and medicine adherence and make any required changes to drug therapy
Control:
• pre-existing routine of post-discharge care; i.e. usual care by primary care physician• outpatient visit to doctor at 6 months after discharge
Outcomes Primary:
• all-cause readmissions at 6 months• all-cause deaths at 6 months
Secondary (6 months):
• event-free survival• days of unplanned readmissions• number of unplanned outpatient visits• participants' clinical status• compliance• adherence to treatment plan• QoL
Notes Data source: published data only
Funding/CoI: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly assigned to receive either the study interven-
tion or the usual care" but gives no details on method of randomisation
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "No patient withdrew from the study. Follow-up data were collected on
every patient."
However, QoL data at 6 months only available from 74/98 in intervention
group and 75/98 in control group
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported
Nucifora 2006  (Continued)
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Other bias Unclear risk More participants in the intervention group were in sinus rhythm compared to
control group (73% vs 52%, P = 0.06). More participants in control group had
previous CABG compared to intervention group (13% vs 5%, P = 0.059)
Nucifora 2006  (Continued)
 
 
Methods Multicentre RCT (6 centres)
Recruiting: October 2011-September 2013 
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: nurse
Participants Country: USA
Participants: randomised N = 1437 (intervention N = 715; control N = 722)
Median (IQR) age: intervention 73 (62-84); control 74 (63-82)
Male sex: intervention 53.4%; control 52.9%
Ethnicity:
• intervention: African American 21.5 (18.5-24.5); Hispanic/Latino 12.0; white 54.7; Asian/Pacific Islan-
der or other 11.8• control: African American 22.7; Hispanic/Latino 10.9; white 54.3; Asian/Pacific Islander or other 12.1
Actual severity of HF in study participants at recruitment:
LVEF (%) intervention 42.7; control 43
NYHA class (mean (95% CI) %):
• intervention: class I, 0.2 (0.0-0.5); class II, 23.4 (20.0-26.9); class III, 65.6 (61.8-69.4); class IV, 10.8
(8.3-13.3);• control: class I,  0.7 (0.0-1.4); class II, 25.8 (22.2-29.4); class III, 63.9 (59.9-67.8); class IV, 9.6 (7.2-12.0)
diabetes: intervention 44.8%; control 47.6%
Inclusion criteria: 
• Individuals admitted as hospital inpatients or on observation status;• ≥ 50 years• receiving active treatment for decompensated HF• expected to be discharged to their home• capable of providing written informed consent in English, Spanish, Farsi, or Russian
"Enrollment criteria were expanded in January 2012 to include all patients being actively treated for
HF instead of just those having a principal diagnosis of HF. This change was made because patients
deemed prospectively as not having a principal diagnosis of HF were being coded as patients with HF
after their discharge because of patients with multiple active problems."
Exclusion criteria:
• transplant recipient/being evaluated/on a waiting list  for a transplant• enrolled or enrolling in hospice• expected to expire shortly after discharge• dementia• being admitted from or expected to be discharged to a skilled nursing facility (SNF)
Ong 2016 
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• lack of phone line/reliable cell service• chronic dialysis• inability to identify a usual source of care (free clinic acceptable) and who will not be assigned a
provider upon discharge.• Also "patients with the following cardiovascular conditions: patients with valvular disorders requiring
surgical intervention (except for those with incidental valvular disease, who will be included), acute
myocardial infarction (except for those with demand ischemia, who will be included); patients who
are unable to use the intervention equipment (e.g., unable to stand on the weight scale), or who are
otherwise unable to comply with the intervention
 
Interventions intervention: 3 components conducted by registered nurses: 
• predischarge HF education by a study nurse, not part of usual care team. Used a booklet and the
‘teach-back’ method to ensure understanding. Also included demonstration of telemonitoring equip-
ment and the important of monitoring physiological variables• regularly scheduled telephone coaching – 9 calls scheduled over 6 months, usually the same call cen-
tre nurse. 1st contact within 2-3 days of discharge to reinforce pre-discharge education, then weekly
for the first month. After first month, calls were made monthly until the end of the 6-month study pe-
riod. Calls were designed to reinforce predischarge education materials• home telemonitoring of weight, blood pressure, heart rate, and symptoms. Results monitored by call
centre nurses.
Comparator: usual care
• "Usual care at the sites included robust pre-discharge education and often a post-discharge follow-up
telephone call. No additional surveillance was provided to control patients beyond whatever may
have been requested as part of routine clinical practice, and the intervention did not substitute for
usual care surveillance. Patients were not precluded from exposure to other readmission reduction
or chronic NRs implemented by hospitals, physician groups, or health plans, such as education about
HF, pharmacist consultation, and post discharge telephone calls."
Outcomes • All-cause mortality• All-cause readmissions• HRQoL (MLHFQ)
Notes Funding: "This study was supported by the Agency for Healthcare Research and Quality; the National
Heart, Lung, and Blood Institute (NHLBI); the National Center for Advancing Translational Science, Clin-
ical and Translational Science Institute; the Robert Wood Johnson Foundation; the Sierra Health Foun-
dation; the University of California Center for Health Quality and Innovation; and by the participating
institutions. The funders had no role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and deci-
sion to submit the manuscript for publication."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Block randomization was conducted within each site using random
blocks of 4 to 8 individuals via a web-based, computerized, random number
generator."
Allocation concealment
(selection bias)
Low risk Web-based implies centralised, and block size was random 4-8
 
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible due to nature of intervention
 
Ong 2016  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk States that survey interviews were conducted "by staI at the coordinating cen-
ter who were unaware of the treatment randomizations"
 
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Self-reported QoL
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk There was an unbalanced dropout rate (15% and 26% for intervention and
control, respectively, although all randomised participants were included in
primary analysis. Hazard models censored data on date of withdrawal for peo-
ple who had fully withdrawn consent.  QoL data only reported for those partic-
ipants who completed follow-up questionnaire (53.6% and 57.2% for interven-
tion and control, respectively). 
 
Selective reporting (re-
porting bias)
Low risk Outcomes match those on clinical trials.gov, posted before trial started
 
Other bias Low risk Outcomes match those on clinical trials.gov, posted before trial started
 
Ong 2016  (Continued)
 
 
Methods Single-centre RCT
Recruitment: July 1996-June 1997
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: pharmacist
Participants Country: USA
Participants: intervention, N = 17 (8 men (47%)); control, N = 17 (9 men (53%))
Actual age of study participants: intervention mean 66.9 (SD 8.7); control mean 72.8 years (SD 10.7)
Male sex: 50%
Ethnicity: NR
Actual severity of HF in study participants at recruitment:
NYHA class, N (%):
• intervention group class II, N = 1 (6%), class III, N = 12 (71%), class IV, N = 4 (24%)• control group class II, N = 4 (24%), class III, N = 11 (65%), class IV, N = 2 (10%)
LVEF: NR
Inclusion criteria:
• all patients with HF in their admission diagnoses and with a history of HF• age ≥ 50 years
Exclusion criteria:
• a more significant concomitant disease (e.g. unstable angina, cardiac arrhythmia, COPD)• living in long-term care facility• significant psychiatric illness• long-term renal dialysis• life expectancy < 3 months
Rainville 1999 
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• no home phone• had a language barrier
Interventions Duration of intervention: 90 days
Intervention: 'pharmacist intervention'
During index hospitalisation:
• "Routine care plus pharmacist and clinical nurse specialist identified patient issues which posed risk
for rehospitalisation and determined corrective action."• before discharge the pharmacist reviewed pathology and treatment of HF, weight monitoring and risk
modifications with the participant or caregiver• participant given information brochure, video, weight log and medication organiser• pharmacist also recommended medication changes to physicians
After discharge:
• pharmacist phoned within 3 days of discharge, and at 7, 30, and 90 days and 12 months to enquire
about any readmissions, respond to questions, reinforce information given before discharge• Pharmacist's phone number provided to participants for further support
Comparator: usual care
• Routine care and preparation for discharge including: written prescription, physician discharge in-
structions, nurse review of diet, treatment plans and medications; participants provided with com-
puter-generated drug information sheets• At 30, and 90 days and 12 months pharmacist contacted participants to ask about readmissions
Outcomes Primary endpoint:
• hospital readmission for HF or death (composite endpoint) at 1 year
Notes Data source: published data and information from author*
Funding/CoI: no information in paper
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated*
Allocation concealment
(selection bias)
Unclear risk Quote: "Information on patient randomisation was concealed from the patient
and all care givers except for the pharmacists involved in the study". It is not
clear who was responsible for allocation.
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information in paper
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk QoL NR
Rainville 1999  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 38 participants randomised, 2 intervention and 1 control participant subse-
quently excluded as tests during initial hospitalisation showed normal LV func-
tion, long-term dialysis was initiated, or participant planned to move out of
state after discharge. 1 control participant was lost to follow-up and excluded
from analysis.
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Rainville 1999  (Continued)
 
 
Methods Single-centre RCT
Recruiting: March 1997-March 1998
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: nurse
Participants Country: Iran
Participants: randomised N = 110 (intervention N = 55, control N = 55) analysed N = 99 (intervention N =
49; control N = 50)
Mean ± SD age: NR
Male sex (%): intervention 61.2, control 54
Ethnicity: NR
Actual severity of HF in study participants at recruitment:
NYHA class (%):
• intervention: class II, 10.2%; class III, 73.5%; class IV, 16.3%• control: class II, 4%; class III, 82%; class IV, 14%
Inclusion criteria:
• people with congestive HF
Exclusion criteria:
• people receiving any surgical intervention• or having any other chronic disease
Interventions Intervention: an education component and a care component:
• educational intervention:* education about drugs, type and amount of activity, diet, adverse events (complications) of dis-
ease, signs of HF, how to change behaviour and lifestyle* educational needs based on checklist homecare of HF participants, symptoms of return (relapse)
of the disease, and immediately referring to the doctor in case of signs and symptoms such as dys-
pnea, severe swelling, and angina pectoris• care intervention:* checking vital signs, weight check, assessing the peripheral swelling* accurate assessment of the amount and timing of drugs
Salehitali 2009 
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• mode of delivery:* face-to-face education using booklet and CD• time of delivery:* interventions delivered when the participants were inpatient in hospital* the interventions continued for 3 more sessions when the participants were at home* to fill the gap between the sessions, there was a phone call following up the interventions• timing of interventions:* home care and education interventions were delivered exactly 1 month post-discharge, 2 months
after first follow-up, and 3 months after second follow-up
Comparator: usual care
Outcomes • All-cause readmissions (average per person)• Costs
Notes Funding: Shahrekord University of Medical Sciences
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "randomised" with no further details
Allocation concealment
(selection bias)
Unclear risk NR
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk NR
 
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Not applicable
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 6/55 intervention group and 5/55 control group dropped out, unclear why
Selective reporting (re-
porting bias)
Unclear risk No protocol identified
Other bias Low risk Nothing identified
Salehitali 2009  (Continued)
 
 
Methods RCT, repeated measures
Recruiting: September 2006-January 2009
Follow-up: 6 months
Intervention category: other
Shively 2013 
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Person delivering the intervention: nurse
Participants Country: USA, community setting
Participants: N = 43 in intervention group, N = 41 in usual-care group
Mean (SD) age: intervention: 63.4 (9.10), usual care: 68.9 (11.73); P = 0.02
Male sex N (%):intervention: 43 (100); usual care: 40 (97.6)
Ethnicity: intervention: 33 (76.6%) white; usual care: 32 (78.0%) white
Actual severity of HF in study participants at recruitment:
NYHA class, N (%):
• intervention class I, N = 1 (2.3%), class II, N = 21 (44.2%), class III, N = 23 (53.5%), class IV, N = 0(0%)• control class I, N = 2 (4.9%), class II, N = 18 (48.6%), class III, N = 21 (51.2%), class IV, N = 0 (0%)
Median EF%: NR
Inclusion criteria:
• documented clinical HF stage C• hospitalisation or ED visit for HF treatment within previous 12 months• aged ≥ 18 years• resident in San Diego county• read and speak English• has telephone access• has a primary care provider for routine medical care
Exclusion criteria:
• inability to provide written consent• acute medical problems within the previous month• considered by the investigators to be medically unstable• enrolled in specialty HF care via the HF Program or telehealth• long-term follow-up by cardiology after a hospital admission as well as severe medical problems• a life expectancy of < 1 year• acute substance abuse or psychiatric problems• homelessness
Interventions Median duration of intervention: 6 months
Intervention: Heart PACT program
• the intervention, given by 1 of 2 APNs, used activation theory and was tailored to each participant’s
activation level, focusing on individualised self-selected goals and moving the participant to a higher
level of activation• goals included the importance of self management, improving confidence and knowledge, skills and
behaviour goals and plans for these under different situations• each participant met with the intervention nurses for 6 sessions, by telephone or in person. During
these meetings, participants’ individualised health behaviour goals were discussed, progress toward
goals was reinforced, barriers were addressed, and questions were answered• the intervention group received a self-management toolkit (blood pressure cuI, weight scale, pe-
dometer, HF self-management DVD, and educational booklet) at the first intervention visit
Comparator:
• routine medical care in primary care and specialty clinics (other than the HF Specialty Clinic) at the
study site.
Shively 2013  (Continued)
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• the usual-care group received the self-management toolkit after the final 6-month assessment
Outcomes Primary outcomes were stated to be:
• activation using the Patient Activation Measure (PAM) total score• self-management using the 3 scale scores (maintenance, management, and self-confidence) from the
Self-Care of Heart Failure Index (SCHFI) and the Medical Outcomes Study (MOS) Specific Adherence
Scale• hospitalizations and ED visits as reported by participants
Notes Data source: published data only
Funding/CoI: NR
Generalisability: 263 screened for eligibility, 103 (39%) were eligible, of whom 19 (18%) declined and 84
(82%) enrolled and were randomised to Heart PACT program (N = 43) or usual care (N = 41). 77 assessed
at 3 months' follow-up, 68 at 6 months.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A stratified blocked randomisation approach based on the baseline Patient Ac-
tivation Measure (PAM) level (low, medium, high) was used to ensure that par-
ticipants were equally distributed between groups by activation level
Allocation concealment
(selection bias)
Unclear risk No information
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
High risk Outcome assessors were not blinded to intervention allocation, hospitalisa-
tion data reported by participants
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No QoL data included in review
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Statistical analyses assessed missing data as missing at random. Additional
analyses used a missing value analyses module using an iterative expectation
and maximisation procedure. The additional hypothesis testing analyses using
imputed values for missing data are also reported in the paper. 68/84 partici-
pants (81%) assessed at follow-up (n NR by group)
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Unclear risk Participants in the intervention group were younger at baseline (63 vs 69)
Shively 2013  (Continued)
 
 
Methods Single-centre RCT
Recruiting: March 1997-May 1998
Duration of follow-up: 6 months
Stewart 1999a 
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Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Australia
Participants: intervention, 100 participants (65 men); control, 100 participants (59 men)
Actual age of study participants: intervention mean 75.2 years (SD 7.1) years; control mean 76.1 years
(SD 9.3)
Male sex: 62%
Ethnicity: NR
Actual severity of HF in study participants at recruitment NYHA class, N:
• intervention group class II, N = 42, class III, N = 46, class IV, N = 12• control group class II, N = 48, class III, N = 43, class IV, N = 9
LVEF: intervention group 37% (SD10); control group mean 37% (SD 11)
Inclusion criteria:
• Admitted to tertiary care hospital under cardiologist and at least 1previous admission for acute HF
(pulmonary congestion or oedema evident on chest X-ray with acute dyspnoea at rest)• NYHA class II-IV• LVEF ≤ 55%• age ≥ 55 years• to be discharged home• lives within hospital catchment area
Study exclusion criteria:
• terminal disease• valvular disease suitable for surgery• intended heart transplantation• HF precipitated by extensive, reversible ischaemia• home address outside hospital catchment area
Interventions Duration of intervention: mainly within 2 weeks of discharge but some phone contact throughout study
Intervention: usual care plus 'Multidisciplinary, home-based intervention'
After discharge:
• comprehensive assessment at home by a cardiac nurse 7-14 days after discharge• after home visit nurse sent report to primary care physician and cardiologist• cardiac nurse arranged a flexible diuretic regimen for participant's weight and symptoms if required• phone call by cardiac nurse to participant contact at 3 and 6 months• participants encouraged to contact the nurse if any problems arose• home visits repeated if a participant had ≥ 2 unplanned readmissions within 6 months of index ad-
mission
Home visit included:
• assessment of clinical status, physical activity, adherence to medication, understanding of disease,
psychosocial support and use of community resources
Stewart 1999a  (Continued)
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• followed by (as appropriate):* "remedial counselling" to participants and their families* strategies to improve adherence* simple exercise regimen* incremental monitoring by family/carers* urgent referral to 10 care physicians• median duration of visit 2 h (range 1-3.5 h)
Comparison Group: usual care
• all study participants could be referred to cardiac rehab nurse, dietician, social worker, pharmacist
and community nurse as appropriate• all participants had appointment with their primary care physician and/or cardiology outpatient ser-
vice within 2 weeks of discharge.• regular outpatient review by the cardiologist was undertaken throughout the follow-up period
Outcomes Primary endpoint (during 6 months follow-up):
• frequency of unplanned readmissions• all-cause out-of-hospital deaths (i.e. composite endpoint)
Other endpoints (6 months):
• time to first primary endpoint (event-free survival)• frequency of unplanned readmissions• days of unplanned readmissions• all-cause deaths• out-of-hospital deaths• cost of hospital and community-based health care (sample of participants only).• Random sample of participants only: MLHFQ and Australian version of SF-36 at baseline, 3 and 6
months
Notes Data source: published data only
Funding: NR. CoI: Simon Stewart is a recipient of a National Heart Foundation of Australia Postgraduate
Medical Research Scholarship
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Telephone call to an investigator who was unaware of the patient's
demographic and clinical profile, who then allocated the individual [to group]
via a computer generated protocol."
Allocation concealment
(selection bias)
Low risk See above
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "all data collection and analysis was done with masking maintained."
Blinding of outcome as-
sessment (detection bias) 
High risk QoL self-reported
Stewart 1999a  (Continued)
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Subjective outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Analyses stated to be ITT, but for QoL, quote: "Equal numbers of patients from
the intervention and usual-care groups were randomly selected for assess-
ment of changes in health-related quality of life"
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Unclear risk Quote: "The two groups were well matched for all but number of admissions
for acute heart failure and creatinine concentration at hospital discharge.”
Stewart 1999a  (Continued)
 
 
Methods Multicentre RCT (3 centres)
Recruitment: June 1997-December 1999
Follow-up: 12 months
Intervention category: clinic
Person delivering the intervention: specialist nurse
Participants Country: Sweden
Number randomised: 106 ( intervention N = 52; control N = 54)
NYHA:
• intervention: class I, N = 0 (0%); class II, N = 7 (13%); class III, N = 39 (75%); class IV, N = 6 (12%)• control: class I, N = 0 (0%); class II, N = 12 (22%); class III, N = 36 (67%); class IV, N = 6 (11%)
LVEF: NR
Age: intervention: 77 (SD 7); control: 78 (SD 6)
Percentage male: intervention: 33/52 (63%); control: 32/54 (59%)
Ethnicity: NR
Inclusion criteria:
• diagnosed HF, either by echocardiography, radiographic evidence of pulmonary congestion or typical
symptoms and signs of HF• all participants had been hospitalised for HF
Exclusion criteria:
• severe chronic pulmonary disease• dementia or other psychiatric illness• short anticipated survival• discharge to a geriatric clinic or home care• already receiving follow-up at the nurse-led HF clinic
Interventions Duration of intervention: not clear
Intervention: nurse-led HF clinic
• 1st visit 2-3 weeks after discharge, nurses evaluated status, assessed treatment and provided educa-
tion about HF and social support
Stromberg 2003 
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• individualised education included both written and verbal information, and was based on guidelines.
It included information on HF, treatment, dietary advice, individually adjusted energy intake advice,
lifestyle advice (including exercise), and promoted self-management• nurses contactable by phone during office hours, Monday-Friday, and nurses called participants to
provide psychosocial support and evaluate drug changes required• HF nurses called participants in order to provide psychosocial support, evaluate drug changes or other
actions• extra appointments to attend HF clinic scheduled for participants unstable with symptoms of wors-
ening HF or if further education was needed• participants referred back to primary health care once they were stable and well informed
Comparator:
• conventional follow-up in primary health care.• some participants got a scheduled visit after discharge, but most were encouraged to phone primary
health care if they had problems due to HF
Outcomes Primary:
• all-cause mortality or all-cause hospital admission after 12 months
Secondary (12 months):
• mortality due to CV disease or other• number of readmissions for any reason• number of days in hospital• self-care behaviour
Notes Data source: published data only
Funding: Health Research Council in the South-East of Sweden, The Swedish Foundation for Healthcare
Science and Allergy Research, The Swedish Heart and Lung Foundation and the Research Foundation
of the University Hospital of Linkoping, Sweden.
No CoI information given
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation was blinded with the use of a computer-generated list of
random numbers and sealed envelopes
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "The assessment and outcome measures were blinded. The nurse do-
ing the assessment and collecting of data was blinded to the intervention and
not involved in the care of the patients."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk QoL NR
Stromberg 2003  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All participants appear to be accounted for, but study authors note that, quote:
"The number of readmissions was significantly lower in the intervention group
after 3, but not after 12 months. The almost 3 times higher mortality in the
control group may have influenced this and we therefore recalculated morbid-
ity data to admissions during time of survival."
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Unclear risk Quote: “There were significantly more patients with hypertension in the inter-
vention group, 26 vs 16 (p<0.05). There were more patients with diabetes in the
control group, 17 vs eight (p=0.05).”
Stromberg 2003  (Continued)
 
 
Methods Multicentre, cluster-RCT (2 centres)
Recruitment: 20 months, dates NR
Follow-up: 6 months
Intervention category: clinic
Person delivering the intervention: specialist nurse
Participants Country: UK
Number randomised: 106 (intervention N = 58; control N = 48)
NYHA:
• intervention: class I-II, N = 14 (24%); class III-IV, N = 44 (76%)• control: class I-II, N = 13 (27%); class III-IV; N = 35 (73%)
LVEF: intervention: 31 (SD 8); control: 29 (SD 11)
Age: intervention: 73 (SD 14); control: 72 (SD 12)
Percentage male: intervention: 72; control: 73
Ethnicity: NR
Inclusion criteria:
• acute admission to hospital with a diagnosis of HF• objective evidence (e.g. echocardiography or coronary angiography) of impaired LVSF as evidenced
by a LVEF of at least 45% immediately prior to study recruitment• discharged to home
Exclusion criteria:
• awaiting an elective cardiac procedure with the intent to reverse the cause of underlying HF (e.g. coro-
nary artery bypass surgery for coronary artery stenosis)• terminal illness other than HF
Interventions Duration of intervention: 6 months
Intervention: "clinic plus home-based intervention"
• appointment with specialist nurse prior to discharge, to receive information on HF and medications• office-hours contact number for nurse specialist
Thompson 2005 
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• home visit with 10 days of hospital discharge, for education on symptom management and lifestyle,
and clinical examination• monthly nurse-led outpatient HF clinic for 6 months post-discharge, including education, clinical ex-
amination and indices monitoring, and starting of new therapeutic drugs where appropriate
Control group: usual care
• explanation of condition• prescribed medications by the ward nurse• referral to appropriate post-discharge support as required).• participants given an outpatient department appointment 6-8 weeks post discharge
Outcomes  Primary:
• event-free survival from either death or recurrent hospitalisation for any reason during the 6-month
follow-up
Secondary (6 months):
• rate of recurrent hospital stay• treatment adherence (NR here)• health-related quality of life
Notes Data source: published data only
Funding: "SS is supported by the National Heart Foundation and theNational Health and Medical Re-
search Council of Australia. This study was supported by a research grant from MerckPharmaceuticals
UK."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a random number allocation was used to allocate equal numbers of
small and large clinics to either post discharge HBI+C or UC.”
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "Data on recurrent hospital stay and/or death were also collated (in a
blinded manner) via the local area hospital record system and death registry."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants accounted for in primary outcome analysis. High risk of attri-
tion bias for QoL as only 46/106 (overall) participants completed a question-
naire at baseline, and 41 completed it at 6 months
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported
Thompson 2005  (Continued)
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Other bias Low risk Quote: “Data on recurrent hospital stay and/or death were also collated (in a
blinded manner) via the local area hospital record system and death registry.”
Thompson 2005  (Continued)
 
 
Methods Multicentre RCT (3 centres)
Recruiting: participants were enrolled from December 2007-March 2010 at 3 cardiology hospitals
Follow-up: 12 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Japan
Participants: N = 161 (intervention, N = 79; usual care, N = 82)
Mean ± SD age: intervention, 76.9 ± 10.9; usual care, 75.8 ± 12.1
Male sex N (%): intervention, 42 (53.2); usual care, 49 (59.8)
Ethnicity: NR, assumed to be predominantly Japanese
Actual severity of HF in study participants at recruitment, NYHA class, N (%):
• intervention: class I, N = 8 (10.1%); class II, N = 67 (84.8%); class III, N = 4 (5.1%); class IV, N = 0• control: class I, N = 14 (17.1%); class II, N = 63 (76.8%); class III, N = 5 (6.1%); class IV, N = 0
Median EF%: NR
Inclusion criteria:
• hospital admission for HF with symptoms and signs of HF• pre-existing history of chronic HF, NYHA II—IV• ≥ 18 years of age
Exclusion criteria:
• end-stage HF, defined as requiring mechanical support or continuous i/v inotropic support• a serious life-threatening illness with a life-expectancy of < 6 months• stroke within the last 3 months• cognitive dysfunction• substance abuse or psychotic disorder• participants whose physician or nurses refused access
Interventions Median duration of intervention: 2 months of home visits, 6 months of phone calls
• all enrolled participants received comprehensive discharge education by cardiologist, nurse, dietit-
ian, and pharmacist using a booklet that provided information on pathophysiology, medical treat-
ment, diet, physical activity, lifestyle modification, self-measurement of body weight, self-monitoring
of worsening HF, and emergency contact methods.
Intervention: home-based disease management programme
• a home visit was made within 14 days after discharge from hospital• nurses visited each participant’s home to assess how the participant was coping in the home environ-
ment, HF status, general health status, adherence to medication, lifestyle modification, daily activity,
and social support needs
Tsuchihashi-Makaya 2013 
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• home visits were made once every 2 weeks until 2 months after discharge• telephone follow-up by nurses in addition to routine follow-up by cardiologists• at the conclusion of home visiting, nurses conducted monthly telephone follow-up until 6 months
after discharge• nurses monitored HF symptoms, participant’s general health status, and requirement for other health
and social support• nurses consulted a multidisciplinary team (cardiologist, dietitian, pharmacist, and social worker) dur-
ing the intervention period to optimise the advice given to each participant
Comparator: usual care
• comprehensive discharge education as detail above• after hospital discharge, participants assigned to the usual-care group continued to receive routine
management by the cardiologist.• no extra follow-up by a HF nurse or multidisciplinary team was provided
Outcomes Primary outcome:
• participant’s psychological status, including depression and anxiety assessed by HADS
secondary outcomes:
• QOL (Short Form-8)• all-cause death• hospitalisation for HF (analysed as time to first event; defined as an unplanned overnight stay in a
hospital because of progression in HF symptoms or directly related to HF)
Notes Data source: published data only
Funding: "This work is supported by the grants from the Japanese Ministry of Health, Labour and Wel-
fare, the Japan Heart Foundation, and Pfizer Health Research Foundation."
CoI: Hiroyuki Tsutsui has received research support from Novartis and honoraria for lectures from
Shionogi, Daiichi Sankyo, Tanabe-Mitsubishi, Novartis, MSD, Pfizer, and Takeda."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomized on a 1:1 basis, no further details given
Allocation concealment
(selection bias)
Unclear risk No information given
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk Quote: "Prognostic data were reported based on medical records or follow-up
by telephone."
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 79/84 (94%) intervention group analysed, 82/84 (97.6%) control group
analysed. The analysis of primary and secondary endpoints was prespecified
Tsuchihashi-Makaya 2013  (Continued)
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to be performed in the per-protocol population, which included all partici-
pants who received usual care or home-based intervention, i.e. was not ITT
Selective reporting (re-
porting bias)
High risk NCT 01284400 outcomes registered in January 2011, after enrollment end-
ed and 2 months before final data collection. Published protocol (Tsuchi-
hashi-Makaya 2011) states that the secondary endpoint is the time to the first
event (all-cause death, cardiac death, sudden cardiac death, or hospitalization
for HF). However, Tsuchihashi-Makaya 2013 reports time to first event for all-
cause death and hospitalisation (i.e. no mention of cardiac death)
Other bias Unclear risk Hospitals were selected on the basis of their organisational capability and en-
thusiasm for participating in the study. The intervention uses a booklet for the
education section and a checklist for follow-up, which could minimise bias if
delivered consistently
Tsuchihashi-Makaya 2013  (Continued)
 
 
Methods Multicentre, 2-stage RCT (only 2nd stage randomised)
Recruitment dates: September 1999-April 2000
Follow-up: 6 months
Intervention category: case management
Person delivering the intervention: other
Participants Country: Canada
Number randomised: 276 (intervention N = 140; usual care N = 136)
NYHA (%):
• intervention: class I, 12%; class II, 48%; class III, 35%; class IV, 5%• control: class I, 14%; class II, 52%); class III, 30%; class IV, 3%
Age: intervention: 71 (SD 12); control: 72 (SD 12)
Percentage male: intervention: 58; control: 58
Ethnicity: NR
Inclusion criteria:
• consecutive patients aged > 18 years, admitted to a hospital with a most responsible, primary, sec-
ondary, or complicating diagnosis of HF
Exclusion criteria:
• known secondary causes of HF (i.e. correctable causes as anaemia or hyperthyroidism)• preserved systolic function• were taking an angiotensin-II antagonist because of known intolerance or contraindication to ACE
inhibitors• had a terminal illness with a life expectancy < 6 months• cognitive impairment• were unable to communicate because of language barriers• were attending a specialised HF clinic for medical management• were participating in a HF clinical trial• absolute contraindication to ACE inhibitors• participants residing outside the region of the participating hospital
Tsuyuki 2004 
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• those discharged to a setting where patients were not responsible for own medication administration
Interventions Duration of intervention: 6 months
Intervention: patient support program
• 5 key areas: salt and fluid restriction, daily weighing, exercise alternating with rest periods, proper
medication use, and early recognition of worsening symptoms• 1-1 education with research co-ordinator prior to discharge using written educational package cov-
ering information on HF (definition, causes, symptoms), nondrug treatment, medication information
(with special emphasis on proven benefits of therapies), and self-monitoring• adherence aids provided prior to discharge (medication organiser, medication administration sched-
ule, and daily weight log)• participants encouraged to contact co-ordinator for ongoing community support• community follow-up to reinforce education and adherence: telephone contact by the local research
co-ordinator at 2 weeks, 4 weeks,and monthly thereafter for up to 6 months post discharge (i.e. 7 calls)• monthly newsletter “Living with Congestive HF”, featuring articles on 5 key components, participant
success stories, salt content of foods, low-salt recipes, and compliance tips• research co-ordinator could also recommend that participant consult physician for ACE inhibitor
dosage titration as appropriate, or if a problem arose which required further investigation
Usual care:
• participants received a general heart disease pamphlet before discharge, but no formal counselling
beyond routine hospital procedure• monthly telephone contact to check for clinical events
Outcomes Primary (6 months):
• medication adherence, as measured by pharmacy records
Secondary (6 months):
• clinical events
Notes Data source: published data only
Funding/CoI: "Dr Johnson is a Population Health Investigator with Alberta Heritage Foundation for
Medical Research and holds a Canada Research Chair in Diabetes Health Outcomes. Funded by an un-
restricted educational grant from Parke Davis Canada (now Pfizer Canada) and the University of Alberta
Hospital Foundation."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was conducted by a computer-generated sequence
using block randomisation (block size of 4), stratified by study site (hospital).”
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk Quote: "Clinical events, the secondary outcome, were recorded by patient re-
port and through examination of hospital records."
Tsuyuki 2004  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk QoL NR
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "All analyses were by intention to treat"
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk No other apparent sources of bias, although monthly follow-up calls to usu-
al-care group could have provided more contact than would otherwise be ex-
pected.
Tsuyuki 2004  (Continued)
 
 
Methods Single-centre RCT
Recruiting: dates NR
Follow-up: 12 months
Intervention category: multidisciplinary
Person delivering the intervention: multidisciplinary
Participants Country: Poland; setting: secondary care
Participants: N = 160 (intervention, 80 (50%); usual care, 80 (50%))
Mean ± SD age: intervention, 67.3 ± 10.2; usual care, 69.5 ± 10.7
Male sex: 48 (60%) in intervention group, 47 (59%) in control group
Ethnicity: NR
Actual severity of HF in study participants at recruitment NYHA class, N (%):
• intervention group class I, N = 0; class II, N = 13 (16%); class III, N = 35 (44%); class IV, N = 32(40%)• control group class I, N = 0; class II, N = 10 (12.5%); class III, N = 40 (50%); class IV, N = 30 (37.5%)
Median EF%: NR
Inclusion criteria:
• hospitalised patients with HF• established diagnosis• on optimal medical treatment
Exclusion criteria: NR
Interventions Duration of intervention: 12 months
Multidisciplinary care:
• follow-up 1:1 visits of 30-40 min duration at the HF Clinic (HFC) 14 days and 1, 3, 6, and 12 months
post-discharge included consultation with cardiologist, HF nurse, physiotherapist and psychologist.
Participants with advanced HF who were unable to come to the clinic were visited at home by HF
nurse, visits lasting about 1 h.
Wierzchowiecki 2006 
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• between visits to the clinic, participants were under the care of their primary care physicians. Partici-
pants and their GPs could access telephone counselling by HF nurse and cardiologist during working
hours• cardiologist determined underlying disease, reasons for any deterioration, prognostic evaluation and
assessment of current treatment, qualifying patients for exercise rehabilitation and psychological re-
ferrals• HF nurse informed participant about multidisciplinary care programme, disease, symptoms, medica-
tion side effects and triggers for contact with clinic or emergency care. HF nurse checked adherence
to the drug regimen and gave advice about salt, fluids and alcohol intake, sexual activity, necessity
of vaccinations, capabilities of a participant to travel or work, etc. He/she also familiarised partici-
pant with techniques for blood pressure/BMI measurement etc. and mentioned potential of self-ad-
justment in drug titration, i.e. furosemide (after telephone call)• participants received a diary in which to record measurement data and an educational booklet on HF• participants received education sessions in the form of a lecture from hospital physicians and HF clinic
cardiologists, regarding the nature, aetiology, diagnosis and therapy of HF• physiotherapist, along with cardiologist, set up and monitored the exercise rehabilitation programme• psychologist presented advice on “how to cope with disease” and performed psychotherapy in par-
ticipants in whom a high level of trait anxiety was observed (depressive syndrome) by cardiologists.
Comparator: usual care
• participants were cared for by their primary care physicians only• did not participate in any educational or therapeutic activities
Outcomes Primary: NR
Outcomes:
• mortality• rate of rehospitalisation• QoL (MLHFQ) and self-care (the European Heart Failure Self-Care Behaviour Scale)
Notes Funding: "This Programme was in part financially supported by the Poznań Department of Health and
Welfare."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information in paper
Allocation concealment
(selection bias)
Unclear risk No information in paper
Blinding of participants
and personnel (perfor-
mance bias)
High risk Not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Unclear risk No information
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Wierzchowiecki 2006  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk Low completion rate for QoL questionnaire that was unbalanced between
treatment groups (56/80 (70%) in intervention group, 35/80 (43.8%) in usu-
al-care group).
Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Unclear risk No other issues identified
Wierzchowiecki 2006  (Continued)
 
 
Methods Single-centre RCT
Recruiting: October 2008-January 2010
Duration of follow-up: 9 months
Intervention category: case management
Person delivering intervention: specialist nurse
Participants Country: Hong Kong, China
Participants: randomised N = 178 (intervention N = 90; control N = 88)
Mean ± SD age: intervention 78.6 (7.1); control 78.7 (6.7)
Male sex N (%): intervention  59 (53.3); control 32 (36.4)
Ethnicity: 100% Chinese
Actual severity of HF in study participants at recruitment NYHA class, N (%):
• intervention: class II, N = 53 (58.9%); class III, N = 34 (37.8%); class IV, N = 3 (3.3%);• control: class II, N = 50 (56.8%); class III, N = 36 (40.9%); class IV, N = 2 (2.3%)
LVEF, mean (SD) %: intervention 41.1 (16.1); control 39.0 (14.3)
Diabetes, N (%): intervention 36 (40.0%); control 43 (48.9%)
Inclusion criteria:
• aged ≥ 60 years• diagnosed with HF according to the Framingham criteria• Chinese• able to communicate• accessible by telephone at home• cognitively intact, as indicated by an Abbreviated Mental Test score (Hong Kong version) of 6 or more
out of 10
Exclusion criteria:
• discharged to long-term care settings• scheduled for cardiac surgery
Interventions Intervention: cardiac nurse implemented transitional care model, with:
• predischarge visit to assess health status, cultural beliefs, practices of self-care, and post-discharge
needs• 2 weekly home visits to assess HF status and self-care implementation at home.
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Customised educational and supportive interventions;
• personal self-care goals and action plan to enable effective self-care.• identification of appropriate community care services (including self-help groups, social activities)• phone call 1 week after 2nd home visit, then every 2 weeks for 3 months and then every 2 months for 6
months. Call was to review self-care goal attainment, identify barriers, give relevant advice, and mod-
ify action plan accordingly. Cardiac nurse monitored symptom severity and provided prompt advice
on self-care decision-making (including when to seek medical consultation).• further home visits offered to participants who had unfulfilled self-care and post-discharge needs• participants had telephone access to cardiac nurse during office hours
Comparator: usual care
• pharmacy dispensers gave brief instructions when participants collected prescribed medications on
hospital discharge.• a regular medical consultation at the specialist clinic was arranged for 4 to 6 weeks after discharge.• no structured educational or supportive postdischarge care was offered
Outcomes • All-cause mortality• All-cause readmissions• HRQoL (MLHFQ)
 
Notes Funding: Hong Kong Jockey Club Charities Trust. No CoI
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Permuted block randomisation (block size = 4, allocation ratio = 1:1), using a
computer-generated random number sequence
 
Allocation concealment
(selection bias)
Unclear risk Computer-generated, but known block size could mean last in block can be
predicted.
Blinding of participants
and personnel (perfor-
mance bias)
High risk Blinding not possible
Blinding of outcome as-
sessment (detection bias) 
Objective outcomes
Low risk Quote: "Another  research  nurse,  who  had  no  information about  subjects’ 
group  status,  conducted  face-to-face  interviews  at  participants’  homes  to 
collect  post-test  data..." 
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Unbalanced dropout (24% usual care, 12% intervention), particular impact on
QoL assessment.
Main analyses followed ITT principle. For the survival analysis, people lost to
follow-up were censored, with no readmission or mortality in the remaining
period. Because of an imbalance in dropout rates, 2 sensitivity analyses were
conducted: 1) per-protocol (only those who completed intervention and out-
come evaluation); 2) worst case scenario analysis – those lost to follow-up as-
sumed to have died or had readmission.
Yu 2015a  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol found
Other bias Low risk Nothing identified
Yu 2015a  (Continued)
ACEI: angiotensin converting enzyme inhibitor; AP(R)N: Advanced Practice (Registered) Nurse; BDI: Beck Depression Inventory; BMI:
body mass index; CABG: coronary artery bypass graN; CAS: Control Attitude Scale; CoI: conflicts of interest; COPD: chronic obstructive
pulmonary disease; CV: cardiovascular; DM: diabetes mellitus; DMP: disease management programme; ECG: electrocardiogram; ED:
Emergency Department; EF: ejection fraction; EHFscBS: European Heart Failure Self-Care Behaviour Scale; ESC: European Society of
Cardiology; GP: general practitioner; HADS: Hospital Anxiety and Depression Scale; HF: heart failure; HRQL: health related quality of life; i/
v: intravenous; IQR: interquartile range; ITT: intention-to-treat; KCCQ: Kansas City Cardiomyopathy Questionnaire; LOS: length of stay; LV:
leN ventricle; LVEF: leN ventricular ejection fraction; LVSF: leN ventricular systolic function; MI: myocardial infarction; MLHFQ: Minnesota
Living with Heart Failure questionnaire; NIH: National Institutes of Health; NIHR: National Institute for Health Research; NINR: National
Institute of Nursing Research; NR: not reported; MMSE: Mini-Mental State Examination; NYHA: New York Heat Association functional class;
PAM: patient activation measure; PVD: peripheral vascular disease; Q: questionnaire; QoL: quality of life; RCT: randomised controlled trial;
Rx: therapy; SD: standard deviation; Tx: transplantation
*information obtained from personal communication with study author
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
ACTRN12609000442202 Terminated, no results
ACTRN12616000099426 Purely educational intervention
ACTRN12616001627448 Wrong patient population
ACTRN12617001143314 Wrong intervention
Adair 2012 Wrong intervention
Agvall 2013 Hospital admission for HF not an inclusion criterion
Aiken 2006 Not HF disease-specific - participants had HF or COPD (palliative care programme)
Akosah 2002 Non-randomised study
Akosah 2004 Non-randomised study
Al-Mobammad 2015 Wrong study design
Andryukhin 2010 Hospital admission for HF not an inclusion criterion
Angermann 2012 Focus on structured phone-based intervention
Anonymous 2016 Follow-up too short
Artinian 2003 Non-randomised study
Ashton 2014 Wrong study design
Austin 2007 Described as cardiac rehab. Hospital admission for HF not an inclusion criterion
Azad 2008 Hospital admission for HF not an inclusion criterion
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Study Reason for exclusion
Azevedo 2002 Non-randomised study
Balaban 2017 Wrong intervention
Baptiste 2016 Wrong study design
Barth 2001 Very small RCT, limited data presented, statistical analyses appear incorrect
Basoor 2011 Wrong intervention
Bekelman 2014 Wrong comparator
Bekelman 2018 Wrong patient group (hospital admission not an inclusion criterion)
Bell 2016 Wrong follow-up
Benatar 2003 RCT both arms received an intervention
Blaha 2000 Paper discusses methodology of the intervention and is not a study or trial
Bocchi 2004 This reference was identified in an earlier version of this review. We screened the Abstract in this
latest update, and found that it did not meet the inclusion criteria, since it is a review of HF clinics
in Brazil
Bocchi 2008 Hospital admission for HF not an inclusion criterion
Bondmass 2007 Secondary analysis of data from a previously excluded study
Boutwell 2014 Wrong study design
Bouvy 2003 Hospital admission for HF not an inclusion criterion
Brannstrom 2013 Wrong intervention
Brannstrom 2014 Wrong intervention
Bucci 2003 Hospital admission for HF not an inclusion criterion, and intervention is HF clinic with pharmacy in-
tervention for some
Byrnes 2012 Hospital admission for HF not an inclusion criterion
Capomolla 2004 Wrong intervention
Chen 2017 Wrong study design
Cleland 2005 Pure telemonitoring intervention
Comin-Colet 2016 Wrong intervention
Cordisco 1999 Non-randomised study
Costantini 2001 Mixed before and after and parallel-group study
de la Porte 2007 Hospital admission for HF not an inclusion criterion
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Study Reason for exclusion
de Lusignan 1999 Hospital admission for HF not an inclusion criterion
Deek 2016 Wrong intervention
Deek 2017 Wrong intervention
Delaney 2013 < 6 months' follow-up
Dewalt 2006 Hospital admission for HF not an inclusion criterion
DeWalt 2012 Control arm received a self-management education session, and hospital admission for HF not an
inclusion criterion
Dickson 2015 Wrong follow-up
Discher 2003 Non- randomised study
Dracup 2012 Wrong intervention
Dracup 2014 Primarily educational focus
DuIy 2005 Description of development of telephone mediated intervention - no evaluative data
Ekman 1998 < 6 months' follow-up
ElGuindy 2013 Wrong intervention
Evans 1993 "Generic intervention" (i.e. not exclusively designed for, or directed at, peoples with CHF)
Fabbri 2007 Not an RCT. This refers to the DIAL study but is an opinion article on the need for disease manage-
ment programs in Italy
Farag 1967 Non-randomised study
Feldman 2004 Hospital admission for HF not an inclusion criterion. Nurse-based CRT
Fermann 2017 Wrong participants
Fitzgerald 1994 'Generic' intervention
Flynn 2005 Not an RCT
Foley 2008 Comment on an included study
Fonarow 2004 Editorial
Freund 2011 Wrong patient population
Galbreath 2004 Hospital admission for HF not an inclusion criterion
Gattis 1999 Hospital admission for HF not an inclusion criterion
GESICA 2005 Phone-based
Goldberg 2003 Purely telemonitoring intervention
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Study Reason for exclusion
Goodyer 1995 Hospital admission for HF not an inclusion criterion
Grancelli 2003 Hospital admission for HF not an inclusion criterion
Gregory 2006 Cost data from Kimmelstiel 2004, but only reported in relation to 90-day data so not meeting 6-
month minimum follow-up inclusion criterion for this review
Grustam 2015 Wrong intervention
Guder 2015 Wrong study design
Hanchett 1967 Hospital admission for HF not an inclusion criterion
Hancock 2012 Hospital admission for HF not an inclusion criterion
Hansen 1992 'Generic' intervention
Harrison 2002 < 6 months' follow-up
Harter 2016 Wrong participants (confirmed by email with author 16 April 2018)
Haruka 2014 Wrong participants
Heidenreich 1999 Non-randomised study
Heisler 2013 Control cipantss recieved more than usual care
Howlett 2011 Wrong participants
Huffman 2011 Not predominantly people with HF
Huffman 2014 Wrong intervention
Hughes 2000 'Generic' intervention
Hui-Ling 2014 Wrong participants
Inglis 2006 Long-term follow-up of 2 Stewart RCTs, only 1 of which was included in this review. Combined data
from the 2 studies presented, so not possible to separate out data from the included and excluded
studies
Iraurgui 2007 Primarily educational intervention
ISRCTN18285541 Trial was abandoned for recruitment problems
ISRCTN71548370 Follow-up too short (1 month)
Jaarsma 2003 Methodology paper, no outcome data
Jain 2005 Not an RCT
Jerant 2001 Small RCT with 3 arms: 13 participants receiving home telecare; 12 participants received telephone
care; 12 received usual care. An interesting paper but excluded form this review because the pre-
sentation and analyses of these data do not allow either of the 2 interventions to be compared with
the control treatment.
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Study Reason for exclusion
Johnson 2000 'Generic' intervention
Kakutani 2014 Wrong follow-up
Kalter-Leibovici 2017 Wrong participants (email clarification with study author (1 May 2018) confirmed that data on hos-
pital admission were not collected)
Karhula 2015 Wrong participants
Kato 2013 Purely educational intervention
Khunti 2007 Not all participants had a previous hospital admission for HF
Laramee 2003 < 6 months' follow-up
Ledwidge 2003 Cost study of participants in the excluded study by McDonald 2002
Liljeroos 2017 Wrong participants
Lin 2001 Non-randomised study
Linden 2005 Non-randomised study
Luttik 2009 Comparator not usual care
Luttik 2014 Wrong intervention
Martensson 2005 Hospital admission for HF not an inclusion criterion
Martín-Lesende 2013 Wrong intervention
Matassini 2016 Wrong study design
McClintock 2014 Wrong study design
McCoy 2007 Non-randomised study
McDonald 2002 < 6 months' follow-up
Melin 2014 Wrong follow-up
Menon 2015 Wrong intervention
Moser 2000 Conference poster, no full publication identified at 2012 update. Conference abstract no longer
available online, unable to contact study author by email (10 September 2018).
Murray 2007 Hospital admission for HF not an inclusion criterion
Nahlen 2016 Wrong intervention
Naylor 1994 "Generic'" intervention
Naylor 1999 "Generic'" intervention
NCT00202150 Intervention not HF-specific
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Study Reason for exclusion
NCT00300261 Intervention is focussed on telemonitoring
NCT01014884 Intervention not HF-specific
NCT01141907 Intervention is focussed on telemonitoring
NCT01342276 Wrong intervention
NCT01698242 Active control
NCT01820780 Intervention is focussed on medication management
NCT01878630 Intervention is focussed on telecare
NCT01886534 Follow-up too short (3 months)
NCT02110433 Intervention is focussed on telemedicine
NCT02425488 Intervention is educational in focus
NCT03035474 Active control
NCT03220204 Not H- specific
NCT03246035 Follow-up too short (90 days)
NCT03317951 Intervention is focussed on telemonitoring
Nguyen 2007 Hospital admission for HF not an inclusion criterion
O'Riordan 2014 Wrong intervention
Ojeda 2005 Non-randomised study. Contacted study author for clarification, who clarified that this is a non-
randomised follow-up of subgroup of participants from the PRICE RCT by Atienza 2004
Oldland 2014 Wrong study design
Oliveira 2017 Wrong follow-up
Otsu 2011 Hospital admission for HF not an inclusion criterion
Palmer 2003 Narrative review
Panella 2005 Not an RCT of the appropriate intervention
Pascual 2011 Generic intervention
Patel 2008 Hospital admission for HF not an inclusion criterion
Pedone 2015 Wrong intervention
Peters-Klimm 2007 Hospital admission for HF not an inclusion criterion
Philbin 2000 Wrong intervention - a quality improvement programme targetted at hospital level
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Study Reason for exclusion
Piamjariyakul 2015 Wrong participants
Powell 2010 No usual-care comparison group
Hospital admission for HF not an inclusion criterion
Powers 2014 Wrong follow-up
Quinn 2006 Non-randomised study
Ramachandran 2008 Hospital admission for HF not an inclusion criterion. Contact with study author indicated some
may have only been clinic outpatients
Rao 2007 Hospital admission for HF not an inclusion criterion
RBR-9c3ssc Follow-up too short (90 days)
Reed 2017 Wrong study design
Reeder 2014 Wrong study design
Rich 1993 < 6 months' follow-up
Rich 1995 < 6 months' follow-up
Riegel 2000 Non-randomised study
Riegel 2002 Purely telemonitoring intervention
Riegel 2016 Wrong comparator
Rodriguez-Gazquez 2012 Hospitalisation for HF not an inclusion criterion
Rondinini 2008 Non-randomised study
Rosen 2017 Wrong study design
Rubens 2014 Wrong study design
Rubin 1992 'Generic' intervention
Sanchez 2015 Wrong study design
Santos 2014 Wrong comparator
Scalvini 2016 Wrong intervention
Schneider 1993 Non-randomised study
Schou 2014 Wrong participants
Serxner 1998 Purely educational intervention
Sezgin 2017 Wrong participants
Shepherd 2015 Wrong intervention
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Study Reason for exclusion
Shively 2005 Hospital admission for HF not an inclusion criterion
Sisk 2006 Hospital admission for HF not an inclusion criterion
Smeulders 2006 Hospital admission for HF not an inclusion criterion
Smeulders 2010 Not all participants previously hospitalised for HF
Smith 2005 Hospital admission for HF not an inclusion criterion
Smith 2014 Wrong comparator
Srisuk 2017 Wrong intervention
Stamp 2016 Wrong intervention
Stewart 1998a 'Generic' intervention
Stewart 1998b Subgroup from a 'generic' study
Stewart 1999b Subgroup from a 'generic' study
Stewart 2002 Follow-up data at 4.2 years combining data from included study (Stewart 1999a), and excluded
study (Stewart 1998a). Data on included study not presented separately
Stewart 2012 Active control arm, not usual care
Stewart 2014 Wrong comparator
TEC4 2016 Wrong intervention
Thompson 2014 Wrong study design
Tibaldi 2009 Active control arm, not usual care
Topp 1998 Non-randomised study
Townsend 1988 'Generic' intervention
Trochu 2003 Not an RCT
Umeda 2014 Wrong intervention
Vaillant-Roussel 2014 Wrong intervention
Valle 2004 < 6 months' follow-up
Van der Kluit 2014 Wrong study design
Van Lieshout 2011 Comparator not usual care
Van Rossum 1993 'Generic' intervention
Villanueva 2015 Wrong intervention
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Study Reason for exclusion
Vorilhon 2016 Wrong intervention
Wagenaar 2015 Wrong intervention
Warber 2011 Not people with CHF
Weinberger 1996 'Generic' intervention
Welsh 2013 Purely educational intervention
Williams 1994 'Generic' intervention
Wongpiriyayothar 2008 Majority of participants had valvular heart disease; not clear if all hospitalised for HF
Woodend 2008 Purely telemonitoring
Yallop 2006 Wrong intervention
Yeshchenko 2014 Wrong intervention
Young 2016 Wrong intervention
Yu 2015b Wrong follow-up
COPD: chronic obstructive pilmonary disease; HF: heart failure; RCT: randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods No information
Participants No information
Interventions No information
Outcomes No information
Notes This is a paper in a Spanish-language journal. It appears to be a cost-benefit analysis of the includ-
ed study Atienza 2004. We have been unable to find even an abstract to this paper so cannot con-
firm any characteristics.
Anguita 2005 
 
 
Methods Prospective randomisation to usual care (N = 249) and to a management programme delivered by
doctors/nurse team (N = 288)
Participants 537 participants, included in the National Heart Failure Registry
Interventions Management programme consists of structured education and follow-up (phone calls)
Outcomes Primary endpoint
Begrambekova 2013 
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• NYHA functional class dynamic• QoL outcomes• economic outcomes (particularly: frequency of unplanned readmissions and emergency calls)
The mean MLHFQ score at baseline was 57.79 in the active group and 56.96 in the control group.
In both groups MLHFQ score significantly decreased at 6 months −11.1; (P < 0.001) and −9,33 (P <
0.001), respectively. The difference between 2 groups was not statistically significant. The HF emer-
gency visits also decreased by 24% (P < 0.001) in active group and by 9.5% (P < 0.015) in control
group
Notes Study author contacted by email 10 April 2018 but no response
Begrambekova 2013  (Continued)
 
 
Methods Secondary analysis of an RCT (Congestive heart failure: a multidisciplinary non-pharmacological
approach for changing in re-hospitalisation and prognosis in patients (CHANCE))
Participants 745 people with HF and depressive symptoms
Interventions Disease management programme
• structured education• regular follow-up (phone calls)
Outcomes • Russian version of HADS• Composite of CV mortality and HF readmission
Notes Study author contacted by email for further details of CHANCE trial 10 April 2018 but no response
Linked conference abstract (Mareev 2010) is for the CHANCE-AND trial, but also mentions the
CHANCE trial. Study author not traceable
Begrambekova 2016 
 
 
Methods RCT of 24 patient-caregiver dyads
Participants 24 people with HF and their family caregivers
Interventions Family cognitive education therapy
• CBT• educational self-care intervention
Outcomes • Depression (Patient Health Questionnaire)• QoL (MLHFQ) at 6 months
Notes Study author contacted by email 23 April 2018 to clarify whether majority of participants had been
admitted to hospital for HF, and whether the intervention was tailored to HF or a 'generic' interven-
tion. No response
Chung 2014 
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Methods Not clear from abstract - "divided into groups"
Participants 145 hospitalised patients with HF
Interventions Education for participants:
• diets• self-management• surveillance of HF symptoms• explanation of drugs or devices used for HF.
Follow-up phone calls for participants in stable condition:
• phone calls every 4 weeks.
Follow-up phone calls for participants in unstable condition:
• phone calls every week.
Visits to the heart clinic to see specialists who major in HF provided treatment:
• adjustment of drug doses• change of drugs• health consultation for participants and their family members
Outcomes • NYHA functional class• LVEF• Self-monitoring indicators• Achievement of target doses of beta-blockers• CV event rate
Notes We assessed this Chinese-language study as potentially meeting the inclusion criteria, but we have
been unable to get a data extraction done for this review
Fan 2010 
 
 
Methods Cluster-RCT
Participants People with HF
Interventions Specialised nurse clinic (intervention) versus conventional HF treatment (control)
Outcomes • ECHO utilisation• Angiotensin convertin enzyme-inhibitor use• Readmission rates
Notes Recruitment status: completed. Enrollment started in 2000, but no results or publications identi-
fied
ISRCTN13668364 
 
 
Methods Multicentre RCT (pilot study), January 2013-April 2014
Mizukawa 2014 
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Participants 59 people with HF
Interventions 3 arms:
• tele-monitoring group* participants had a device to measure noninvasive blood pressure, heart rate, body weight mea-
surements that automatically sent data to the monitor centre* nurses gave participants teleconsultation when the data were out of the optimal values* participants also received a disease management programme to gain self-management skills• disease management programme* participants write the value of blood pressure, heart rate, and body weight to monitor their
conditions.• usual-care group* standard self-management education once from a nurse* participants visited the physicians as usual
Outcomes • Readmission for HF
Notes Emailed only traceable study author (toshirok@hiroshima-u.ac.jp) on 1 May 2018 to ask for further
details on whether hospitalisation for HF was an inclusion criterion and whether results published
in full, but no response
Mizukawa 2014  (Continued)
 
 
Methods Factorial RCT
Participants HF
Interventions 3 arms:
• patient family education (intervention 1)• family partnership intervention (intervention 2)• usual care (control)
Outcomes Primary:
• adherence to dietary sodium and medication-taking behaviour• physical status• psychological status• HRQoL
 
Secondary:
• health resource utilisation• autonomy support• perceived family criticism• knowledge
Notes Recruitment status: completed. Study completion date: May 2011. No results found
NCT00166049 
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Methods Cluster -RCT
Participants HF
Interventions Primary case-based disease management strategy
Outcomes Primary:
• process-of-care composite score,• ACEI-inhibitor use
Secondary:
• disease-specific QoL,• NYHA functional class• all-cause hospitalisation• HF hospitalisation• ED visits for HF• referral to HF clinic• quality-adjusted survival• overall costs
Notes Recruitment status: unknown.  Study completion date was October 2006. No results found and
comparator unclear
NCT00182182 
 
 
Methods RCT
Participants Adults with HF
Interventions Family-focused nursing vs treatment as usual
Outcomes Primary:
• HRQoL
Secondary:
• change in European Heart Failure Self-Care Behavior Scale• change in Family Functioning, Health and Social Support Scale• change in Self-Efficacy for Managing Chronic Disease 6-item scale• change in Major Depression Inventory diagnostic scale• re-admissions• HF re-admissions• mortality
Notes Recruitment status: completed. Study completion date: January 2017. No results published/posted
NCT01378247 
 
 
Methods RCT
NCT01461681 
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Participants Adults with HF
Interventions Symptom management service for HF versus usual cardiology care
Outcomes Primary:
• change in depression assessed at baseline, 3 months and 6 months
Secondary outcomes: NR
Notes Recruitment status: completed. Study completion date: December 2013. No results pub-
lished/posted
NCT01461681  (Continued)
 
 
Methods Cluster-RCT
Participants Adults and children (≥ 16 years) with HF
Interventions Discharge planning services versus standard care
Outcomes Primary:
• time to composite of all-cause readmissions• emergency department visits• death at 30 days and 3 months
Secondary:
• preparedness for discharge• QoL on admission, at 6 weeks and 6 months post-discharge• healthcare costs
Notes Recruitment status: completed. Study completion date: June 2016. No results published/posted
NCT02112227 PACT-HF 
 
 
Methods RCT: "A disease management study targeted to reduce health care utilization for patients with con-
gestive heart failure". Start date January 2010, estimated study completion date June 2016
Participants Estimated enrolment: 10,000 adults with ≥ 1 unplanned inpatient occasion with primary diagnosis
of HF during the last 12 months
Interventions Disease management intervention (DMI):
• nurse-managed• regularly delivered by telephone or, when necessary, in person
Control - not receiving the DMI
Outcomes Primary outcomes (at 2 years)
• number of hospitalisations• number of outpatient visits to medical doctor
NCT02251899 
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Secondary outcomes (at 2 years)
• mortality• length of hospital stays• total health care cost
Notes Gustaf Edgren (gustaf@pheph.se) contacted 16 April 2018 to see if any results are available yet - no
response
NCT02251899  (Continued)
 
 
Methods 3-arm RCT
Participants Adults > 40 years with HF
Interventions • Feedback with associated encouragement about daily activity (intervention 1)• Health coaching with associated individualised home exercise programme (intervention 2)• Usual care (control)
Outcomes Primary:
• change in Medtronic implanted device patient activity measure
 Secondary:
• ActiGraph daily activity• 6-min walk test• 30 seconds timed chair rise• QoL• health care utilisation
Notes Recruitment status: completed. Study completion date: July 2016. No results published/posted 
NCT02331524 
 
 
Methods RCT
2011-2013, patients were prospectively randomly allocated (1: 2) to standard care or intervention
Participants 127 patients with reduced EF
Interventions • Nurse-led clinic cross intervention programme (health education and drug treatment optimisa-
tion)• Standard care
Outcomes Primary composite endpoint
• mortality and hospital readmissions from any cause.
Secondary endpoints
• all-cause mortality• all-cause hospital readmissions• HF readmissions
Ortiz 2017 
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• time to 1st admission• QoL improvements (assessed by MLHFQ)
Notes Emailed study author for clarification of whether majority of participants had been admitted to
hospital for HF (1 May 2018). No response
Ortiz 2017  (Continued)
 
 
Methods RCT
Participants 120 HF outpatients in the medical centre
Interventions Self-management intervention.
"Diet control" strategy focused on sodium and fluid restriction:
• appraisal• goal setting• self-monitoring of diet control, symptoms and daily weight.
Comparison
• did not receive this intervention
Outcomes • Self-efficacy for salt and fluid control• HF self-management behavior• HF symptoms• Depressive symptoms• Daily weight monitoring• HF health services utilisation
Notes Emailed study author (1 May 2018) for clarification of whether majority of participants had been ad-
mitted to hospital for HF, and whether the conference abstract was now published as a full paper.
No response
Shao 2014 
ACEI: angiotensin converting enzyme inhibitor; CV: cardiovascular; ED: Emergency Department; EF: ejection fraction; HADS: Hospital
Anxiety and Depression Scale; HRQoL: health-related quality of life; MLHFQ: Minnesota Living with Heart Failure questionnaire; NYHA:
New York Heart Association; QoL: quality of life; RCT: randomised controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title OSICAT
Methods Prospective, multicentre RCT
Participants People with chronic HF
Interventions Ttelecardiology programme:
• daily scale assessment• a device asking the participants daily questions on the symptoms associated with their HF• regular telephone calls made by nurses
Bendelac 2014 
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Outcomes • All-cause mortality assessed at 6, 12 and 18 months• Hospitalisation assessed at 6, 12 and 18 months• Cost-utility study: the economic analysis will adopt the healthcare payer’s perspective and will
take into account direct costs, indirect costs and informal care costs.• Social and organisational acceptability
Starting date 2014
Contact information Pro Galinier: galinier.m@chu-toulouse.fr
Notes Contact with Prof Galinier (16 April 2018) confirmed that this study has not yet been completed.
Bendelac 2014  (Continued)
 
 
Trial name or title Innovative telemonitoring enhanced care programme for chronic heart failure (ITEC-CHF) to im-
prove guideline compliance and collaborative care: protocol of a multicentre randomised con-
trolled trial
Methods Mutlicentre RCT
Participants 300 people with chronic HF
Interventions Innovative telemonitoring enhanced care programme for HF (ITEC-CHF)
• usual care• additional telemonitoring service* remote weight monitoring* structured telephone support* nurse-led collaborative care
Comparator:
• usual care
Outcomes Primary outcomes:
• compliance rates with the best-practice guidelines for daily weight monitoring
Secondary outcomes:
• compliance with other guideline recommendations (health maintenance, medication, diet and
exercise),• health (HRQoL, risk factors, functional capacity and psychological states)• economic outcomes related to the use of healthcare resources such as hospital readmissions and
GP/ED visits
Starting date Recruitment started 20 January 2015, anticipated last enrolment was 31 March 2017
Contact information Trial registration number: registered with Australian New Zealand Clinical Trial Registry (AC-
TRN12614000916640).
Hang.Ding@csiro.au
Notes Email contact with study author (31 May 2018) confirmed that the trial is complete but the results
paper is being drafted so results not yet available
Ding 2017 
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Trial name or title The evaluation of a nurse-led intervention to improve self-management for patients admitted to
hospital with a diagnosis of heart failure (due to leN ventricular systolic dysfunction)
Methods RCT
Participants 250 participants (125 in intervention arm, 125 in control arm)
Interventions The intervention is designed to enhance participants' sense of self efficacy (confidence) in their
ability to adhere to medication and other aspects of their treatment regime including:
• fluid restriction• diet• exercise• self-monitoring for signs of deteriorating HF• using a problem-solving approach
Outcomes Primary endpoints during 1st 3 months after discharge:
• all-cause hospital readmissions• HF hospital readmissions
Numerous secondary endpoints including mortality and 12-month data.
Starting date NA, study likely to be completed in 2005
Contact information Dr. Suzanna Hardman Consultant Cardiologist with an interest in Community Cardiology,
The Whittington & UCL Hospitals, Clinical & Academic Department of Cardiovascular Medicine, St
Mary's Wing, Whittington Hospital, Highgate Hill, London N19 5NF, UK.
Notes Contacted study author July 2010, publication expected soon. Contacted 11 September 2018 for
further update as no publications identified, no update
Hardman S 
 
 
Trial name or title A controlled trial of heart failure management programs
Methods Controlled trial
Participants 147 patients with symptomatic HF at 5 VA facilities
Interventions 3 groups:
• usual care• nurse manager• home monitoring
Also in two sites patients randomised to HF clinic
Outcomes Death or hospitalisation for a cardiac cause
Starting date NA
Contact information NA
Massie 2001 
Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
172
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Notes Poster abstract only. Study author contacted, full trial not published. No further publications iden-
tified
Massie 2001  (Continued)
 
 
Trial name or title Blended collaborative care for heart failure and co-morbid depression
Methods RCT
Participants HF and depression
Interventions • Collaborative care for HF and depression (intervention 1)• Collaborative care for HF only (intervention 2)• Usual care for HF and depression (control)
Outcomes Primary:
• mental HRQoL
Secondary:
• HF-related QoL• mood symptoms• rehospitalisation• mortality (all-cause and cardiovascular)• costs• employment
Starting date February 2014
Contact information Principal Investigator: Bruce L. Rollman, University of Pittsburgh
Notes Estimated study completion date: June 2019.
NCT02044211 
 
 
Trial name or title MEDIC-HF
Methods RCT
Participants Adults with HF
Interventions • Group medical visits• Usual care
Outcomes Primary:
• QoL
Secondary:
• time to hospitalisation or death
NCT02481921 
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Starting date 1 June 2015
Contact information Contact: Wen-Chih H Wu (wen-chih.wu@va.gov), Tracey Taveira (tracey.taveira@va.gov)
Notes Recruitment status: recruiting
NCT02481921  (Continued)
 
 
Trial name or title MOTIVATE-HF
Methods RCT
Participants Adults with HF
Interventions • Motivational interviewing only for participants (intervention 1)• Motivational interviewing for participants and caregivers (intervention 2)• No intervention (control)
Outcomes Primary:
• self-care in participants and care-givers
Secondary:
• burden of HF symptoms• QoL• participant hospitalisation• use of emergency services• death
Starting date June 2014
Contact information Contact: Ercole Vellone (ercole.vellone@uniroma2.it), Rosaria Alvaro (rosaria.alvaro@uniroma2.it)
Notes Estimated study completion date: December 2018
NCT02894502 
 
 
Trial name or title DIVERT-CARE
Methods RCT
Participants Adults ≥ 19 years with HF and COPD
Interventions • Cardio-respiratory management model• Standard care
Outcomes Primary:
• first unplanned ED visit• total care costs• changes in participant activation
NCT03012256 
Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
174
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• number of symptoms
Secondary:
• number of unplanned ED visits• HRQoL
Follow-up: 6 months
Starting date 6 February 2018
Contact information Contact: Andrew Costa (acosta@mcmaster.ca), Graham Campbell (campbg4@mcmaster.ca)
Notes Recruitment status: recruiting. Estimated study completion date: December 2019
NCT03012256  (Continued)
 
 
Trial name or title EduStra-HF
Methods RCT
Participants HF
Interventions • Therapeutic education• Usual care
Outcomes Primary:
• number of rehospitalisations for acute HF
Secondary:
• participants' knowledge about illness• QoL• length of stay for HF and all-cause hospitalisations• hospitalisation rate for CVDs except HF• CV and all-cause mortality rate,• BNP or NT pro-BNP levels
Other:
• cost-effectiveness
Follow-up: 1 year
Starting date 1 April 2017
Contact information  
Notes Estimated study completion date: 30 June 2020
NCT03035123 
 
 
Trial name or title HOM-HEMP 
NCT03108235 
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Methods RCT
Participants Adults ≥ 55 years with chronic HF
Interventions • Home-based self-management psychosocial educational programme (HOM-HEMP) (intervention
1)• HOM-HEMP with smartphone app (intervention 2)• Standard care (control)
Outcomes Primary:
• cardiac self-efficacy scale
Secondary:
• HADS,• HRQoL• Social Support Questionnaire• Self-Care Heart Failure Index
Other:
• 6-minute walk test• NYHA functional class• LVEF• unplanned health services use• process evaluation
Starting date 1 January 2018
Contact information Contact: Wenru Wang (nurww@nus.edu.sg)
Notes Estimated study completion date: 30 December 2019
NCT03108235  (Continued)
 
 
Trial name or title Intervention by a cardiologist and geriatrician in elderly patients after admission due to heart fail-
ure
Methods RCT
Participants Patients > 75 years with a recent admission for HF (within the previous 10 days)
Interventions Intervention:
• participants randomised to a combined ambulatory follow-up with a cardiologist and a geriatri-
cian
Comparator:
• participants randomised to usual care (ambulatory follow-up with a cardiologist)
Outcomes Primary:
• all-cause hospitalisation
Secondary:
NCT03555318 
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• HF hospitalisation• QoL• functional capacity• medication use• number of outpatient visits• ED visits• hospitalisations
Starting date Not yet recruiting (as of June 13, 2018) Estimated study completion is June 14, 2020
Contact information Nuria Farre, NFarreLopez@parcdesalutmar.cat
Notes  
NCT03555318  (Continued)
 
 
Trial name or title TERVA: Tele-based health coaching program for chronic disease in primary care (NCT00552903)
Methods RCT
Participants 1570 patients with type 2 diabetes, coronary artery disease or congestive HF
Interventions Intervention:
• monthly individual health coaching by telephone from a specially trained nurse for 12- months• routine social and healthcare
Control:
• routine social and health care
Outcomes • HRQoL (15D instrument to measure utility)• Cost-effectiveness ratios (ICER, QALY)
Starting date Unclear
Contact information NCT00552903 Kristiina Patja <kristiina.patja@promedico.fi>
Notes Contact with study author (14 May 2018) indicated that the full 8-year clinical outcome data are not
yet published or available for this study, nor the relevant clinical outcome data for the Patja 2012
reference. The Oksman 2017 paper contains cost-effectiveness data and a measure of health utility.
Oksman 2017 
 
 
Trial name or title Nursing case management for elderly heart failure patients
Methods Not clear
Participants 200 patients aged ≥ 65 years hospitalised at 1 centre for the treatment of HF
Interventions Intervention:
• enhanced discharge planning
Pugh 1999 
Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
177
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• taught to manage their HF within parameters set by their physician using a workbook for guidance• receive participant-specific printed material• ongoing assessment and follow-up by a nurse for a 6-month period through phone calls and visits
Outcomes • Morbidity• Mortality• QoL• Functional status
At 6 months and 1 year after discharge
Starting date NA, in July 1998 57 participants had been recruited
Contact information NA
Notes No publications identified
Pugh 1999  (Continued)
 
 
Trial name or title Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) facilitated self-care rehabilitation
intervention in heart failure patients and caregivers
Methods Multicentre, parallel, 2-group RCT
Participants 216 patients with systolic HF and their caregivers
Interventions Intervention:
• self-help manual delivered by specially trained facilitators over a 12-week period• usual care
Control
• usual care alone (control)
Outcomes Primary:
• participants' disease-specific HRQoL (MLHFQ) at 12 months' follow-up.
Secondary:
• survival• HF hospitalisation• blood biomarkers• psychological well-being• exercise capacity• physical activity• other measures of QoL• participant safety and QoL• psychological well-being• perceived burden of caregivers at 4, 6 and 12 months' follow-up.
A cost-effectiveness evaluation will also be carried out.
Starting date 13 November 2014
Taylor 2015 
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Contact information Trial registration number: ISRCTN86234930
r.taylor@exeter.ac.uk
Notes Pilot paper by Greaves 2016 does not contain outcomes relevant to this review. Full publication ex-
pected soon
Taylor 2015  (Continued)
 
 
Trial name or title MOTIVATE-HF; NCT02894502
Methods 3-arm, multicentre RCT
Participants 240 people with HF and their caregivers
Interventions Motivational interviewing; 3 arms:
• motivational interviewing intervention to only participants• motivational interviewing intervention to participants and caregivers• standard care to participants and caregivers
Outcomes • Self-care maintenance; self-care management, self-care confidence,• HF somatic symptom perception• Generic and disease-specific QoL• Anxiety and depression• Cognition• Sleep quality• Mutuality with caregiver• Hospitalisations• Use of emergency services• Mortality
Starting date June 2014, estimated study completion date December 2018
Contact information ercole.vellone@uniroma2.it
Notes Email from study author (1 May 2018) confirmed that data collection is now complete but the main
article is not yet ready for dissemination.
Vellone 2017 
COPD: chronic obstructive pulmonary disease;CV: cardiovascular; CVD: cardiovascular disease; ED: Emergency Department; GP: General
Practitioner; HADS: Hospital Anxiety and Depression Scale; HF: heart failure; HRQoL: health-related quality of life; ICER: incremental
cost eIectiveness ratio LVEF: leN ventricular ejection fraction; NYHA: New York Heart Association; QALY: quality-adjusted life year; RCT:
randomised controlled trial
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Comparison 1.   Case management vs usual care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All-cause mortality - main
analysis
26 6903 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.68, 0.90]
2 All-cause mortality - subgroup
analysis by length of follow-up
26 6903 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.68, 0.90]
2.1 6 months' follow-up 10 3253 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.70, 1.11]
2.2 More than 6 months' fol-
low-up
16 3650 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.88]
3 All-cause mortality - subgroup
analysis by person delivering
the intervention
26 6903 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.68, 0.90]
3.1 Specialist nurse 13 2268 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.61, 1.01]
3.2 Nurse/community nurse 6 2645 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.69, 1.03]
3.3 Pharmacist/community
pharmacist
3 507 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.25, 1.67]
3.4 Multidisciplinary 2 869 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.50, 1.03]
3.5 Other 2 614 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.42, 1.71]
4 All-cause mortality - sensitivity
analysis with low risk of bias
10 3514 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.55, 0.82]
5 HF readmissions - main analy-
sis
12 2528 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.53, 0.78]
6 HF readmissions - subgroup
analysis by length of follow-up
12 2528 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.53, 0.78]
6.1 6 months' follow-up 4 778 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.88]
6.2 More than 6 months' fol-
low-up
8 1750 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.45, 0.81]
7 HF readmissions - subgroup
analysis by person delivering
the intervention
12 2528 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.53, 0.78]
7.1 Specialist nurse 7 945 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.47, 0.70]
7.2 Nurse/community nurse 1 252 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.42, 1.16]
7.3 Pharmacist/community
pharmacist
1 34 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.16, 1.03]
7.4 Multidisciplinary 1 683 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.84, 1.39]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
7.5 Other 2 614 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.45, 0.88]
8 HF readmissions - sensitivity
analysis with low risk of bias
4 741 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.50, 0.77]
9 All-cause readmissions - main
analysis
14 4539 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.83, 1.01]
10 All-cause readmissions - sub-
group analysis by length of fol-
low-up
14 4539 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.83, 1.01]
10.1 6 months' follow-up 5 2120 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.11]
10.2 More than 6 months' fol-
low-up
9 2419 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.01]
11 All-cause readmissions - sub-
group analysis by person deliv-
ering the intervention
14 4539 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.83, 1.01]
11.1 Specialist nurse 6 853 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.73, 0.99]
11.2 Nurse/community nurse 4 2255 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.92, 1.09]
11.3 Pharmacist/community
pharmacist
1 134 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.45, 1.03]
11.4 Multidisciplinary 1 683 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.92, 1.21]
11.5 Other 2 614 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.57, 1.38]
12 All-cause readmissions - sen-
sitivity analysis with low risk of
bias
6 2217 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.74, 1.02]
13 Quality of life (MLHFQ mean
score at end of follow-up)
8   Mean Difference (Random, 95% CI) Totals not selected
14 Quality of life (subgroup by
length of intervention)
8   Mean Difference (Random, 95% CI) -5.76 [-10.64, -0.88]
14.1 Less than 6 months' fol-
low-up
6   Mean Difference (Random, 95% CI) -3.32 [-8.59, 1.96]
14.2 More than 6 months' fol-
low-up
2   Mean Difference (Random, 95% CI) -12.14 [-16.48, -7.79]
15 Quality of life (subgroup by
person delivering intervention)
8   Mean Difference (Random, 95% CI) -5.76 [-10.64, -0.88]
15.1 Specialist nurse 6   Mean Difference (Random, 95% CI) -7.87 [-14.36, -1.39]
15.2 Nurse/community nurse 2   Mean Difference (Random, 95% CI) -0.91 [-8.48, 6.67]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
15.3 Pharmacist/community
pharmacist
0   Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
15.4 Multidisciplinary 0   Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
15.5 Other 0   Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Case management vs usual care, Outcome 1 All-cause mortality - main analysis.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Aldamiz-Echevarria 2007 22/137 21/142 4.56% 1.09[0.63,1.88]
Atienza 2004 30/164 51/174 6.82% 0.62[0.42,0.93]
Berger 2010 21/96 35/90 5.79% 0.56[0.36,0.89]
Blue 2001 25/84 25/81 5.72% 0.96[0.61,1.53]
Brotons 2009 26/144 29/138 5.54% 0.86[0.53,1.38]
de Souza 2014 10/123 18/129 2.97% 0.58[0.28,1.21]
DeBusk 2004 21/228 29/234 4.78% 0.74[0.44,1.26]
Dunbar 2014 2/70 2/64 0.52% 0.91[0.13,6.3]
Holland 2007 30/169 24/170 5.28% 1.26[0.77,2.06]
Jaarsma 2000 22/84 16/95 4.3% 1.56[0.88,2.76]
Jaarsma 2008 83/344 99/339 10.13% 0.83[0.64,1.06]
Kasper 2002 7/102 13/98 2.21% 0.52[0.22,1.24]
Kimmelstiel 2004 11/103 14/97 2.92% 0.74[0.35,1.55]
Krumholz 2002 9/44 13/44 2.92% 0.69[0.33,1.45]
Kwok 2008 4/49 8/56 1.39% 0.57[0.18,1.78]
Leventhal 2011 2/22 4/20 0.75% 0.45[0.09,2.22]
Lopez 2006 9/70 19/64 3.07% 0.43[0.21,0.89]
Mehralian 2014 2/55 4/55 0.69% 0.5[0.1,2.62]
Naylor 2004 11/118 32/121 3.69% 0.35[0.19,0.67]
Nucifora 2006 14/99 8/101 2.45% 1.79[0.78,4.07]
Ong 2016 100/715 114/722 10.19% 0.89[0.69,1.13]
Rainville 1999 1/17 4/17 0.44% 0.25[0.03,2.01]
Stewart 1999a 18/100 28/100 4.88% 0.64[0.38,1.08]
Tsuchihashi-Makaya 2013 8/79 8/82 1.99% 1.04[0.41,2.63]
Tsuyuki 2004 16/140 12/136 3.12% 1.3[0.64,2.64]
Yu 2015a 9/90 17/88 2.84% 0.52[0.24,1.1]
   
Total (95% CI) 3446 3457 100% 0.78[0.68,0.9]
Total events: 513 (Case management), 647 (Usual care)  
Heterogeneity: Tau2=0.03; Chi2=35.94, df=25(P=0.07); I2=30.44%  
Test for overall effect: Z=3.39(P=0)  
Favours case management 1000.01 100.1 1 Favours usual care
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Analysis 1.2.   Comparison 1 Case management vs usual care, Outcome
2 All-cause mortality - subgroup analysis by length of follow-up.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 6 months' follow-up  
de Souza 2014 10/123 18/129 2.97% 0.58[0.28,1.21]
Dunbar 2014 2/70 2/64 0.52% 0.91[0.13,6.3]
Holland 2007 30/169 24/170 5.28% 1.26[0.77,2.06]
Kasper 2002 7/102 13/98 2.21% 0.52[0.22,1.24]
Kwok 2008 4/49 8/56 1.39% 0.57[0.18,1.78]
Mehralian 2014 2/55 4/55 0.69% 0.5[0.1,2.62]
Nucifora 2006 14/99 8/101 2.45% 1.79[0.78,4.07]
Ong 2016 100/715 114/722 10.19% 0.89[0.69,1.13]
Stewart 1999a 18/100 28/100 4.88% 0.64[0.38,1.08]
Tsuyuki 2004 16/140 12/136 3.12% 1.3[0.64,2.64]
Subtotal (95% CI) 1622 1631 33.71% 0.88[0.7,1.11]
Total events: 203 (Case management), 231 (Usual care)  
Heterogeneity: Tau2=0.02; Chi2=11, df=9(P=0.28); I2=18.19%  
Test for overall effect: Z=1.09(P=0.28)  
   
1.2.2 More than 6 months' follow-up  
Aldamiz-Echevarria 2007 22/137 21/142 4.56% 1.09[0.63,1.88]
Atienza 2004 30/164 51/174 6.82% 0.62[0.42,0.93]
Berger 2010 21/96 35/90 5.79% 0.56[0.36,0.89]
Blue 2001 25/84 25/81 5.72% 0.96[0.61,1.53]
Brotons 2009 26/144 29/138 5.54% 0.86[0.53,1.38]
DeBusk 2004 21/228 29/234 4.78% 0.74[0.44,1.26]
Jaarsma 2000 22/84 16/95 4.3% 1.56[0.88,2.76]
Jaarsma 2008 83/344 99/339 10.13% 0.83[0.64,1.06]
Kimmelstiel 2004 11/103 14/97 2.92% 0.74[0.35,1.55]
Krumholz 2002 9/44 13/44 2.92% 0.69[0.33,1.45]
Leventhal 2011 2/22 4/20 0.75% 0.45[0.09,2.22]
Lopez 2006 9/70 19/64 3.07% 0.43[0.21,0.89]
Naylor 2004 11/118 32/121 3.69% 0.35[0.19,0.67]
Rainville 1999 1/17 4/17 0.44% 0.25[0.03,2.01]
Tsuchihashi-Makaya 2013 8/79 8/82 1.99% 1.04[0.41,2.63]
Yu 2015a 9/90 17/88 2.84% 0.52[0.24,1.1]
Subtotal (95% CI) 1824 1826 66.29% 0.74[0.62,0.88]
Total events: 310 (Case management), 416 (Usual care)  
Heterogeneity: Tau2=0.04; Chi2=22.91, df=15(P=0.09); I2=34.53%  
Test for overall effect: Z=3.34(P=0)  
   
Total (95% CI) 3446 3457 100% 0.78[0.68,0.9]
Total events: 513 (Case management), 647 (Usual care)  
Heterogeneity: Tau2=0.03; Chi2=35.94, df=25(P=0.07); I2=30.44%  
Test for overall effect: Z=3.39(P=0)  
Test for subgroup differences: Chi2=1.48, df=1 (P=0.22), I2=32.51%  
Favours case management 1000.01 100.1 1 Favours usual care
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Analysis 1.3.   Comparison 1 Case management vs usual care, Outcome 3 All-
cause mortality - subgroup analysis by person delivering the intervention.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Specialist nurse  
Blue 2001 25/84 25/81 5.72% 0.96[0.61,1.53]
Brotons 2009 26/144 29/138 5.54% 0.86[0.53,1.38]
Dunbar 2014 2/70 2/64 0.52% 0.91[0.13,6.3]
Jaarsma 2000 22/84 16/95 4.3% 1.56[0.88,2.76]
Kasper 2002 7/102 13/98 2.21% 0.52[0.22,1.24]
Kimmelstiel 2004 11/103 14/97 2.92% 0.74[0.35,1.55]
Krumholz 2002 9/44 13/44 2.92% 0.69[0.33,1.45]
Leventhal 2011 2/22 4/20 0.75% 0.45[0.09,2.22]
Naylor 2004 11/118 32/121 3.69% 0.35[0.19,0.67]
Nucifora 2006 14/99 8/101 2.45% 1.79[0.78,4.07]
Stewart 1999a 18/100 28/100 4.88% 0.64[0.38,1.08]
Tsuchihashi-Makaya 2013 8/79 8/82 1.99% 1.04[0.41,2.63]
Yu 2015a 9/90 17/88 2.84% 0.52[0.24,1.1]
Subtotal (95% CI) 1139 1129 40.74% 0.79[0.61,1.01]
Total events: 164 (Case management), 209 (Usual care)  
Heterogeneity: Tau2=0.08; Chi2=19.85, df=12(P=0.07); I2=39.55%  
Test for overall effect: Z=1.85(P=0.06)  
   
1.3.2 Nurse/community nurse  
Aldamiz-Echevarria 2007 22/137 21/142 4.56% 1.09[0.63,1.88]
de Souza 2014 10/123 18/129 2.97% 0.58[0.28,1.21]
DeBusk 2004 21/228 29/234 4.78% 0.74[0.44,1.26]
Kwok 2008 4/49 8/56 1.39% 0.57[0.18,1.78]
Mehralian 2014 2/55 4/55 0.69% 0.5[0.1,2.62]
Ong 2016 100/715 114/722 10.19% 0.89[0.69,1.13]
Subtotal (95% CI) 1307 1338 24.6% 0.84[0.69,1.03]
Total events: 159 (Case management), 194 (Usual care)  
Heterogeneity: Tau2=0; Chi2=3, df=5(P=0.7); I2=0%  
Test for overall effect: Z=1.7(P=0.09)  
   
1.3.3 Pharmacist/community pharmacist  
Holland 2007 30/169 24/170 5.28% 1.26[0.77,2.06]
Lopez 2006 9/70 19/64 3.07% 0.43[0.21,0.89]
Rainville 1999 1/17 4/17 0.44% 0.25[0.03,2.01]
Subtotal (95% CI) 256 251 8.8% 0.65[0.25,1.67]
Total events: 40 (Case management), 47 (Usual care)  
Heterogeneity: Tau2=0.45; Chi2=7.16, df=2(P=0.03); I2=72.08%  
Test for overall effect: Z=0.9(P=0.37)  
   
1.3.4 Multidisciplinary  
Berger 2010 21/96 35/90 5.79% 0.56[0.36,0.89]
Jaarsma 2008 83/344 99/339 10.13% 0.83[0.64,1.06]
Subtotal (95% CI) 440 429 15.92% 0.72[0.5,1.03]
Total events: 104 (Case management), 134 (Usual care)  
Heterogeneity: Tau2=0.04; Chi2=2.08, df=1(P=0.15); I2=51.99%  
Test for overall effect: Z=1.8(P=0.07)  
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Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.5 Other  
Atienza 2004 30/164 51/174 6.82% 0.62[0.42,0.93]
Tsuyuki 2004 16/140 12/136 3.12% 1.3[0.64,2.64]
Subtotal (95% CI) 304 310 9.94% 0.85[0.42,1.71]
Total events: 46 (Case management), 63 (Usual care)  
Heterogeneity: Tau2=0.18; Chi2=3.1, df=1(P=0.08); I2=67.77%  
Test for overall effect: Z=0.47(P=0.64)  
   
Total (95% CI) 3446 3457 100% 0.78[0.68,0.9]
Total events: 513 (Case management), 647 (Usual care)  
Heterogeneity: Tau2=0.03; Chi2=35.94, df=25(P=0.07); I2=30.44%  
Test for overall effect: Z=3.39(P=0)  
Test for subgroup differences: Chi2=0.87, df=1 (P=0.93), I2=0%  
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Analysis 1.4.   Comparison 1 Case management vs usual care, Outcome
4 All-cause mortality - sensitivity analysis with low risk of bias.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Aldamiz-Echevarria 2007 22/137 21/142 9.24% 1.09[0.63,1.88]
Berger 2010 21/96 35/90 11.78% 0.56[0.36,0.89]
Brotons 2009 26/144 29/138 11.25% 0.86[0.53,1.38]
de Souza 2014 10/123 18/129 5.99% 0.58[0.28,1.21]
Kasper 2002 7/102 13/98 4.44% 0.52[0.22,1.24]
Kwok 2008 4/49 8/56 2.8% 0.57[0.18,1.78]
Lopez 2006 9/70 19/64 6.2% 0.43[0.21,0.89]
Naylor 2004 11/118 32/121 7.46% 0.35[0.19,0.67]
Ong 2016 100/715 114/722 21.03% 0.89[0.69,1.13]
Stewart 1999a 18/100 28/100 9.9% 0.64[0.38,1.08]
Stewart 1999a 18/100 28/100 9.9% 0.64[0.38,1.08]
   
Total (95% CI) 1754 1760 100% 0.67[0.55,0.82]
Total events: 246 (Case management), 345 (Usual care)  
Heterogeneity: Tau2=0.03; Chi2=14.64, df=10(P=0.15); I2=31.67%  
Test for overall effect: Z=3.9(P<0.0001)  
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Analysis 1.5.   Comparison 1 Case management vs usual care, Outcome 5 HF readmissions - main analysis.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Atienza 2004 39/164 79/174 13.01% 0.52[0.38,0.72]
Blue 2001 12/84 26/81 6.74% 0.45[0.24,0.82]
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Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
de Souza 2014 20/123 30/129 8.46% 0.7[0.42,1.16]
Jaarsma 2008 92/344 84/339 14.86% 1.08[0.84,1.39]
Kasper 2002 26/102 35/98 10.25% 0.71[0.47,1.09]
Krumholz 2002 9/44 17/44 5.7% 0.53[0.27,1.06]
Lang 2018 0/25 4/25 0.45% 0.11[0.01,1.96]
Leventhal 2011 1/22 2/20 0.68% 0.45[0.04,4.64]
Naylor 2004 40/118 72/121 13.78% 0.57[0.43,0.76]
Rainville 1999 4/17 10/17 3.52% 0.4[0.16,1.03]
Tsuchihashi-Makaya 2013 16/79 28/82 8.06% 0.59[0.35,1.01]
Tsuyuki 2004 53/140 70/136 14.49% 0.74[0.56,0.96]
   
Total (95% CI) 1262 1266 100% 0.64[0.53,0.78]
Total events: 312 (Case management), 457 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=22.42, df=11(P=0.02); I2=50.93%  
Test for overall effect: Z=4.42(P<0.0001)  
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Analysis 1.6.   Comparison 1 Case management vs usual care, Outcome
6 HF readmissions - subgroup analysis by length of follow-up.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 6 months' follow-up  
de Souza 2014 20/123 30/129 8.46% 0.7[0.42,1.16]
Kasper 2002 26/102 35/98 10.25% 0.71[0.47,1.09]
Lang 2018 0/25 4/25 0.45% 0.11[0.01,1.96]
Tsuyuki 2004 53/140 70/136 14.49% 0.74[0.56,0.96]
Subtotal (95% CI) 390 388 33.65% 0.72[0.58,0.88]
Total events: 99 (Case management), 139 (Usual care)  
Heterogeneity: Tau2=0; Chi2=1.7, df=3(P=0.64); I2=0%  
Test for overall effect: Z=3.16(P=0)  
   
1.6.2 More than 6 months' follow-up  
Atienza 2004 39/164 79/174 13.01% 0.52[0.38,0.72]
Blue 2001 12/84 26/81 6.74% 0.45[0.24,0.82]
Jaarsma 2008 92/344 84/339 14.86% 1.08[0.84,1.39]
Krumholz 2002 9/44 17/44 5.7% 0.53[0.27,1.06]
Leventhal 2011 1/22 2/20 0.68% 0.45[0.04,4.64]
Naylor 2004 40/118 72/121 13.78% 0.57[0.43,0.76]
Rainville 1999 4/17 10/17 3.52% 0.4[0.16,1.03]
Tsuchihashi-Makaya 2013 16/79 28/82 8.06% 0.59[0.35,1.01]
Subtotal (95% CI) 872 878 66.35% 0.6[0.45,0.81]
Total events: 213 (Case management), 318 (Usual care)  
Heterogeneity: Tau2=0.1; Chi2=20.53, df=7(P=0); I2=65.9%  
Test for overall effect: Z=3.39(P=0)  
   
Total (95% CI) 1262 1266 100% 0.64[0.53,0.78]
Total events: 312 (Case management), 457 (Usual care)  
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Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.05; Chi2=22.42, df=11(P=0.02); I2=50.93%  
Test for overall effect: Z=4.42(P<0.0001)  
Test for subgroup differences: Chi2=0.94, df=1 (P=0.33), I2=0%  
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Analysis 1.7.   Comparison 1 Case management vs usual care, Outcome 7
HF readmissions - subgroup analysis by person delivering the intervention.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.7.1 Specialist nurse  
Blue 2001 12/84 26/81 6.74% 0.45[0.24,0.82]
Kasper 2002 26/102 35/98 10.25% 0.71[0.47,1.09]
Krumholz 2002 9/44 17/44 5.7% 0.53[0.27,1.06]
Lang 2018 0/25 4/25 0.45% 0.11[0.01,1.96]
Leventhal 2011 1/22 2/20 0.68% 0.45[0.04,4.64]
Naylor 2004 40/118 72/121 13.78% 0.57[0.43,0.76]
Tsuchihashi-Makaya 2013 16/79 28/82 8.06% 0.59[0.35,1.01]
Subtotal (95% CI) 474 471 45.66% 0.58[0.47,0.7]
Total events: 104 (Case management), 184 (Usual care)  
Heterogeneity: Tau2=0; Chi2=3.07, df=6(P=0.8); I2=0%  
Test for overall effect: Z=5.48(P<0.0001)  
   
1.7.2 Nurse/community nurse  
de Souza 2014 20/123 30/129 8.46% 0.7[0.42,1.16]
Subtotal (95% CI) 123 129 8.46% 0.7[0.42,1.16]
Total events: 20 (Case management), 30 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.38(P=0.17)  
   
1.7.3 Pharmacist/community pharmacist  
Rainville 1999 4/17 10/17 3.52% 0.4[0.16,1.03]
Subtotal (95% CI) 17 17 3.52% 0.4[0.16,1.03]
Total events: 4 (Case management), 10 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.9(P=0.06)  
   
1.7.4 Multidisciplinary  
Jaarsma 2008 92/344 84/339 14.86% 1.08[0.84,1.39]
Subtotal (95% CI) 344 339 14.86% 1.08[0.84,1.39]
Total events: 92 (Case management), 84 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
1.7.5 Other  
Atienza 2004 39/164 79/174 13.01% 0.52[0.38,0.72]
Tsuyuki 2004 53/140 70/136 14.49% 0.74[0.56,0.96]
Subtotal (95% CI) 304 310 27.49% 0.63[0.45,0.88]
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Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 92 (Case management), 149 (Usual care)  
Heterogeneity: Tau2=0.04; Chi2=2.6, df=1(P=0.11); I2=61.5%  
Test for overall effect: Z=2.73(P=0.01)  
   
Total (95% CI) 1262 1266 100% 0.64[0.53,0.78]
Total events: 312 (Case management), 457 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=22.42, df=11(P=0.02); I2=50.93%  
Test for overall effect: Z=4.42(P<0.0001)  
Test for subgroup differences: Chi2=16.54, df=1 (P=0), I2=75.82%  
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Analysis 1.8.   Comparison 1 Case management vs usual care,
Outcome 8 HF readmissions - sensitivity analysis with low risk of bias.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
de Souza 2014 20/123 30/129 18.15% 0.7[0.42,1.16]
Kasper 2002 26/102 35/98 26.03% 0.71[0.47,1.09]
Lang 2018 0/25 4/25 0.57% 0.11[0.01,1.96]
Naylor 2004 40/118 72/121 55.26% 0.57[0.43,0.76]
   
Total (95% CI) 368 373 100% 0.62[0.5,0.77]
Total events: 86 (Case management), 141 (Usual care)  
Heterogeneity: Tau2=0; Chi2=2.34, df=3(P=0.51); I2=0%  
Test for overall effect: Z=4.3(P<0.0001)  
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Analysis 1.9.   Comparison 1 Case management vs usual care, Outcome 9 All-cause readmissions - main analysis.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Atienza 2004 68/164 101/174 9.56% 0.71[0.57,0.89]
Blue 2001 47/84 49/81 8% 0.92[0.71,1.2]
de Souza 2014 38/123 49/129 5.45% 0.81[0.58,1.15]
DeBusk 2004 116/227 117/234 11.64% 1.02[0.85,1.22]
Jaarsma 2000 31/85 47/94 5.41% 0.73[0.52,1.03]
Jaarsma 2008 194/344 181/339 14.3% 1.06[0.92,1.21]
Kwok 2008 23/49 32/56 4.81% 0.82[0.56,1.19]
Lang 2018 4/25 7/25 0.71% 0.57[0.19,1.71]
Leventhal 2011 10/22 6/20 1.26% 1.52[0.67,3.41]
Lopez 2006 23/70 31/64 4.02% 0.68[0.45,1.03]
Naylor 2004 53/118 67/121 8.11% 0.81[0.63,1.05]
Ong 2016 363/715 355/722 16.38% 1.03[0.93,1.15]
Tsuyuki 2004 59/140 51/136 6.89% 1.12[0.84,1.5]
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Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Yu 2015a 25/90 27/88 3.48% 0.91[0.57,1.43]
   
Total (95% CI) 2256 2283 100% 0.92[0.83,1.01]
Total events: 1054 (Case management), 1120 (Usual care)  
Heterogeneity: Tau2=0.01; Chi2=22.78, df=13(P=0.04); I2=42.92%  
Test for overall effect: Z=1.82(P=0.07)  
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Analysis 1.10.   Comparison 1 Case management vs usual care, Outcome
10 All-cause readmissions - subgroup analysis by length of follow-up.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.10.1 6 months' follow-up  
de Souza 2014 38/123 49/129 5.45% 0.81[0.58,1.15]
Kwok 2008 23/49 32/56 4.81% 0.82[0.56,1.19]
Lang 2018 4/25 7/25 0.71% 0.57[0.19,1.71]
Ong 2016 363/715 355/722 16.38% 1.03[0.93,1.15]
Tsuyuki 2004 59/140 51/136 6.89% 1.12[0.84,1.5]
Subtotal (95% CI) 1052 1068 34.23% 0.99[0.89,1.11]
Total events: 487 (Case management), 494 (Usual care)  
Heterogeneity: Tau2=0; Chi2=4.42, df=4(P=0.35); I2=9.6%  
Test for overall effect: Z=0.12(P=0.91)  
   
1.10.2 More than 6 months' follow-up  
Atienza 2004 68/164 101/174 9.56% 0.71[0.57,0.89]
Blue 2001 47/84 49/81 8% 0.92[0.71,1.2]
DeBusk 2004 116/227 117/234 11.64% 1.02[0.85,1.22]
Jaarsma 2000 31/85 47/94 5.41% 0.73[0.52,1.03]
Jaarsma 2008 194/344 181/339 14.3% 1.06[0.92,1.21]
Leventhal 2011 10/22 6/20 1.26% 1.52[0.67,3.41]
Lopez 2006 23/70 31/64 4.02% 0.68[0.45,1.03]
Naylor 2004 53/118 67/121 8.11% 0.81[0.63,1.05]
Yu 2015a 25/90 27/88 3.48% 0.91[0.57,1.43]
Subtotal (95% CI) 1204 1215 65.77% 0.89[0.78,1.01]
Total events: 567 (Case management), 626 (Usual care)  
Heterogeneity: Tau2=0.02; Chi2=16.48, df=8(P=0.04); I2=51.45%  
Test for overall effect: Z=1.84(P=0.07)  
   
Total (95% CI) 2256 2283 100% 0.92[0.83,1.01]
Total events: 1054 (Case management), 1120 (Usual care)  
Heterogeneity: Tau2=0.01; Chi2=22.78, df=13(P=0.04); I2=42.92%  
Test for overall effect: Z=1.82(P=0.07)  
Test for subgroup differences: Chi2=1.7, df=1 (P=0.19), I2=41.27%  
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Analysis 1.11.   Comparison 1 Case management vs usual care, Outcome 11 All-
cause readmissions - subgroup analysis by person delivering the intervention.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.11.1 Specialist nurse  
Blue 2001 47/84 49/81 8% 0.92[0.71,1.2]
Jaarsma 2000 31/85 47/94 5.41% 0.73[0.52,1.03]
Lang 2018 4/25 7/25 0.71% 0.57[0.19,1.71]
Leventhal 2011 10/22 6/20 1.26% 1.52[0.67,3.41]
Naylor 2004 53/118 67/121 8.11% 0.81[0.63,1.05]
Yu 2015a 25/90 27/88 3.48% 0.91[0.57,1.43]
Subtotal (95% CI) 424 429 26.97% 0.85[0.73,0.99]
Total events: 170 (Case management), 203 (Usual care)  
Heterogeneity: Tau2=0; Chi2=3.82, df=5(P=0.58); I2=0%  
Test for overall effect: Z=2.12(P=0.03)  
   
1.11.2 Nurse/community nurse  
de Souza 2014 38/123 49/129 5.45% 0.81[0.58,1.15]
DeBusk 2004 116/227 117/234 11.64% 1.02[0.85,1.22]
Kwok 2008 23/49 32/56 4.81% 0.82[0.56,1.19]
Ong 2016 363/715 355/722 16.38% 1.03[0.93,1.15]
Subtotal (95% CI) 1114 1141 38.27% 1[0.92,1.09]
Total events: 540 (Case management), 553 (Usual care)  
Heterogeneity: Tau2=0; Chi2=2.87, df=3(P=0.41); I2=0%  
Test for overall effect: Z=0.08(P=0.93)  
   
1.11.3 Pharmacist/community pharmacist  
Lopez 2006 23/70 31/64 4.02% 0.68[0.45,1.03]
Subtotal (95% CI) 70 64 4.02% 0.68[0.45,1.03]
Total events: 23 (Case management), 31 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.81(P=0.07)  
   
1.11.4 Multidisciplinary  
Jaarsma 2008 194/344 181/339 14.3% 1.06[0.92,1.21]
Subtotal (95% CI) 344 339 14.3% 1.06[0.92,1.21]
Total events: 194 (Case management), 181 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
   
1.11.5 Other  
Atienza 2004 68/164 101/174 9.56% 0.71[0.57,0.89]
Tsuyuki 2004 59/140 51/136 6.89% 1.12[0.84,1.5]
Subtotal (95% CI) 304 310 16.45% 0.89[0.57,1.38]
Total events: 127 (Case management), 152 (Usual care)  
Heterogeneity: Tau2=0.09; Chi2=5.92, df=1(P=0.01); I2=83.12%  
Test for overall effect: Z=0.53(P=0.6)  
   
Total (95% CI) 2256 2283 100% 0.92[0.83,1.01]
Total events: 1054 (Case management), 1120 (Usual care)  
Heterogeneity: Tau2=0.01; Chi2=22.78, df=13(P=0.04); I2=42.92%  
Test for overall effect: Z=1.82(P=0.07)  
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Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Chi2=8, df=1 (P=0.09), I2=50.02%  
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Analysis 1.12.   Comparison 1 Case management vs usual care, Outcome
12 All-cause readmissions - sensitivity analysis with low risk of bias.
Study or subgroup Case man-
agement
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
de Souza 2014 38/123 49/129 14.83% 0.81[0.58,1.15]
Kwok 2008 23/49 32/56 13.23% 0.82[0.56,1.19]
Lang 2018 4/25 7/25 2.09% 0.57[0.19,1.71]
Lopez 2006 23/70 31/64 11.21% 0.68[0.45,1.03]
Naylor 2004 53/118 67/121 21.1% 0.81[0.63,1.05]
Ong 2016 363/715 355/722 37.54% 1.03[0.93,1.15]
   
Total (95% CI) 1100 1117 100% 0.87[0.74,1.02]
Total events: 504 (Case management), 541 (Usual care)  
Heterogeneity: Tau2=0.02; Chi2=8.64, df=5(P=0.12); I2=42.15%  
Test for overall effect: Z=1.74(P=0.08)  
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Analysis 1.13.   Comparison 1 Case management vs usual care,
Outcome 13 Quality of life (MLHFQ mean score at end of follow-up).
Study or subgroup case man-
agement
usual care Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Brotons 2009 101 97 -12.5 (2.755) -12.54[-17.94,-7.14]
Dunbar 2014 54 54 -6.3 (4.937) -6.3[-15.98,3.38]
Holland 2007 78 80 3.7 (3.776) 3.73[-3.67,11.13]
Kasper 2002 94 85 -12.6 (3.766) -12.6[-19.98,-5.22]
Lang 2018 22 23 -9.5 (8.346) -9.5[-25.86,6.86]
Nucifora 2006 74 75 4 (2.97) 4[-1.82,9.82]
Ong 2016 383 413 -4.1 (1.774) -4.13[-7.61,-0.65]
Yu 2015a 70 50 -11.4 (3.732) -11.4[-18.71,-4.09]
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Analysis 1.14.   Comparison 1 Case management vs usual care,
Outcome 14 Quality of life (subgroup by length of intervention).
Study or subgroup case man-
agement
usual care Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.14.1 Less than 6 months' follow-up  
Dunbar 2014 54 54 -6.3 (4.937) 10.51% -6.3[-15.98,3.38]
Holland 2007 0 0 3.7 (3.776) 12.69% 3.73[-3.67,11.13]
Kasper 2002 94 85 -12.6 (3.766) 12.7% -12.6[-19.98,-5.22]
Lang 2018 22 23 -9.5 (8.346) 5.95% -9.5[-25.86,6.86]
Nucifora 2006 74 75 4 (2.97) 14.27% 4[-1.82,9.82]
Ong 2016 383 413 -4.1 (1.774) 16.42% -4.13[-7.61,-0.65]
Subtotal (95% CI)       72.54% -3.32[-8.59,1.96]
Heterogeneity: Tau2=27.38; Chi2=16.69, df=5(P=0.01); I2=70.04%  
Test for overall effect: Z=1.23(P=0.22)  
   
1.14.2 More than 6 months' follow-up  
Brotons 2009 101 97 -12.5 (2.755) 14.69% -12.54[-17.94,-7.14]
Yu 2015a 70 50 -11.4 (3.732) 12.77% -11.4[-18.71,-4.09]
Subtotal (95% CI)       27.46% -12.14[-16.48,-7.79]
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.81); I2=0%  
Test for overall effect: Z=5.48(P<0.0001)  
   
Total (95% CI)       100% -5.76[-10.64,-0.88]
Heterogeneity: Tau2=34.62; Chi2=29.59, df=7(P=0); I2=76.35%  
Test for overall effect: Z=2.31(P=0.02)  
Test for subgroup differences: Chi2=6.4, df=1 (P=0.01), I2=84.38%  
Favours case mangement 10050-100 -50 0 Favours usual care
 
 
Analysis 1.15.   Comparison 1 Case management vs usual care, Outcome
15 Quality of life (subgroup by person delivering intervention).
Study or subgroup case man-
agement
usual care Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.15.1 Specialist nurse  
Brotons 2009 101 97 -12.5 (2.755) 14.69% -12.54[-17.94,-7.14]
Dunbar 2014 54 54 -6.3 (4.937) 10.51% -6.3[-15.98,3.38]
Kasper 2002 94 85 -12.6 (3.766) 12.7% -12.6[-19.98,-5.22]
Lang 2018 22 23 -9.5 (8.346) 5.95% -9.5[-25.86,6.86]
Nucifora 2006 74 75 4 (2.97) 14.27% 4[-1.82,9.82]
Yu 2015a 70 50 -11.4 (3.732) 12.77% -11.4[-18.71,-4.09]
Subtotal (95% CI)       70.9% -7.87[-14.36,-1.39]
Heterogeneity: Tau2=47.15; Chi2=21.39, df=5(P=0); I2=76.62%  
Test for overall effect: Z=2.38(P=0.02)  
   
1.15.2 Nurse/community nurse  
Holland 2007 0 0 3.7 (3.776) 12.69% 3.73[-3.67,11.13]
Ong 2016 383 413 -4.1 (1.774) 16.42% -4.13[-7.61,-0.65]
Subtotal (95% CI)       29.1% -0.91[-8.48,6.67]
Heterogeneity: Tau2=22.19; Chi2=3.55, df=1(P=0.06); I2=71.83%  
Favours case management 10050-100 -50 0 Favours usual care
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Study or subgroup case man-
agement
usual care Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Test for overall effect: Z=0.23(P=0.81)  
   
1.15.3 Pharmacist/community pharmacist  
Subtotal (95% CI)       Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.15.4 Multidisciplinary  
Subtotal (95% CI)       Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.15.5 Other  
Subtotal (95% CI)       Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI)       100% -5.76[-10.64,-0.88]
Heterogeneity: Tau2=34.62; Chi2=29.59, df=7(P=0); I2=76.35%  
Test for overall effect: Z=2.31(P=0.02)  
Test for subgroup differences: Chi2=1.87, df=1 (P=0.17), I2=46.63%  
Favours case management 10050-100 -50 0 Favours usual care
 
 
Comparison 2.   Clinic-based intervention vs usual care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All-cause mortality - main analy-
sis
7 1686 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.68, 1.10]
2 All-cause mortality - subgroup
analysis by length of follow-up
7 1686 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.68, 1.10]
2.1 6 months' follow-up 2 306 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.32, 1.27]
2.2 More than 6 months' follow-up 5 1380 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.67, 1.17]
3 All-cause mortality - subgroup
analysis by person delivering the
intervention
7 1686 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.68, 1.10]
3.1 Specialist nurse 4 1081 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.53, 1.15]
3.2 Nurse/community nurse 1 208 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.83, 1.73]
3.3 Pharmacist/community phar-
macist
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Multidisciplinary 2 397 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.47, 1.17]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 All-cause mortality - sensitivity
analysis with low risk of bias
2 296 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.23, 1.88]
5 All-cause mortality - sensitivity
analysis without cluster-RCT
6 1489 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.66, 1.15]
6 HF readmissions - main analysis 2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
7 HF readmissions - subgroup
analysis by person delivering the
intervention
2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
7.1 Specialist nurse 1 679 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.77, 1.30]
7.2 Nurse/community nurse 1 208 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
7.3 Pharmacist/community phar-
macist
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Multidisciplinary 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 HF readmissions - subgroup
analysis by length of follow-up
2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
8.1 6 months' follow-up 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 More than 6 months' follow-up 2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
9 All-cause readmissions 4 1129 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.12]
10 All-cause readmissions - sub-
group analysis by length of fol-
low-up
4 1129 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.12]
10.1 6 months' follow-up 1 106 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.29, 0.91]
10.2 More than 6 months' fol-
low-up
3 1023 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.85, 1.16]
11 All-cause readmissions - sub-
group analysis by person deliver-
ing the intervention
4 1129 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.12]
11.1 Specialist nurse 3 921 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.52, 1.19]
11.2 Nurse/community nurse 1 208 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
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Analysis 2.1.   Comparison 2 Clinic-based intervention vs usual care, Outcome 1 All-cause mortality - main analysis.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bohmer 2011 11/140 7/60 6.13% 0.67[0.27,1.65]
Cline 1998 24/80 31/110 17.1% 1.06[0.68,1.67]
Doughty 2002 19/100 24/97 13.72% 0.77[0.45,1.31]
Jaarsma 2008 90/340 99/339 29.51% 0.91[0.71,1.16]
Mejhert 2004 40/103 34/105 21.24% 1.2[0.83,1.73]
Stromberg 2003 7/52 20/54 7.89% 0.36[0.17,0.79]
Thompson 2005 5/58 7/48 4.42% 0.59[0.2,1.74]
   
Total (95% CI) 873 813 100% 0.87[0.68,1.1]
Total events: 196 (Clinic), 222 (Usual care)  
Heterogeneity: Tau2=0.04; Chi2=9.58, df=6(P=0.14); I2=37.39%  
Test for overall effect: Z=1.17(P=0.24)  
Favours Clinic 100.1 50.2 20.5 1 Favours Usual Care
 
 
Analysis 2.2.   Comparison 2 Clinic-based intervention vs usual care,
Outcome 2 All-cause mortality - subgroup analysis by length of follow-up.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 6 months' follow-up  
Bohmer 2011 11/140 7/60 6.13% 0.67[0.27,1.65]
Thompson 2005 5/58 7/48 4.42% 0.59[0.2,1.74]
Subtotal (95% CI) 198 108 10.55% 0.64[0.32,1.27]
Total events: 16 (Clinic), 14 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.86); I2=0%  
Test for overall effect: Z=1.27(P=0.2)  
   
2.2.2 More than 6 months' follow-up  
Cline 1998 24/80 31/110 17.1% 1.06[0.68,1.67]
Doughty 2002 19/100 24/97 13.72% 0.77[0.45,1.31]
Jaarsma 2008 90/340 99/339 29.51% 0.91[0.71,1.16]
Mejhert 2004 40/103 34/105 21.24% 1.2[0.83,1.73]
Stromberg 2003 7/52 20/54 7.89% 0.36[0.17,0.79]
Subtotal (95% CI) 675 705 89.45% 0.89[0.67,1.17]
Total events: 180 (Clinic), 208 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=8.48, df=4(P=0.08); I2=52.83%  
Test for overall effect: Z=0.83(P=0.41)  
   
Total (95% CI) 873 813 100% 0.87[0.68,1.1]
Total events: 196 (Clinic), 222 (Usual care)  
Heterogeneity: Tau2=0.04; Chi2=9.58, df=6(P=0.14); I2=37.39%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=0.76, df=1 (P=0.38), I2=0%  
Favours Clinic 100.1 50.2 20.5 1 Favours Usual Care
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Analysis 2.3.   Comparison 2 Clinic-based intervention vs usual care, Outcome 3
All-cause mortality - subgroup analysis by person delivering the intervention.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 Specialist nurse  
Cline 1998 24/80 31/110 17.1% 1.06[0.68,1.67]
Jaarsma 2008 90/340 99/339 29.51% 0.91[0.71,1.16]
Stromberg 2003 7/52 20/54 7.89% 0.36[0.17,0.79]
Thompson 2005 5/58 7/48 4.42% 0.59[0.2,1.74]
Subtotal (95% CI) 530 551 58.91% 0.78[0.53,1.15]
Total events: 126 (Clinic), 157 (Usual care)  
Heterogeneity: Tau2=0.08; Chi2=6.33, df=3(P=0.1); I2=52.63%  
Test for overall effect: Z=1.25(P=0.21)  
   
2.3.2 Nurse/community nurse  
Mejhert 2004 40/103 34/105 21.24% 1.2[0.83,1.73]
Subtotal (95% CI) 103 105 21.24% 1.2[0.83,1.73]
Total events: 40 (Clinic), 34 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
   
2.3.3 Pharmacist/community pharmacist  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.3.4 Multidisciplinary  
Bohmer 2011 11/140 7/60 6.13% 0.67[0.27,1.65]
Doughty 2002 19/100 24/97 13.72% 0.77[0.45,1.31]
Subtotal (95% CI) 240 157 19.85% 0.74[0.47,1.17]
Total events: 30 (Clinic), 31 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.81); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
   
Total (95% CI) 873 813 100% 0.87[0.68,1.1]
Total events: 196 (Clinic), 222 (Usual care)  
Heterogeneity: Tau2=0.04; Chi2=9.58, df=6(P=0.14); I2=37.39%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=3.52, df=1 (P=0.17), I2=43.25%  
Favours Clinic 100.1 50.2 20.5 1 Favours Usual Care
 
 
Analysis 2.4.   Comparison 2 Clinic-based intervention vs usual care,
Outcome 4 All-cause mortality - sensitivity analysis with low risk of bias.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cline 1998 24/80 31/110 54.38% 1.06[0.68,1.67]
Stromberg 2003 7/52 20/54 45.62% 0.36[0.17,0.79]
   
Total (95% CI) 132 164 100% 0.65[0.23,1.88]
Favours Clinic 100.1 50.2 20.5 1 Favours Usual Care
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Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 31 (Clinic), 51 (Usual care)  
Heterogeneity: Tau2=0.48; Chi2=5.66, df=1(P=0.02); I2=82.34%  
Test for overall effect: Z=0.79(P=0.43)  
Favours Clinic 100.1 50.2 20.5 1 Favours Usual Care
 
 
Analysis 2.5.   Comparison 2 Clinic-based intervention vs usual care,
Outcome 5 All-cause mortality - sensitivity analysis without cluster-RCT.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bohmer 2011 11/140 7/60 7.93% 0.67[0.27,1.65]
Cline 1998 24/80 31/110 20.2% 1.06[0.68,1.67]
Jaarsma 2008 90/340 99/339 31.71% 0.91[0.71,1.16]
Mejhert 2004 40/103 34/105 24.29% 1.2[0.83,1.73]
Stromberg 2003 7/52 20/54 10.06% 0.36[0.17,0.79]
Thompson 2005 5/58 7/48 5.81% 0.59[0.2,1.74]
   
Total (95% CI) 773 716 100% 0.87[0.66,1.15]
Total events: 177 (Clinic), 198 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=9.17, df=5(P=0.1); I2=45.47%  
Test for overall effect: Z=0.96(P=0.34)  
Favours Clinic 100.1 50.2 20.5 1 Favours Usual Care
 
 
Analysis 2.6.   Comparison 2 Clinic-based intervention vs usual care, Outcome 6 HF readmissions - main analysis.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Jaarsma 2008 84/340 84/339 35.25% 1[0.77,1.3]
Mejhert 2004 69/103 69/105 64.75% 1.02[0.84,1.24]
   
Total (95% CI) 443 444 100% 1.01[0.87,1.18]
Total events: 153 (Clinic), 153 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
Favours Clinic 1000.01 100.1 1 Favours Usual Care
 
 
Analysis 2.7.   Comparison 2 Clinic-based intervention vs usual care, Outcome
7 HF readmissions - subgroup analysis by person delivering the intervention.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.7.1 Specialist nurse  
Jaarsma 2008 84/340 84/339 35.25% 1[0.77,1.3]
Subtotal (95% CI) 340 339 35.25% 1[0.77,1.3]
Favours Clinic 1000.01 100.1 1 Favours Usual Care
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Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 84 (Clinic), 84 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.98)  
   
2.7.2 Nurse/community nurse  
Mejhert 2004 69/103 69/105 64.75% 1.02[0.84,1.24]
Subtotal (95% CI) 103 105 64.75% 1.02[0.84,1.24]
Total events: 69 (Clinic), 69 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
   
2.7.3 Pharmacist/community pharmacist  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.7.4 Multidisciplinary  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 443 444 100% 1.01[0.87,1.18]
Total events: 153 (Clinic), 153 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.89), I2=0%  
Favours Clinic 1000.01 100.1 1 Favours Usual Care
 
 
Analysis 2.8.   Comparison 2 Clinic-based intervention vs usual care,
Outcome 8 HF readmissions - subgroup analysis by length of follow-up.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.8.1 6 months' follow-up  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.8.2 More than 6 months' follow-up  
Jaarsma 2008 84/340 84/339 35.25% 1[0.77,1.3]
Mejhert 2004 69/103 69/105 64.75% 1.02[0.84,1.24]
Subtotal (95% CI) 443 444 100% 1.01[0.87,1.18]
Total events: 153 (Clinic), 153 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
   
Favours Clinic 1000.01 100.1 1 Favours Usual Care
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Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 443 444 100% 1.01[0.87,1.18]
Total events: 153 (Clinic), 153 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
Test for subgroup differences: Not applicable  
Favours Clinic 1000.01 100.1 1 Favours Usual Care
 
 
Analysis 2.9.   Comparison 2 Clinic-based intervention vs usual care, Outcome 9 All-cause readmissions.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cline 1998 22/56 43/80 18.86% 0.73[0.5,1.07]
Jaarsma 2008 192/340 181/339 37.41% 1.06[0.92,1.21]
Mejhert 2004 69/103 69/105 32.7% 1.02[0.84,1.24]
Thompson 2005 13/58 21/48 11.02% 0.51[0.29,0.91]
   
Total (95% CI) 557 572 100% 0.9[0.72,1.12]
Total events: 296 (Clinic), 314 (Usual care)  
Heterogeneity: Tau2=0.03; Chi2=8.59, df=3(P=0.04); I2=65.06%  
Test for overall effect: Z=0.94(P=0.35)  
Favours Clinic 1000.01 100.1 1 Favours Usual Care
 
 
Analysis 2.10.   Comparison 2 Clinic-based intervention vs usual care, Outcome
10 All-cause readmissions - subgroup analysis by length of follow-up.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.10.1 6 months' follow-up  
Thompson 2005 13/58 21/48 11.02% 0.51[0.29,0.91]
Subtotal (95% CI) 58 48 11.02% 0.51[0.29,0.91]
Total events: 13 (Clinic), 21 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.27(P=0.02)  
   
2.10.2 More than 6 months' follow-up  
Cline 1998 22/56 43/80 18.86% 0.73[0.5,1.07]
Jaarsma 2008 192/340 181/339 37.41% 1.06[0.92,1.21]
Mejhert 2004 69/103 69/105 32.7% 1.02[0.84,1.24]
Subtotal (95% CI) 499 524 88.98% 0.99[0.85,1.16]
Total events: 283 (Clinic), 293 (Usual care)  
Heterogeneity: Tau2=0.01; Chi2=3.19, df=2(P=0.2); I2=37.21%  
Test for overall effect: Z=0.07(P=0.94)  
   
Total (95% CI) 557 572 100% 0.9[0.72,1.12]
Total events: 296 (Clinic), 314 (Usual care)  
Heterogeneity: Tau2=0.03; Chi2=8.59, df=3(P=0.04); I2=65.06%  
Test for overall effect: Z=0.94(P=0.35)  
Favours Clinic 1000.01 100.1 1 Favours Usual Care
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Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Chi2=4.76, df=1 (P=0.03), I2=78.99%  
Favours Clinic 1000.01 100.1 1 Favours Usual Care
 
 
Analysis 2.11.   Comparison 2 Clinic-based intervention vs usual care, Outcome 11
All-cause readmissions - subgroup analysis by person delivering the intervention.
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.11.1 Specialist nurse  
Cline 1998 22/56 43/80 18.86% 0.73[0.5,1.07]
Jaarsma 2008 192/340 181/339 37.41% 1.06[0.92,1.21]
Thompson 2005 13/58 21/48 11.02% 0.51[0.29,0.91]
Subtotal (95% CI) 454 467 67.3% 0.79[0.52,1.19]
Total events: 227 (Clinic), 245 (Usual care)  
Heterogeneity: Tau2=0.1; Chi2=8.47, df=2(P=0.01); I2=76.4%  
Test for overall effect: Z=1.13(P=0.26)  
   
2.11.2 Nurse/community nurse  
Mejhert 2004 69/103 69/105 32.7% 1.02[0.84,1.24]
Subtotal (95% CI) 103 105 32.7% 1.02[0.84,1.24]
Total events: 69 (Clinic), 69 (Usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
   
Total (95% CI) 557 572 100% 0.9[0.72,1.12]
Total events: 296 (Clinic), 314 (Usual care)  
Heterogeneity: Tau2=0.03; Chi2=8.59, df=3(P=0.04); I2=65.06%  
Test for overall effect: Z=0.94(P=0.35)  
Test for subgroup differences: Chi2=1.23, df=1 (P=0.27), I2=18.89%  
Favours Clinic 1000.01 100.1 1 Favours Usual Care
 
 
Comparison 3.   Multidisciplinary vs usual care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 HF mortality - main analysis 2 277 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.23, 0.95]
2 All-cause mortality - main analy-
sis
8 1764 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.54, 0.83]
3 All-cause mortality - subgroup
analysis by length of follow-up
8 1764 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.54, 0.83]
3.1 6 months' follow-up 2 478 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.47, 1.49]
3.2 More than 6 months' follow-up 6 1286 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.49, 0.81]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 All-cause mortality - sensitivity
analysis with low risk of bias
2 342 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.34, 1.25]
5 HF readmissions - main analysis 5 1108 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.50, 0.92]
6 HF readmissions - subgroup
analysis by length of follow-up
5 1108 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.50, 0.92]
6.1 6 months' follow-up 2 478 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.55, 1.40]
6.2 More than 6 months' follow-up 3 630 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.44, 0.75]
7 All-cause readmissions - main
analysis
5 1152 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.71, 1.01]
8 All-cause readmissions - sub-
group analysis by length of fol-
low-up
5 1152 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.71, 1.01]
8.1 6 months follow up 2 478 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.54, 1.33]
8.2 more than 6 months follow up 3 674 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.70, 1.02]
9 Quality of life - MLHFQ 2 140 Mean Difference (IV, Random, 95% CI) -12.21 [-16.43, -7.99]
 
 
Analysis 3.1.   Comparison 3 Multidisciplinary vs usual care, Outcome 1 HF mortality - main analysis.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gonzalez-Guerrero 2014 3/59 10/58 33.51% 0.29[0.09,1.02]
Wierzchowiecki 2006 7/80 12/80 66.49% 0.58[0.24,1.41]
   
Total (95% CI) 139 138 100% 0.46[0.23,0.95]
Total events: 10 (Multidisciplinary), 22 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.78, df=1(P=0.38); I2=0%  
Test for overall effect: Z=2.1(P=0.04)  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
 
 
Analysis 3.2.   Comparison 3 Multidisciplinary vs usual care, Outcome 2 All-cause mortality - main analysis.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bekelman 2015 8/187 19/197 7.47% 0.44[0.2,0.99]
Bernocchi 2017 1/56 1/56 0.64% 1[0.06,15.59]
Cavusoglu 2017 15/125 13/123 9.8% 1.14[0.56,2.29]
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
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Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Del Sindaco 2007 27/86 32/87 27.65% 0.85[0.56,1.29]
Ducharme 2005 12/115 19/115 10.53% 0.63[0.32,1.24]
Gonzalez-Guerrero 2014 13/59 22/58 14.16% 0.58[0.32,1.04]
Mao 2015 15/165 36/175 15.1% 0.44[0.25,0.78]
Wierzchowiecki 2006 15/80 23/80 14.66% 0.65[0.37,1.16]
   
Total (95% CI) 873 891 100% 0.67[0.54,0.83]
Total events: 106 (Multidisciplinary), 165 (Usual care)  
Heterogeneity: Tau2=0; Chi2=6.99, df=7(P=0.43); I2=0%  
Test for overall effect: Z=3.61(P=0)  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
 
 
Analysis 3.3.   Comparison 3 Multidisciplinary vs usual care, Outcome
3 All-cause mortality - subgroup analysis by length of follow-up.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 6 months' follow-up  
Cavusoglu 2017 15/125 13/123 9.8% 1.14[0.56,2.29]
Ducharme 2005 12/115 19/115 10.53% 0.63[0.32,1.24]
Subtotal (95% CI) 240 238 20.33% 0.84[0.47,1.49]
Total events: 27 (Multidisciplinary), 32 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=1.4, df=1(P=0.24); I2=28.48%  
Test for overall effect: Z=0.59(P=0.55)  
   
3.3.2 More than 6 months' follow-up  
Bekelman 2015 8/187 19/197 7.47% 0.44[0.2,0.99]
Bernocchi 2017 1/56 1/56 0.64% 1[0.06,15.59]
Del Sindaco 2007 27/86 32/87 27.65% 0.85[0.56,1.29]
Gonzalez-Guerrero 2014 13/59 22/58 14.16% 0.58[0.32,1.04]
Mao 2015 15/165 36/175 15.1% 0.44[0.25,0.78]
Wierzchowiecki 2006 15/80 23/80 14.66% 0.65[0.37,1.16]
Subtotal (95% CI) 633 653 79.67% 0.63[0.49,0.81]
Total events: 79 (Multidisciplinary), 133 (Usual care)  
Heterogeneity: Tau2=0; Chi2=4.6, df=5(P=0.47); I2=0%  
Test for overall effect: Z=3.68(P=0)  
   
Total (95% CI) 873 891 100% 0.67[0.54,0.83]
Total events: 106 (Multidisciplinary), 165 (Usual care)  
Heterogeneity: Tau2=0; Chi2=6.99, df=7(P=0.43); I2=0%  
Test for overall effect: Z=3.61(P=0)  
Test for subgroup differences: Chi2=0.81, df=1 (P=0.37), I2=0%  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
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Analysis 3.4.   Comparison 3 Multidisciplinary vs usual care, Outcome
4 All-cause mortality - sensitivity analysis with low risk of bias.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bernocchi 2017 1/56 1/56 5.69% 1[0.06,15.59]
Ducharme 2005 12/115 19/115 94.31% 0.63[0.32,1.24]
   
Total (95% CI) 171 171 100% 0.65[0.34,1.25]
Total events: 13 (Multidisciplinary), 20 (Usual care)  
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=1.3(P=0.19)  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
 
 
Analysis 3.5.   Comparison 3 Multidisciplinary vs usual care, Outcome 5 HF readmissions - main analysis.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cavusoglu 2017 37/125 35/123 24.87% 1.04[0.7,1.54]
Del Sindaco 2007 28/86 49/87 26.71% 0.58[0.4,0.83]
Ducharme 2005 12/115 19/115 13.5% 0.63[0.32,1.24]
Gonzalez-Guerrero 2014 14/59 18/58 15.86% 0.76[0.42,1.39]
Mao 2015 18/165 41/175 19.05% 0.47[0.28,0.78]
   
Total (95% CI) 550 558 100% 0.68[0.5,0.92]
Total events: 109 (Multidisciplinary), 162 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=7.68, df=4(P=0.1); I2=47.91%  
Test for overall effect: Z=2.53(P=0.01)  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
 
 
Analysis 3.6.   Comparison 3 Multidisciplinary vs usual care, Outcome
6 HF readmissions - subgroup analysis by length of follow-up.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.6.1 6 months' follow-up  
Cavusoglu 2017 37/125 35/123 24.87% 1.04[0.7,1.54]
Ducharme 2005 12/115 19/115 13.5% 0.63[0.32,1.24]
Subtotal (95% CI) 240 238 38.37% 0.88[0.55,1.4]
Total events: 49 (Multidisciplinary), 54 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=1.59, df=1(P=0.21); I2=37.25%  
Test for overall effect: Z=0.55(P=0.58)  
   
3.6.2 More than 6 months' follow-up  
Del Sindaco 2007 28/86 49/87 26.71% 0.58[0.4,0.83]
Gonzalez-Guerrero 2014 14/59 18/58 15.86% 0.76[0.42,1.39]
Mao 2015 18/165 41/175 19.05% 0.47[0.28,0.78]
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
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Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 310 320 61.63% 0.58[0.44,0.75]
Total events: 60 (Multidisciplinary), 108 (Usual care)  
Heterogeneity: Tau2=0; Chi2=1.54, df=2(P=0.46); I2=0%  
Test for overall effect: Z=4.11(P<0.0001)  
   
Total (95% CI) 550 558 100% 0.68[0.5,0.92]
Total events: 109 (Multidisciplinary), 162 (Usual care)  
Heterogeneity: Tau2=0.05; Chi2=7.68, df=4(P=0.1); I2=47.91%  
Test for overall effect: Z=2.53(P=0.01)  
Test for subgroup differences: Chi2=2.35, df=1 (P=0.13), I2=57.5%  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
 
 
Analysis 3.7.   Comparison 3 Multidisciplinary vs usual care, Outcome 7 All-cause readmissions - main analysis.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bekelman 2015 55/187 59/197 19.3% 0.98[0.72,1.34]
Cavusoglu 2017 47/125 43/123 17.68% 1.08[0.77,1.5]
Del Sindaco 2007 48/86 65/87 27.16% 0.75[0.6,0.93]
Ducharme 2005 45/115 66/115 21.88% 0.68[0.52,0.9]
Gonzalez-Guerrero 2014 26/59 28/58 13.98% 0.91[0.62,1.35]
   
Total (95% CI) 572 580 100% 0.85[0.71,1.01]
Total events: 221 (Multidisciplinary), 261 (Usual care)  
Heterogeneity: Tau2=0.02; Chi2=6.7, df=4(P=0.15); I2=40.28%  
Test for overall effect: Z=1.89(P=0.06)  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
 
 
Analysis 3.8.   Comparison 3 Multidisciplinary vs usual care, Outcome
8 All-cause readmissions - subgroup analysis by length of follow-up.
Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.8.1 6 months follow up  
Cavusoglu 2017 47/125 43/123 17.68% 1.08[0.77,1.5]
Ducharme 2005 45/115 66/115 21.88% 0.68[0.52,0.9]
Subtotal (95% CI) 240 238 39.55% 0.85[0.54,1.33]
Total events: 92 (Multidisciplinary), 109 (Usual care)  
Heterogeneity: Tau2=0.08; Chi2=4.32, df=1(P=0.04); I2=76.86%  
Test for overall effect: Z=0.72(P=0.47)  
   
3.8.2 more than 6 months follow up  
Bekelman 2015 55/187 59/197 19.3% 0.98[0.72,1.34]
Del Sindaco 2007 48/86 65/87 27.16% 0.75[0.6,0.93]
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
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Study or subgroup Multidis-
ciplinary
Usual care Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gonzalez-Guerrero 2014 26/59 28/58 13.98% 0.91[0.62,1.35]
Subtotal (95% CI) 332 342 60.45% 0.84[0.7,1.02]
Total events: 129 (Multidisciplinary), 152 (Usual care)  
Heterogeneity: Tau2=0; Chi2=2.4, df=2(P=0.3); I2=16.67%  
Test for overall effect: Z=1.79(P=0.07)  
   
Total (95% CI) 572 580 100% 0.85[0.71,1.01]
Total events: 221 (Multidisciplinary), 261 (Usual care)  
Heterogeneity: Tau2=0.02; Chi2=6.7, df=4(P=0.15); I2=40.28%  
Test for overall effect: Z=1.89(P=0.06)  
Test for subgroup differences: Chi2=0, df=1 (P=0.98), I2=0%  
Favours multidisciplinary 1000.01 100.1 1 Favours usual care
 
 
Analysis 3.9.   Comparison 3 Multidisciplinary vs usual care, Outcome 9 Quality of life - MLHFQ.
Study or subgroup Multidisciplinary Usual care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bernocchi 2017 45 -11 (12.6) 35 -0.5 (11.9) 61.16% -10.5[-15.9,-5.1]
Chen 2018 31 19.4 (12.2) 29 34.3 (14.4) 38.84% -14.9[-21.68,-8.12]
   
Total *** 76   64   100% -12.21[-16.43,-7.99]
Heterogeneity: Tau2=0; Chi2=0.99, df=1(P=0.32); I2=0%  
Test for overall effect: Z=5.67(P<0.0001)  
Favours multidisciplinary 10050-100 -50 0 Favours usual care
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Study Phone
fol-
low-up
Largely
educa-
tional
Self-
man-
age-
ment
Weight
moni-
toring
Dietary
advice
Exercise
promo-
tion
Medica-
tion re-
view
Social/
psycho-
logical
support
Duration of
interven-
tion (may
be shorter
than study
follow-up)
Agren 2012     Y         Y 3 months
Aldamiz-Echevarria 2007 Y Y Y   Y   Y   15 days
Atienza 2004 Y Y Y   Y Y Y   Median dura-
tion 509 days
Bekelman 2015 Y   Y Y Y   Y Y 12 months
Berger 2010 Y   Y Y     Y   12 months
Bernocchi 2017 Y Y Y   Y Y     4 months
Blue 2001 Y Y Y         Y Up to 12
months
Bohmer 2011 Y           Y   6 months
Brotons 2009 Y Y Y Y     Y   12 months
Capomolla 2002   Y Y Y Y Y   Y Not clear
Cavusoglu 2017 Y Y Y Y Y Y Y   6 months
Chen 2018 Y Y Y Y Y Y Y   6 months
Clark 2015 Y Y Y Y Y Y Y Y 6 months
Cline 1998   Y Y Y         12 months
DeBusk 2004 Y Y Y Y Y   Y   1 year
de Souza 2014 Y Y Y Y   Y Y   4 months
Del Sindaco 2007 Y           Y   24 months
Table 1.   Intervention components 
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Doughty 2002   Y Y Y Y Y     12 months
Ducharme 2005 Y     Y Y   Y   6 months
Dunbar 2014 Y Y Y Y Y Y Y   4.5 months
Gonzalez-Guerrero 2014 Y   Y   Y Y Y   6 months
Holland 2007   Y   Y Y Y     6-8 weeks
Jaarsma 2000 Y Y             Around 1
week
Jaarsma 2008 Y (basic
and in-
tensive
interven-
tions)
    Y (inten-
sive in-
terven-
tion)
Y (inten-
sive in-
terven-
tion)
      18 months
Kasper 2002 Y     Y Y Y     6 months
Kimmelstiel 2004 Y Y   Y Y   Y   90 days +
longer for un-
stable partici-
pants
Krumholz 2002 Y Y             12 months
Kwok 2008 Y       Y Y Y Y 6 months
Lang 2018 Y Y Y Y Y Y   Y 12 weeks
Leventhal 2011 Y Y Y Y Y       12 months
Lopez 2006 Y Y     Y       12 months
Mao 2015 Y Y Y Y Y Y Y   Intensive
phase 6
months, then
phone fol-
low-up every
2-3 months;
overall fol-
Table 1.   Intervention components  (Continued)
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low-up 24
months
Mehralian 2014   Y             6 months
Mejhert 2004     Y Y Y   Y   18 months
Naylor 2004 Y Y Y   Y Y Y   Intervention
3 months, fol-
low-up 1 year
Nucifora 2006 Y   Y       Y   6 months
Ong 2016 Y Y Y Y Y Y     6 months
Rainville 1999 Y     Y     Y   3 months
Salehitali 2009 Y Y Y Y Y Y Y   6 months
Shively 2013 Y   Y Y Y Y     6 months
Stewart 1999a Y         Y     Intervention
concentrat-
ed in first 2
weeks but
some phone
contact up
to end of fol-
low-up (6
months)
Stromberg 2003 Y Y Y Y Y Y Y Y Unclear
Thompson 2005   Y Y Y         6 months
Tsuchihashi-Makaya 2013 Y Y Y   Y Y   Y 6 months
Tsuyuki 2004 Y Y Y Y Y Y     6 months
Wierzchowiecki 2006 Y Y Y Y Y Y Y   12 months
Yu 2015a Y   Y Y       Y 9 months
Table 1.   Intervention components  (Continued)
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  All-cause mortality All-cause readmissions HF readmissions
Intervention component Ratio of
RR
P value Ratio of RR P value Ratio of RR P value
Phone follow-up 0.72
(0.37 to
1.38)
0.31 n/a n/a n/a n/a
Largely educational 1.16
(0.80 to
1.68)
0.42 0.93 (0.71 to 121) 0.53 0.65 (0.46 to 0.93) 0.02
Self-management 1.03
(0.72 to
1.46)
0.87 1.05 (0.81 to 1.36) 0.68 0.72 (0.48 to 1.07) 0.09
Weight management 0.96
(0.68 to
1.35)
0.81 1.32 (1.09 to 1.60) 0.008 1.53 (1.07 to 2.18) 0.03
Dietary advice 0.95
(0.67 to
1.35)
0.78 1.15 (0.89 to 1.48) 0.26 1.29 (0.76 to 2.18) 0.31
Exercise promotion 0.93
(0.66 to
1.30)
0.65 0.95 (0.75 to 1.19) 0.61 0.89 (0.55 to 1.45) 0.61
Medication review 0.86
(0.62 to
1.20)
0.36 0.86 (0.71 to 1.03) 0.09 0.78 (0.50 to 1.22) 0.25
Social/psychological
support
0.98
(0.59 to
1.61)
0.92 0.92 (0.68 to 1.26) 0.58 0.76 (0.40 to 1.43) 0.35
Table 2.   Metaregression results 
HF: heart failure; RR: risk ratio
Phone follow-up was dropped from the model for all-cause readmissions and HF readmissions due to collinearity, so we could not calculate
ratio of RR or P value.
 
 
A P P E N D I C E S
Appendix 1. Search strategies January 2018
CENTRAL via CRS Web
#1MeSH descriptor: [Heart Failure] explode all trees
#2((heart* or cardiac* or myocard*) near2 (fail* or insuI*))
#3(heart* near2 decomp*)
#4#1 or #2 or #3
#5MeSH descriptor: [Disease Management] this term only
#6(disease* near5 manag*)
#7MeSH descriptor: [Patient Care Management] this term only
#8MeSH descriptor: [Medication Therapy Management] this term only
#9MeSH descriptor: [Patient Care Team] explode all trees
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#10MeSH descriptor: [Patient-Centered Care] this term only
#11(patient* near3 manag*)
#12(patient* near4 (care or caring))
#13(deliver* near2 care)
#14(manag* near5 care)
#15(management near5 program*)
#16(case near5 manag*)
#17MeSH descriptor: [Home Care Services] this term only
#18MeSH descriptor: [Home Care Services, Hospital-Based] this term only
#19(home near5 (intervention* or care))
#20(home near visit*)
#21homecare
#22MeSH descriptor: [Ambulatory Care] this term only
#23(ambulatory near2 (care or caring))
#24MeSH descriptor: [Patient Discharge] this term only
#25(discharg* near5 program*)
#26(practice next guideline*)
#27MeSH descriptor: [Practice Guidelines as Topic] this term only
#28(comprehensive* near5 (care or caring))
#29multidisciplinary
#30(treatment* near5 plan*)
#31(nurse* next led)
#32(discharg* near5 plan*)
#33#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
or #26 or #27 or #28 or #29 or #30 or #31 or #32
#34#4 and #33
MEDLINE Ovid
1. exp Heart Failure/
2. ((heart* or cardiac* or myocard*) adj2 (fail* or insuI*)).tw.
3. (heart* adj2 decomp*).tw.
4. or/1-3
5. disease management/
6. (disease* adj5 manag*).tw.
7. Patient Care Management/
8. Medication Therapy Management/
9. exp Patient Care Team/
10. Patient-Centered Care/
11. (patient* adj3 manag*).tw.
12. (patient* adj4 (care or caring)).tw.
13. (deliver* adj2 care).tw.
14. (manag* adj5 care).tw.
15. ((management or care) adj5 program*).tw.
16. (case adj5 manag*).tw.
17. Home Care Services/
18. Home Care Services, Hospital-Based/
19. (home adj5 (intervention* or care)).tw.
20. (home adj visit*).tw.
21. homecare.tw.
22. Ambulatory Care/
23. (ambulatory adj2 (care or caring)).tw.
24. Patient Discharge/
25. (discharg* adj5 program*).tw.
26. (practice adj guideline*).tw.
27. Practice Guidelines as Topic/
28. (comprehensive* adj5 (care or caring)).tw.
29. multidisciplinary.tw.
30. (treatment* adj5 plan*).tw.
31. (nurse* adj5 led).tw.
32. (discharg* adj5 plan*).tw.
33. or/5-32
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34. 4 and 33
35. randomized controlled trial.pt.
36. controlled clinical trial.pt.
37. randomized.ab.
38. placebo.ab.
39. clinical trials as topic.sh.
40. randomly.ab.
41. trial.ti.
42. 35 or 36 or 37 or 38 or 39 or 40 or 41
43. exp animals/ not humans.sh.
44. 42 not 43
45. 34 and 44
Embase Ovid
1. exp heart failure/
2. ((heart* or cardiac* or myocard*) adj2 (fail* or insuI*)).tw.
3. (heart* adj2 decomp*).tw.
4. or/1-3
5. disease management/
6. (disease* adj5 manag*).tw.
7. patient care/
8. medication therapy management/
9. (patient* adj3 manag*).tw.
10. (patient* adj4 (care or caring)).tw.
11. (deliver* adj2 care).tw.
12. (manag* adj5 care).tw.
13. ((management or care) adj5 program*).tw.
14. (case adj5 manag*).tw.
15. home care/
16. (home adj5 (intervention* or care)).tw.
17. (home adj visit*).tw.
18. homecare.tw.
19. ambulatory care/
20. (ambulatory adj2 (care or caring)).tw.
21. hospital discharge/
22. (discharg* adj5 program*).tw.
23. (practice adj guideline*).tw.
24. (comprehensive* adj5 (care or caring)).tw.
25. multidisciplinary.tw.
26. (treatment* adj5 plan*).tw.
27. (nurse* adj5 led).tw.
28. (discharg* adj5 plan*).tw.
29. or/5-28
30. 4 and 29
31. random$.tw.
32. factorial$.tw.
33. crossover$.tw.
34. cross over$.tw.
35. cross-over$.tw.
36. placebo$.tw.
37. (doubl$ adj blind$).tw.
38. (singl$ adj blind$).tw.
39. assign$.tw.
40. allocat$.tw.
41. volunteer$.tw.
42. crossover procedure/
43. double blind procedure/
44. randomized controlled trial/
45. single blind procedure/
46. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45
47. (animal/ or nonhuman/) not human/
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48. 46 not 47
49. 30 and 48
50. limit 49 to embase
CINAHL
S53 S51 AND S52
S52 EM 20140212-20180109
S51 S32 AND S50
S50 S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49
S49 TX cross-over*
S48 TX crossover*
S47 TX volunteer*
S46 (MH "Crossover Design")
S45 TX allocat*
S44 TX control*
S43 TX assign*
S42 TX placebo*
S41 (MH "Placebos")
S40 TX random*
S39 TX (doubl* N1 mask*)
S38 TX (singl* N1 mask*)
S37 TX (doubl* N1 blind*)
S36 TX (singl* N1 blind*)
S35 TX (clinic* N1 trial?)
S34 PT clinical trial
S33 (MH "Clinical Trials+")
S32 S4 AND S31
S31 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR
S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30
S30 (discharg* N5 plan*)
S29 (nurse* N2 led)
S28 (treatment* N5 plan*)
S27 multidisciplinary
S26 (comprehensive* N5 (care or caring))
S25 (practice N2 guideline*)
S24 (discharg* N5 program*)
S23 (MH "Patient Discharge")
S22 (ambulatory N2 (care or caring))
S21 (MH "Ambulatory Care")
S20 homecare
S19 (home N4 visit*)
S18 (home N5 (intervention* or care))
S17 (MH "Shared Services, Health Care")
S16 (MH "Home Health Care")
S15 (case N5 manag*)
S14 ((management or care) N5 program*)
S13 (manag* N5 care)
S12 (deliver* N2 care)
S11 (patient* N4 (care or caring))
S10 (patient* N3 manag*)
S9 (MH "Patient Centered Care")
S8 (MH "Multidisciplinary Care Team")
S7 (MH "Patient Care Plans+")
S6 (disease* N5 manag*)
S5 (MH "Disease Management")
S4 S1 OR S2 OR S3
S3 (heart* N2 decomp*)
S2 ((heart* or cardiac* or myocard*) N2 (fail* or insuI*))
S1 (MH "Heart Failure+")
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DARE via Cochrane Library
#1MeSH descriptor: [Heart Failure] explode all trees
#2((heart* or cardiac* or myocard*) near/2 (fail* or insuI*))
#3(heart* near/2 decomp*)
#4#1 or #2 or #3
#5MeSH descriptor: [Disease Management] this term only
#6(disease* near/5 manag*)
#7MeSH descriptor: [Patient Care Management] this term only
#8MeSH descriptor: [Medication Therapy Management] this term only
#9MeSH descriptor: [Patient Care Team] explode all trees
#10MeSH descriptor: [Patient-Centered Care] this term only
#11(patient* near/3 manag*)
#12(patient* near/4 (care or caring))
#13(deliver* near/2 care)
#14(manag* near/5 care)
#15(management near/5 program*)
#16(case near/5 manag*)
#17MeSH descriptor: [Home Care Services] this term only
#18MeSH descriptor: [Home Care Services, Hospital-Based] this term only
#19(home near/5 (intervention* or care))
#20(home near visit*)
#21homecare
#22MeSH descriptor: [Ambulatory Care] this term only
#23(ambulatory near/2 (care or caring))
#24MeSH descriptor: [Patient Discharge] this term only
#25(discharg* near/5 program*)
#26(practice next guideline*)
#27MeSH descriptor: [Practice Guidelines as Topic] this term only
#28(comprehensive* near/5 (care or caring))
#29multidisciplinary
#30(treatment* near/5 plan*)
#31(nurse* next led)
#32(discharg* near/5 plan*)
#33#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
or #26 or #27 or #28 or #29 or #30 or #31 or #32
Clinicaltrials.gov
Condition or disease: “heart failure”
Other: randomized
Intervention/treatment: (“disease management” OR “self care”) AND (other OR behavioral)
Applied filters: interventional, adult, older adult
ICTRP
heart failure AND disease management AND random*
W H A T ' S   N E W
 
Date Event Description
3 October 2018 New citation required but conclusions
have not changed
22 new studies added. Conclusions unchanged but findings now
more robust due to increased number of studies and partici-
pants.
2 October 2018 New search has been performed We re-ran the searches on 9 January 2018.
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H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 2, 2005
 
Date Event Description
23 December 2011 New citation required and conclusions
have changed
Updated with results of new searches. 16 new studies included,
and 10 from the original review removed as not meeting revised
inclusion criteria.
Change in authorship reflects changes in team over time
8 September 2008 Amended Converted to new review format
1 February 2005 New citation required and conclusions
have changed
Substantive amendment
 
C O N T R I B U T I O N S   O F   A U T H O R S
AT is guarantor of the review.
ST, and AT conceived and designed this update.
ST, NM and AT screened search results against inclusion criteria and carried out data extraction.
AT and NM appraised the risk of bias and GRADE rating of included studies.
AT wrote to authors of papers for additional information.
AT managed the data for the review, entered the data into Review Manager 5 (Review Manager 2014) and analysed the data.
AT and NM wrote the review, with ST and RT providing methodological perspective, clinical perspective and general advice.
D E C L A R A T I O N S   O F   I N T E R E S T
AT: none known
NM: none known
RT: none known
ST: none known
S O U R C E S   O F   S U P P O R T
Internal sources• No sources of support supplied
External sources• This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Heart. The
views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health, UK.• This research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health
Research and Care North Thames at Bart’s Health NHS Trust (NIHR CLAHRC North Thames). The views expressed in this article are those
of the review author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care, UK.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
No protocol was published for this update, so we are including diIerences between the last update (Takeda 2012) and the current update.
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Changes in authorship have taken place since the protocol was registered, since two new researchers (AT, NM) joined the team and others
have moved on to other fields.
• The title of this review has been changed from 'Clinical Service Organisation for Heart Failure' to reflect changes in terminology, with
an emphasis on disease management programmes rather than organisation of services.• The objective of the review has been simplified by merging the original primary and secondary objectives into one.• The original review contained four diIerent mortality outcomes and four diIerent readmission outcomes as primary outcomes, and
four secondary outcomes. For this update, we amended these to simplify the review and focus on user-important outcomes.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
ANercare  [*organization & administration];  Case Management  [*organization & administration];  Cause of Death;  Chronic Disease;
  Health Status;  Heart Failure  [mortality]  [*therapy];  Length of Stay;  Patient Readmission  [*statistics & numerical data];  Practice
Patterns, Nurses'  [organization & administration];  Quality of Life;  Randomized Controlled Trials as Topic
MeSH check words
Aged; Aged, 80 and over; Humans
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